| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| A Pilot Study of Urinary Carcinogen Biomarkers in the Golestan Cohort Study | Research Initiative | CDC, FDA | NCI | A pilot study in the Golestan Cohort to compare exposure to different types of carcinogens (nicotine metabolites, polycyclic aromatic hydrocarbons [PAHs], tobacco-specific nitrosamines [TSNAs], and volatile organic compounds [VOCs]) and creatine in the urine of self-reported cigarette, chewing nass, water pipe, and opium users, and never users of these products. The study will examine the stability of these markers over time by taking advantage of repeated samples that were collected from a subset of participants. Results from the pilot study will then be used to evaluate the potential of future studies and evaluate their design. |
| A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews | Research Initiative | CDC | NCI | NCI and CDC are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure. |
| A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation | Committee, Work group, Advisory group, or Task Force | OS | CC | THe NIH Clinical Center is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management. |
| A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial | Research Initiative | CDC | NIAID | The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using new regimens, including high-dose rifapentine. |
| Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) | Research Initiative | FDA | NIDA | Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health. http://www.acttion.org/news/3_1_12.html |
| Accelerating Medicines Partnership | Other | FDA | OD/OSP, NIA, NIAMS, NIDDK | The Accelerating Medicines Partnership (AMP) is a public-private partnership, between NIH, FDA, 10 biopharmaceutical companies and multiple non-profit organizations, and managed by the Foundation for NIH (FNIH), to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics. The ultimate goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. AMP was launched in February 2014, with projects in three disease areas (Alzheimer’s disease; type 2 diabetes; and autoimmune disorders of rheumatoid arthritis and systemic lupus erythematous). Steering committees for each of the three disease areas, with representation from all partners, meet regularly to review ongoing progress and milestones. The steering committees are managed by FNIH under the direction of an AMP Executive Committee comprised of representatives from NIH, participating industry leaders, FDA, and non-profit organizations. https://www.nih.gov/research-training/accelerating-medicines-partnership-amp#governance |
| AccessGUDID | Resource Development | FDA | NLM | The Global Unique Device Identification Database (GUDID) contains key device identification information submitted to the FDA about medical devices that have Unique Device Identifiers (UDI). The National Library of Medicine (NLM), in collaboration with the FDA, has created the AccessGUDID portal to make device identification information in the GUDID available for everyone, including patients, caregivers, health care providers, hospitals, and industry. https://accessgudid.nlm.nih.gov |
| Action for Health in Diabetes (Look AHEAD) | Research Initiative | CDC, IHS | NIDDK, NHLBI | This study is a 16-center, randomized clinical trial investigating the long-term health consequences of weight loss. Enrollment occurred between 2001-2004 with a planned follow-up of up to 13.5 years. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. The study intervention was discontinued in Sept. 2012 on the recommendation of the Data and Safety Monitoring Board (DSMB), as there were no differences between the two groups after up to 11 years of follow-up. The study will continue to follow participants for study outcomes. http://www.lookaheadtrial.org |
| Action Plan for Children in Adversity (APCA)/PL 109-95 | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA | NICHD | The Action Plan on Children in Adversity is the first-ever whole-of-government strategic guidance for U.S. Government international assistance for children. The goal of the U.S. Government Action Plan on Children in Adversity is to achieve a world in which all children grow up within protective family care and free from deprivation, exploitation, and danger. The plan is grounded in evidence that shows a promising future belongs to those nations that invest wisely in their children, while failure to do so undermines social and economic progress. Child development is a cornerstone for all development, and it is central to U. S. development and diplomatic efforts. The plan seeks to integrate internationally recognized, evidence-based good practices into all of its international assistance initiatives for the best interests of the child. The Action Plan has three principal objectives and three supporting objectives to promote greater U.S. Government coherence and accountability for whole-of-government assistance to vulnerable children. http://www.childreninadversity.gov/about/how/action-plan |
| Addiction Technology Transfer Centers (ATTCs) | Resource Development | SAMHSA | NIDA | Accelerating the dissemination of research-based drug abuse treatment into clinical practice is a priority for the National Institute on Drug Abuse (NIDA) and represents the core mission of the Blending Initiative. NIDA and the Substance Abuse and Mental Health Services Administration (SAMHSA) joined together to create the Blending Initiative in 2001 to reduce the gap that exists between the publication of research results and impact on treatment delivery. This initiative incorporates collaboration between clinicians, scientists, and experienced trainers to catalyze the creation of user-friendly treatment tools and products and facilitate the adoption of research-based interventions into front-line clinical settings. Through this initiative, NIDA and SAMHSA’s Addiction Technology Transfer Centers (ATTCs) disseminate treatment and training products based on results from studies conducted by the National Drug Abuse Clinical Trials Network (CTN) as well as other NIDA-supported research. http://www.drugabuse.gov/blending-initiative |
| Adjuvant Working Group | Committee, Work group, Advisory group, or Task Force | FDA, OS | NIAID, NCI | Staff from all National Institute of Allergy and Infectious Diseases (NIAID) Divisions, program staff from the Biomedical Advanced Research and Development Authority (BARDA), and regulatory staff from the Food and Drug Administration (FDA) exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources. |
| Administrative Supplements on HIV Pre-Exposure Prophylaxis Implementation Science in CDC-Funded Public Health Demonstration Projects | Research Initiative | CDC | NIMH | The National Institute of Mental Health (NIMH), in collaboration with the Centers for Disease Control and Prevention (CDC), developed a request for applications to call for administrative supplements to currently funded NIH grants. These supplements would support implementation science research related to a CDC-funded public health initiative to reduce HIV infections in men who have sex with men (MSM) and transgender individuals through improved HIV pre-exposure prophylaxis (PrEP) planning, outreach, and delivery. Eight supplements were awarded. https://grants.nih.gov/grants/guide/pa-files/PA-16-199.html |
| Adolescent Brain Cognitive Development (ABCD) Study | Research Initiative | CDC | NIDA, NCI, NIAAA, NICHD, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR | The Adolescent Brain Cognitive Development (ABCD) project, a landmark longitudinal study of brain development and child health, will increase our understanding of how diverse experiences during adolescence interact with changing biology to influence brain, cognitive and social/emotional development of youth. In partnership with area public and private schools, researchers at twenty-one research sites across the country will recruit 10,000 children at age 9-10 from diverse races and ethnicities, education and income levels, and living environments and follow them through their teens and into early adulthood. Throughout this period, researchers will assess each child’s physical and mental health, substance use, sleep patterns, genetics, childhood experiences, and cultural/environmental influences, as well as track brain and cognitive development with non-invasive magnetic resonance imaging scans at regular intervals. To enrich the value of the study, ABCD will release anonymized data annually to the research community in an open science model to allow scientists from all over the world to conduct analyses and pool resources to rapidly expand the types of scientific questions that can be answered. The actionable information coming out of this study will enable education, substance use prevention, and other health promotion policies to ensure the wellbeing and success of the Nation’s children. http://abcdstudy.org/ |
| Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) | Committee, Work group, Advisory group, or Task Force | CDC | FIC, NIAID, NICHD, NIMH, OD/DPCPSI/OAR | The Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) aims to enhance the effective use of evidence and help overcome implementation challenges related to prevention, screening and treatment of HIV among adolescents (ages 15 to 24) in sub-Saharan Africa by catalyzing collaboration and communication among implementation scientists, program implementers and policymakers. The goals of the Alliance are to: 1) provide a platform for cross-fertilization and exchange of ideas and information among implementation scientists and other stakeholders focusing on different aspects of HIV in adolescents; 2) enable the research to be better informed by programmatic challenges and questions; 3) inform policymakers of promising evidence and encourage use of the data in decision making; and 4) extend the reach and impact of implementation science related to adolescent HIV prevention and treatment. https://www.fic.nih.gov/About/center-global-health-studies/Pages/adolescent-hiv-prevention-treatment-implementation-science-alliance.aspx |
| Advanced Anticonvulsant System Interagency Product Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS | The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure. |
| Adverse Event Reporting and Medical Countermeasures | Resource Development | FDA | NLM | NLM is working with the FDA to provide advice on key mobile technologies for targeted adverse event reporting and medical counter measures in emergency settings. The group helped direct the design and development of the mobile app that was co-developed with programmers from Booz Allen Hamilton (BAH), the FDA contractor. BAH was responsible for the Web app that could be encapsulated within Android or iOS frameworks. NLM focused on the iOS framework and developed plugins for encryption, data caching and communications, audio capture, and overall app development. The app can send data to a cloud-based server under the aegis of the FDA. The app was demonstrated to the FDA leadership in June, 2014 and future R&D directions were outlined at the meeting. In addition to the design of the mobile app, NLM advised the FDA team on usability issues and provided guidance on distribution strategies. |
| Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | CC, NHLBI | The Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) is a 31-member federal advisory committee that provides advice to the Secretary of Health and Human Services through the Assistant Secretary for Health on a range of policy issues related to blood, blood products, and tissues. https://www.hhs.gov/ohaidp/initiatives/blood-tissue-safety/advisory-committee/index.html |
| Advisory Committee on Heritable Disorders in Newborn and Children | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD | The Advisory Committee on Heritable Disorders in Newborns and Children was established under the Public Health Service Act, Title XI, § 1109 (42 U.S.C. 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (P.L. 113-240). The mission of the Advisory Committee on Heritable Disorders in Newborns and Children is to reduce morbidity and mortality in newborns and children who have, or are at risk for, heritable disorders. The Committee recommends that every newborn screening program include a Uniform Screening Panel that screens for 32 core disorders and 26 secondary disorders. The Committee advises the Secretary, U.S. Department of Health and Human Services on the most appropriate application of universal newborn screening tests, technologies, policies, guidelines and standards. Specifically, the committee provides to the Secretary, the following: Advice and recommendations concerning grants and projects authorized awarded or funded related to screening heritable disorders in newborns and children, technical information to develop Heritable Disorders Program policies and priorities that will enhance the ability of the state and local health agencies to provide screening, counseling and health care services for newborns and children who have or are at risk for heritable disorders, and recommendations, advice and information to enhance, expand or improve the ability of the Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. The committee was chartered on May 7, 2015. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/ |
| Advisory Committee on Organ Transplantation (ACOT) | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID | The Advisory Committee on Organ Transplantation (ACOT) was established to assist the HHS Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system. http://organdonor.gov/legislation/advisory.html |
| Agricultural Health Study | Research Initiative | CDC | NCI, NIEHS | The Agricultural Health Study (AHS) is a prospective study of cancer and other health outcomes in a cohort of licensed pesticide applicators and their spouses from Iowa and North Carolina. The AHS began in 1993 with the goal of answering important questions about how agricultural, lifestyle and genetic factors affect the health of farming populations. The study is a collaborative effort involving investigators from National Cancer Institute, the National Institute of Environmental Health Sciences, the Environmental Protection Agency, and the National Institute for Occupational Safety and Health. More than 89,000 farmers and their spouses in Iowa and North Carolina have participated in the study. Their participation has provided, and continues to provide, the data that researchers need to help the current and future generations of farmers and their families live healthier lives https://aghealth.nih.gov/index.html |
| AHRQ National Guidelines Clearinghouse/National Quality Measures Clearinghouse (NQMC/NGC) Editorial Board | Committee, Work group, Advisory group, or Task Force | AHRQ | NLM | The AHRQ’s National Guidelines Clearinghouse/National Quality Measures Clearinghouse (NQMC/NGC) Editorial Board is composed of health care professionals with collective expertise in evidence-based quality measures and clinical practice guidelines. This is an expert public-private panel that provides guidance concerning the content and presentation of the related but distinct AHRQ resources, the National Guidelines Clearinghouse, and the National Quality Measures Clearinghouse. The Board also serves as a resource for feedback and guidance on developments in health care that inform future work. NLM is a member of this editorial board. http://www.qualitymeasures.ahrq.gov/index.aspx |
| AHRQ Patient Safety Workgroup | Committee, Work group, Advisory group, or Task Force | AHRQ | NLM | AHRQ Patient Safety Network (PSNet) is a national web-based resource featuring the latest news and essential resources on patient safety. The AHRQ Patient Safety Workgroup is an expert public-private panel that provides guidance to AHRQ concerning implementation of legislation related to patient safety reporting and monitoring, including the “AHRQ Patient Safety Common Formats” for reporting patient safety events. NLM serves on this workgroup. https://psnet.ahrq.gov/ |
| AHRQ Registry of Patient Registries (RoPR) | Resource Development | AHRQ | NLM | The Registry of Patient Registries (RoPR) is a database of registry-specific information intended to promote collaboration, reduce redundancy, and improve transparency. ClinicalTrials.gov worked with RoPR to implement a mechanism for patient registries to be registered in ClinicalTrials.gov and additional information provided directly at RoPR. https://patientregistry.ahrq.gov/ |
| AIDSinfo/InfoSIDA | Public Education Campaign | CDC, CMS, HRSA | OD/DPCPSI/OAR, NIAID, NLM | AIDSinfo, a service of the U.S. Department of Health and Human Services (HHS), offers access to the latest, federally approved HIV/AIDS medical practice guidelines, HIV treatment and prevention clinical trials, and other research information for health care providers, researchers, people affected by HIV/AIDS, and the general public. http://aidsinfo.nih.gov/ |
| Alaska Native Tumor Registry | Resource Development | CDC, IHS | NCI | In collaboration with CDC, IHS, and NCI, and with technical assistance from the Surveillance, Epidemiology, and End Results Program (SEER), the Alaska Native Tumor Registry collects information on cancer cases among Alaskan Native populations residing in Alaska. http://seer.cancer.gov/registries/alaska.html |
| Alcohol Clinical Trial Initiative (ACTIVE) | Committee, Work group, Advisory group, or Task Force | FDA | NIAAA, NIDA | A workgroup was formed under the auspices of the American College of Neuropsychopharmacology, known as the ACTIVE (Alcohol Clinical Trials Initiative) group, to evaluate data from completed clinical trials to develop a consensus on key issues in the conduct of clinical trials in alcohol dependence. ACTIVE consists of academic experts, industry representatives, and staff from the Food and Drug Administration, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse. http://www.ncbi.nlm.nih.gov/pubmed/21900883 |
| All-Hazards Plan | Resource Development | OS | NLM | This activity is to develop an interactive webtool to help state and local health departments prepare for and respond to disasters in their regions. https://allhazards.nlm.nih.gov/login |
| Alzheimer''s Disease Neuroimaging Initiative (ADNI) | Research Initiative | FDA | NIA, NIBIB | The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease. ADNI researchers collect, validate and utilize data such as MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors for the disease. Data from the North American ADNI’s study participants, including Alzheimer’s disease patients, mild cognitive impairment subjects and elderly controls, are available on a website run by NLM. http://adni.loni.usc.edu/ |
| America''s Children Forum on Health and Family Statistics | Resource Development | SAMHSA | NIDA | As a member of this collaboration, NIDA contributes data from the, “Monitoring the Future Survey on Illicit Drugs, Alcohol and Tobacco Trends”. http://www.childstats.gov/index.asp |
| American Academy of Pediatrics (AAP) Committee on Drugs | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The AAP Committee on Drugs reviews all aspects of pediatric pharmacology, including drug indications, contraindications, absorption rates, routes of administration, dosing, use precautions, and mode of action as they apply to children. The Committee also advises the Board of Directors in matters related to drug labeling, safety and efficacy for both prescription and over-the-counter drugs; monitors federal legislation related to the drug approval process; and promotes the need for expanded pediatric drug trials. https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/pages/Committee-on-Drugs.aspx |
| American Academy of Pediatrics (AAP) Committee on Genetics | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The APP Committee on Genetics (COG) studies and makes recommendations to the AAP Board of Directors on recent advances in genetics and provides support to chapters on state legislative issues as they relate to genetics. https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Pages/Committee-on-Genetics.aspx |
| American Academy of Pediatrics (AAP) Committee on Pediatric AIDS | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The AAP Committee on Pediatric AIDS (COPA) provides guidelines and recommendations for the care and treatment of infants, children, and adolescents with HIV and their families through the development of AAP Policy Statements and the provision of guidance and consultation to other policy making bodies as well as to local and federal governances. https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/Pages/Committee-On-Pediatric-AIDS.aspx |
| American Academy of Pediatrics (AAP) Council on Injury, Violence and Poison Prevention (COIVPP) | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The AAP Council on Injury, Violence, and Poison Prevention, was formed on July 1, 2011, with the merging of the former Section and Committee on Injury, Violence, and Poison Prevention. This new leadership body addresses all facets of injury prevention policy, programs, advocacy, and education of general pediatricians, pediatric subspecialists, and families as a unified group. http://www2.aap.org/sections/ipp/ |
| American Academy of Pediatrics (AAP) Disaster Activity Council, Federal Liaison | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD | The American Academy of Pediatrics (AAP) created the Disaster Preparedness Advisory Council (DPAC) in May 2007 to develop and implement a strategic plan for disaster preparedness and oversee/support AAP disaster preparedness initiatives while working collaboratively with AAP committees, sections, and councils and key partner organizations. https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Children-and-Disasters/Pages/Disaster-Preparedness-Advisory-Council.aspx |
| American Academy of Pediatrics (AAP) Task Force on SIDS | Other | CDC | NICHD | The American Academy of Pediatrics appointed the Task Force on SIDS in 1990 to provide evidence-based practice recommendations regarding SIDS risk reduction. Members of the Task Force on SIDS are selected and approved by the Board of Directors and The Executive Committee of the AAP based on their expertise of SIDS and infant mortality |
| American Community Survey (ACS) Content Review Working Group | Committee, Work group, Advisory group, or Task Force | OS | NICHD | The American Community Survey (ACS) is an ongoing survey that provides vital information on a yearly basis about our nation and its people. Information from the survey generates data that help determine how more than $400 billion in federal and state funds are distributed each year. Public officials, planners, and entrepreneurs use this information to assess the past and plan the future. https://www.census.gov/programs-surveys/acs/about.html |
| American Conference for the Treatment of HIV (ACTHIV) | Meeting/ Workshop | CDC, FDA, HRSA | OD/DPCPSI/OAR | The American Conference for the Treatment of HIV (ACTHIV) is a state-of-the-science conference for frontline health care professionals, in scientific collaboration with multiple federal and independent agencies. The conference is designed for all frontline clinicians providing HIV care for various population groups. http://acthiv.org |
| Americas Region Interagency Coordination Group on Zika Virus | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD, NIAID, NIEHS | This committee was established to allow for information exchange among federal agencies involved with addressing the Zika virus. |
| Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks | Committee, Work group, Advisory group, or Task Force | FDA | NINDS, NCATS, NCI, NIAAA, NIDA | The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health. http://www.acttion.org/ |
| Anti-Infective Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and make appropriate recommendations to the FDA Commissioner. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/default.htm |
| Antiretroviral Pregnancy Registry | Resource Development | CDC, FDA, HRSA | NICHD | This is a registry of use of antiretroviral drugs in pregnancy that is sponsored by various pharmaceutical companies and has a committee of external experts and government staff from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The registry provides a resource for clinicians and researchers to improve the healthcare quality and patient safety for HIV infected mothers and their infants. http://www.apregistry.com/ |
| Asia-Pacific Economic Cooperation (APEC) Cervical Cancer Initiative | Meeting/ Workshop | OS | NCI | NCI and the Office of the Secretary have been supporting a collaborative effort to strengthen cervical cancer control through the Asia-Pacific Economic Forum (APEC). Effective cervical cancer control strategies exist all along the cervical cancer control continuum, including primary prevention, screening, treatment, and palliative care. Recent research has demonstrated the effectiveness of lower cost screening techniques, and ongoing research is exploring additional reduced-cost cervical cancer control options. The large number of interventions currently available and on the horizon means that the integration of these approaches into health systems is possible for economies of many different resource levels and can have substantial impact on public health, the workforce, and the broader economy. http://www.cancer.gov/about-nci/organization/cgh/research/apec |
| Assay Guidance Workshop For High Throughput Screening And Lead Discovery | Meeting/ Workshop | FDA | NCATS, CC, NCI, NEI, NHGRI, NHLBI, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NINDS | More than 100 participants attended the “Assay Guidance Workshop for High-Throughput Screening and Lead Discovery” on April 5–6, 2016, in College Park, Maryland. Hosted by NCATS and the Food and Drug Administration (FDA), the workshop was designed to provide participants with a broad and practical perspective on how to develop and implement robust assays for early-stage drug discovery projects. Participants included researchers from thirteen NIH centers, FDA, National Institute of Standards and Technology, the Department of Defense, industry and academia. Workshop leaders with more than 20 years of drug discovery experience covered a broad range of critical concepts underlying robust assay development and screening strategies. There were also open discussions for participants to share experiences and seek practical advice about individual research interests. https://ncats.nih.gov/enews/issues/vol05-iss04/assay-guidance-workshop |
| Assessment of Occupational Exposure to Coal Tar Pitch Volatiles Containing Polycyclic Aromatic Hydrocarbons (PAHs) in Coal Tar Sealant Applications | Research Initiative | CDC | NIEHS | This study is a collaboration between NIH and CDC that is measuring exposure of coal tar sealant applicators to polycyclic aromatic hydrocarbons (PAHs) compounds. |
| Assessment of Occupational Exposure to Flame Retardants | Research Initiative | CDC | NIEHS | This study aims to characterize occupational exposure to flame retardants among U.S. workers who are manufacturing or installing flame retardant materials. |
| Assisted Outpatient Treatment | Research Initiative | HRSA, SAMHSA | NIMH | This collaboration supports the development and implementation of a rigorous and objective cross-site impact evaluation of an Assisted Outpatient Treatment (AOT) Grant Program for Individuals with Serious Mental Illness. The Department of Health and Human Services, Assistant Secretary for Planning and Evaluation (ASPE) has primary responsibility for the solicitation, management, and implementation of the evaluation contract in consultation with the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute of Mental Health (NIMH). The Center for Behavioral Health Statistics and Quality (CBHSQ), an entity within SAMHSA that serves as a focal point for data collection, analysis, and the dissemination of critical public health data, will provide consultation on the cross-site evaluation of the AOT grant program. ASPE, in consultation with the NIMH, brings expertise in evaluation design and implementation that benefits SAMHSA in its priority of having a rigorous multi-site evaluation. The objective of the multi-site evaluation is to measure the effectiveness of the AOT programs in improving rates of appropriate health care utilization and reducing rates of incarceration, health care utilization, and homelessness for individuals with serious mental illness, and to identify key program components. |
| Association Between Urinary PAH and Esophageal Squamous Dysplasia in the STEP study in Western Kenya | Research Initiative | CDC | NCI | This activity is a collaboration between NCI and CDC that aims to measure metabolites of polycyclic aromatc hydrocarbons (PAHs), cotinine and creatinine in the urine samples from individuals with and without precancerous lesions of the esophagus. |
| ASTM International F-2529-13--Standard Guide for In-Vivo Evaluation of Osteoinductive Potential for Materials Containing Demineralized Bone (DBM) | Research Initiative | FDA | NIDCR | Provide a guide based on consensus of viewpoints used to determine the osteoinductive potential of a DBM containing products utilizing the arthymic rodent model. http://www.astm.org/Standards/F2529 |
| Auditory (Hearing) Screening Supplement for Early Childhood Longitudinal Study | Health Survey | CDC | NIDCD | The objective of this Inter-Agency Agreement is to implement a hearing examination protocol in the Early Childhood Longitudinal Study of the Kindergarten Class of 2010–11. This is a large (n=20,000), nationally representative school-based exam and interview survey sponsored by the National Center for Education Statistics (NCES), U.S. Department of Education. The last NCES longitudinal cohort study of school age children began with the 1998 Kindergarten Class. In this earlier cohort, there were no hearing exams (nor vision exams) and the number of young children with hearing loss (reported by parents or teachers) shrank considerably after the initial enrollment of Kindergarteners. A randomly selected sub-sample of about 4500 children were identified for more frequent follow-up and these children have also been selected for the hearing examination; they are also included in a “selected” (protected) subsample for more intensive tracking in follow-up waves of the survey. Children in the selected subsample will be tracked to new schools when possible if they are later enrolled in (moved to) a school that was not in the original school sample, e.g., when families relocate. In addition to hearing, the ECLS-K: 2010-11 will track several other outcome measures (e.g., general health, social and physical development, achievement scores, and parental and teacher-reported communication problems) associated with educational performance. Hearing will be tested when the children are examined with achievement testing in the school setting. http://nces.ed.gov/ecls/ |
| Autoimmune Diseases Coordinating Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NIAID, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR | The purpose of the Autoimmune Diseases Coordinating Committee (ADCC) is to provide a forum for the coordination of research efforts in autoimmunity and autoimmune diseases among various stakeholders including the NIH, other federal agencies such as the FDA and the CDC, and private organizations with an interest in autoimmune diseases. The ADCC meets twice yearly to discuss a broad range of basic, preclinical and clinical endeavors. http://www.niaid.nih.gov/topics/autoimmune/Pages/coordComm.aspx |
| B-24 Project | Research Initiative | CDC, FDA | NICHD | NICHD has played a lead role in the evolution of the process to include infants/children from birth to 24 months and pregnant women in future (2020 and beyond) iterations of the Dietary Guidelines for Americans; the "B-24 Project." An offshoot of that project was the effort to develop guidelines for nutritional care of preterm infants (the "Pre-B Project"). Both projects have included members of the CDC and FDA on working groups constituted to develop the initial reports that will serve as the basis for the subsequent systematic review and guideline development process. https://www.cnpp.usda.gov/birthto24months |
| Behavioral Aspects of Prep Counseling HIV Prevention Trials Network (HPTN) Protocol #067: The ADAPT Study (Y01-MH-0315) | Research Initiative | CDC | NIMH, NIAID | This behavioral research study is evaluating whether non-daily medication regimens for HIV Pre-Exposure Prophylaxis (PrEP) may be more acceptable and foster better adherence to treatment. PrEP represents a novel biomedical approach to HIV prevention in which individuals at-risk for HIV take antiretroviral medications to help prevent HIV infection. The HPTN 067 study is conducted through the HIV Prevention Trials Network led by the National Institute of Allergy and Infectious Diseases (NIAID). An interagency agreement between the National Institute of Mental Health (NIMH) and the Centers for Disease Control and Prevention (CDC) supports the implementation of this international study at a clinical research site in Bangkok, Thailand. |
| Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Best Pharmaceuticals for Children Act (BPCA) Data Coordinating Center (DCC) is responsible for managing all aspects of BPCA clinical trials including developing trial design, collecting and analyzing trial data, monitoring data quality, conducting site monitoring, collecting and preparing safety reports, organizing and submitting documentation to the FDA, and managing the Data Monitoring Committee. |
| Best Pharmaceuticals for Children Act Working Group (BPCA) | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | This working group supports the goals of the Best Pharmaceuticals for Children Act (BPCA). The BPCA seeks to improve the level of information—in scientific publications and on the label—about pharmaceuticals used to treat children. The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations and publish a list of drugs/needs in pediatric therapeutics. https://bpca.nichd.nih.gov/prioritization/status/Documents/Priority_List_07082014.pdf |
| Big Data to Knowledge (BD2K) | Research Initiative | AHRQ, CMS, FDA, OS | OD/DPCPSI, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ORIP, OD/DPCPSI/ORWH, OD/DPCPSI/OSC | The Big Data to Knowledge (BD2K) program aims to facilitate broad use of biomedical big data, develop and disseminate analysis methods and software, enhance training for disciplines relevant for large-scale data analysis, and establish centers of excellence for biomedical big data. BD2K had held discussions with other HHS agencies who have shared interests in Big Data. In FY16, BD2K participated in a joint funding opportunity with the National Science Foundation (NSF) to support collaborations between biomedical researchers and data scientists on Quantiative Approaches to Biomedical Big Data (QuBBD). http://commonfund.nih.gov/bd2k/index |
| Biological Select Agents and Toxins Interagency Policy Committee (BSAT IPC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Coordinating group with senior level leadership from CDC, FDA, and NIH that discusses appropriate oversight of Select Agents and Toxins. |
| Biological Select Agents and Toxins sub-Interagency Policy Committee (BSAT Sub-IPC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Coordinating sub-group of FDA, CDC, and NIH staff that discuss the appropriate oversight of Select Agents and Toxins. This is a Subcomitte of the Biological Select Agents and Toxins Interagency Policy Committee (BSAT IPC) |
| Bioresource Development, Validation Tools, and Integrating High-Throughput Screening Technology Standards in Complementary and Alternative Medicine (CAM) Product Use in Children | Research Initiative | CDC, HRSA, SAMHSA | NCCIH, NICHD | Collaborative efforts between the FDA and NIH for substantiating health benefit claims for probiotics under Investigational New Drug Applications (INDs) were placed in the framework of U01 Cooperative Agreements that began in 2008. The successful evaluation of the initiative has recently developed into an invitation to develop a Memorandum of Understanding (MoU) to promote resource sharing and exchange of research expertise; development of demonstration project(s); and the initiation of trans-agency research initiatives focused on the integration of advanced molecular technologies that lead to harmonization standards and improved diagnostics for safety and substantiation of the health benefits of probiotic interventions. In 2011, a collaboration with FDA was initiated to expand the validation tool. In 2012, a Materials Transfer Agreement [MTA] was approved and the FDA received the entire data collection to undergo testing employing their novel microarray multi-loci sequence testing system [MLST]. |
| Blood Products Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | CC, NHLBI | The FDA Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility, and advises the Commissioner of Food and Drugs of its findings. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ |
| Blood, Organ, and Tissue Safety Committee (BOTSEC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | CC, NHLBI | The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from HHS organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the OASH Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director. https://www.hhs.gov/ohaidp/initiatives/blood-tissue-safety/blood-organ-and-tissue-senior-executive-council/index.html |
| Body Mass and Mortality Relationships | Research Initiative | CDC | NCI | This collaboration between CDC and NIH is a study of the relationships between categories of body mass and mortality in the U.S. population. http://epi.grants.cancer.gov/bmi/ |
| Botulism Guidelines Working Group | Committee, Work group, Advisory group, or Task Force | CDC | CC | The NIH Clinical Center is participating in a working group with CDC to develop clinical guidelines for treatment of botulism and use of botulism antitoxin. |
| Brain Attack Coalition | Committee, Work group, Advisory group, or Task Force | CDC | NINDS | The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke. http://www.brainattackcoalition.org |
| Breastfeeding and Human Lactation Research Scientific Interest Group (BALSIG) Special Interest Group | Other | FDA, OSG | NICHD, NCI, NIDDK, OD/DPCPSI/ORWH | In August 2012, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) formed a trans-U.S. Department of Health and Human Services (HHS) scientific interest group, Breastfeeding and Human Lactation Research Scientific Interest Group (BALSIG), to provide an intellectual platform for the scientists from HHS agencies interested in breastfeeding and human lactation research activities. http://www.surgeongeneral.gov/library/calls/breastfeeding/calltoactiontosupportbreastfeeding.pdf |
| Bridging Knowledge Gaps to Understand How Zika virus (ZIKV) Exposure and Infection Affect Child Development Workshop | Meeting/ Workshop | CDC, FDA, HRSA, OS | NICHD, FIC, NCI, NHGRI, NIAAA, NIAID, NIDCR, NIEHS, NIGMS, NIMH, NINDS, NINR | ZIKV is a growing, global epidemic. ZIKV has been associated with numerous birth and developmental defects, such as microcephaly, and other pregnancy and birth-related problems, including miscarriages, stillbirths, and other in utero complications. Because of these health issues, it is imperative that the scientific community understand the effects of ZIKV on pregnancy and pregnancy outcomes. The purpose of this workshop is to identify optimal approaches for treating and caring for the generation of children exposed to ZIKV in the womb. https://www.nichd.nih.gov/about/meetings/2016/Pages/092216.aspx |
| Burkholderia Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OS | NIAID | This interagency working group coordinates activities related to the Burkholderia research portfolios of NIAID, Biomedical Advanced Research and development Authority (BARDA), and Defense Threat Reduction Agency, and shares data related to the regulatory pathway of existing and novel medical countermeasures against melioidosis and glanders. |
| Cancer and Women''s Health Interagency Agreement | Research Initiative | FDA | NCI | This formal agreement establishes the framework and procedures to enhance collaborations and exchange of information between the FDA’s Office of Women’s Health (OWH) and the NCI’s Center to Reduce Cancer Health Disparities (CRCHD). Working together, FDA and NCI seek to increase scientific knowledge and understanding of cancer in women through targeted basic, clinical, bio-behavioral, translational, and community-based participatory research approaches/efforts. FDA and NCI both recognize the need for a unified approach to advancing scientific knowledge related to cancer and women’s health. This harmonized approach will aid in advancing the public health of all women through innovation in cancer research and medical therapies. |
| Cancer Control Plan, Link, Act, Network with Evidence-Based Tools (P.L.A.N.E.T) | Resource Development | AHRQ, CDC, SAMHSA | NCI | Cancer control planners, program staff, and researchers have the same goals: to reduce cancer risk, the number of new cancer cases, and the number of deaths from cancer, as well as enhance the quality of life for cancer survivors. While many share the same goals, all do not have easy access to resources that can facilitate the transfer of evidence-based research findings into practice. This Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network with Evidence-based Tools) portal provides access to data and resources that can help planners, program staff, and researchers to design, implement and evaluate evidence-based cancer control programs. http://ccplanet.cancer.gov/index.html |
| Cancer Moonshot Blue Ribbon Panel | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP, NCI | The Cancer Moonshot Blue Ribbon Panel led the efforts of seven working groups that developed recommendations to accelerate the pace of cancer research, so as to achieve a decade''s worth of progress in just five years. The panel and the working groups consisted of scientific experts from various fields that span academia, industry, government, and advocacy organizations. https://www.cancer.gov/brp |
| CDC and HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment (CHACHSPT) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR | The CDC / HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment shall advise the Secretary; the Director, CDC; and the Administrator and Associate Administrator for HIV/AIDS, and HRSA, regarding objectives, strategies, policies, and priorities for HIV and STD/hepatitis prevention and treatment efforts including surveillance of HIV infection, AIDS, STDs/hepatitis, and related behaviors; epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS and STDs/hepatitis; identification of policy issues related to HIV/STD/hepatitis professional education, patient healthcare delivery, and prevention services; agency policies about prevention of HIV/AIDS and other STDs, treatment, healthcare delivery, and research and training; strategic issues influencing the ability of CDC and HRSA to fulfill their missions of providing prevention and treatment services; programmatic efforts to prevent and treat HIV and STDs/hepatitis; and support to the agencies in their development of responses to emerging health needs related to HIV and other STDs/hepatitis. https://www.cdc.gov/maso/facm/facmchachspt.html |
| CDC Chronic Kidney Disease Surveillance | Health Survey | CDC | NIDDK | NIDDK assists CDC in its surveillance program of chronic kidney disease. http://nccd.cdc.gov/ckd/ |
| CDC Community Guide: Review Various Interventions to Reduce Alcohol-Related Problems | Resource Development | CDC, SAMHSA | NIAAA, NIDA | The Community Guide is a free resource to help people choose the most effective programs and policies to improve health and prevent disease in their communities. http://www.thecommunityguide.org/index.html |
| CDC Elimination of Pediatric HIV in US Stakeholders Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD, NIAID | The CDC Elimination of Pediatric HIV in US Stakeholders Group is a working group of federal and non-federal individuals to assist the CDC in developing initiatives to eliminate mother to child HIV transmission in the US. |
| CDC Malaria Study | Research Initiative | CDC | NIAID | This collaboration is pursuing the development of a safe and effective malaria vaccine. Current efforts include a Phase 1 clinical trial of a radiation-attenuated sporozoite vaccine for malaria. Malaria remains one of the most devastating diseases in the world, and a malaria vaccine that provides long-term protection is urgently needed to reduce mortality and eliminate transmission. |
| CDC-NIH Lyme Disease Serum Sample Repository | Resource Development | CDC, OS | NIAID | Initiated in 2008, this resource was made available to the scientific community on a broad basis in late 2011. Lyme disease and related serum samples are available upon request for testing and comparison of new and current diagnostic tests with a common serum sample set for standardization. Samples are distributed by the CDC. CDC and NIH both provided support to acquire the samples and continue to work together to ensure the scientific community has access to samples needed for Lyme disease diagnostic test development. |
| CDC/ National Center for Health Statistics (NCHS) Balance/Dizziness Problems | Health Survey | CDC | NIDCD | The purpose of this agreement is for NIDCD to provide financial support to the National Center for Health Statistics (NCHS) for the inclusion of Balance/Dizziness Supplements for a representative sample of US adults (age 18+ years) and children (age 3–17 years) in the 2016 National Health Interview Survey (NHIS). Previously, NIDCD negotiated an IAA with NCHS for collaboration and funding of the 2008 Adult Balance/Dizziness Supplement and the 2012 Child Balance/Dizziness Supplement to the NHIS. The current fiscal year funds will provide partial support for the renewal of this collaborative effort between NCHS and NIDCD to fund the 2016 Adult and Child Balance/Dizziness Supplements to the NHIS. The new NHIS Supplements will include many of the same questions on Balance/Dizziness included in the earlier 2008 and 2012 studies, although revisions have been made to eliminate some questions in order to include new ones that higher on the current priority list. These questions on the new Balance/Dizziness Supplements will assist NIDCD to make program planning decisions on priorities with respect to the funding of research on the prevention of falls related to dizziness and balance. The results will also be analyzed for use in tracking the Department of Health and Human Services’ (DHHS) objectives in Healthy People 2020. Results from this nationally-representative survey of the U.S. non-institutionalized, civilian population will help NIDCD make budget allocations to subject areas where needs are found to be most critical. http://www.cdc.gov/nchs/nhis.htm |
| CDC/ National Institute of Occupational Safety and Health (NIOSH) for Audiometric Support for 3 NIDCD-Sponsored, Population-Based Surveys | Health Survey | CDC | NIDCD | The purpose of this agreement is to provide funding for scientific and technical support as well as quality assurance of three large audiometric examination surveys funded by NIDCD. These health surveys are: (i) The National Health and Nutrition Examination Survey (NHANES), (ii) Age, Gene/Environment Susceptibility Study–Reykjavik Study (AGES–RS), and (iii) the Early Childhood Longitudinal Study – Kindergarten Class of 2010/2011 (ECLS–K:2010/2011). http://www.cdc.gov/niosh/ |
| CDC’s Division of Select Agents and Toxins (DSAT) Work Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The workgroup held biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the CDC’s manual “Biosafety in Microbiological and Biomedical Laboratories.” http://www.cdc.gov/phpr/dsat.htm |
| CDC’s Field Epidemiology Training Program (FELP) Cancer Curriculum | Training Initiative | CDC | NCI | CDC and NCI (Center for Global Health and Cancer Prevention Fellowship Program) are collaborating to add a cancer curriculum to CDC’s Field Epidemiology Training Program. https://www.tephinet.org |
| CDRH Retinal Devices Seminar: Focus on the Patient Experience with Inherited Retinal Degeneration | Meeting/ Workshop | FDA | NEI | A meeting with low-vision/blind patients at FDA to share perspectives regarding their experience living with retinal degenerations in order to enrich the knowledge of CDRH staff involved in the review of these devices. |
| Centers for Medicare and Medicare Services (CMS)- NIH Data Access Committee | Committee, Work group, Advisory group, or Task Force | CMS | NINR, CC, CSR, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/OSP | Observational studies based, in part, on available Centers for Medical and Medicare Services (CMS) data could generate important knowledge and policy relevant findings. NIH and CMS established a Data Access Committee to identify and pursue short and long term research priorities. Current initiatives include: implementation of an Inter-Agency Agreement wherein NIH directly purchases blanket access to CMS data from CMS, instead of paying grantees to access these data individually (which incurs high indirect cost rates for NIH); and convening quarterly meetings of the CMS-NIH Data Access Committee to discuss data policy and access issues. Future meetings may include presentations by NIH-funded investigators and in-house CMS data analyses. |
| Characterize Emerging HIV Strains from Blood Donors and Patients | Resource Development | FDA | NIAID | This initiative will characterize emerging HIV strains from blood donors and patients to determine viral tropism based on co-receptor usage strains. It will update the global viral panels to analyze multiple, diverse isolates from different parts of the world. This activity is part of NIAID’s ongoing efforts to develop a well-characterized repository for diagnostics, and drug and vaccine studies. https://eqapol.dhvi.duke.edu/ |
| Chemical Integrated Program Team (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD | This workgroup is a Public Health Energy Enterprise. The Chemical Integrated Program Team (IPT) working group provides an end-to-end vision of medical countermeasures needed for a particular threat type (e.g., anthrax, radiation/nuclear, etc.). The scope of their work includes setting requirements for the stockpiling of Medical Countermeasures (MCMs), MCM delivery, and dispensing and monitoring MCM development. The IPTs also advise the Enterprise Executive Committee as to threat- or capability-specific MCM priorities for improving preparedness, to inform leadership consideration of cross-threat prioritizations and strategic goal setting. |
| Chemical, Biologic, Radiologic, Nuclear and Explosive (CBRNE) Branch Subject Matter Advisory Resource Team (SMART) | Committee, Work group, Advisory group, or Task Force | OS | NICHD | The Subject Matter Advisory Resource Team (SMART) works to conduct analysis of response issues or problems in an unencumbered, academic environment to triage potential issues out or provide decision support when indicated. Participation is generally limited to facilitate rapid analysis and fluid discussion. Depending on the natural of any incident (e.g. Chem, Bio, Nuke/Rad, etc.), this list will be augmented and subject specific participants may be added or subtracted. https://wg.aspr.hhs.gov/aspr/hhscapabilities/resourcedocs/Chemical%20Biologic%20Radiologic%20Nuclear%20and%20Explosive%20Disaster%20Response%20and%20Recovery%20Resources.pdf |
| CHEMM (Chemical Hazards Emergency Medical Management) | Resource Development | ATSDR, CDC, OS | NLM, NICHD | This activity is to develop and maintain a comprehensive web resource and mobile app (in conjunction with the Wireless Information System for Emergency Responders [WISER]). Chemical Hazards Emergency Medical Management (CHEMM) is a tool designed to provide access to comprehensive sets of information about chemical hazards and emergency medical management via a user-friendly interface. https://chemm.nlm.nih.gov |
| Chronic Fatigue Syndrome Advisory Committee (CFSAC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | NINDS, CSR, NCATS, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIEHS, NIMH, NINR, NLM, OD/DPCPSI/OBSSR | The Chronic Fatigue Syndrome Advisory Committee (CFSAC) provides advice and recommendations to the Secretary of Health and Human Services via the Assistant Secretary for Health of the U.S. Department of Health and Human Services on issues related to myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS). These include: 1) factors affecting access and care for persons with ME/CFS; 2) the science and definition of ME/CFS; and 3) broader public health, clinical, research and educational issues related to ME/CFS. http://www.hhs.gov/advcomcfs/ |
| Clinical and Translational Research Course for PhD Students | Training Initiative | FDA | CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NINDS | The Clinical and Translational Research Course for Ph.D. Students is a two-week intensive introductory course for graduate students in the basic biomedical sciences who have at least one year of graduate study. The purpose of the course is to demonstrate and highlight the roles of PhD scientists in clinical and translational research, to provide an overview and examples of how basic science and clinical observations lead to translational research, and to increase awareness and access to Ph.D. role models, research resources, and potential career opportunities at the NIH. http://www.cc.nih.gov/training/phdcourse |
| Clinical Decision Support (CDS) Federal Collaboratory and Inventory of Federal Clinical Decision Support Activities | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, HRSA, IHS, OS | NLM, CC | A federal community of interest focused on clinical decision support (CDS), and a compilation of project summaries describing CDS activities that are either funded by the US Federal government, or that are being executed by agencies of the government. CDS encompasses a variety of tools and technologies that are used within electronic clinical information systems to improve the quality, safety, efficiency and effectiveness of patient care. CDS provides clinicians, staff, patients, and other key decision makers with knowledge and person-specific information, intelligently filtered at appropriate times, to enhance health and health care. CDS encompasses computerized alerts and reminders, clinical guidelines, order sets, order entry feedback, patient data reports and dashboards, documentation templates, diagnostic support, and the presentation of contextually relevant reference information within clinical information systems. NLM has submitted to the Collaboratory and Inventory summaries of NLM projects involving Clinical Decision Support. https://www.healthit.gov/policy-researchers-implementers/cds-activities |
| Clinical Intervention to Help Pregnant Women Quit Smoking in the US | Research Initiative | CDC | NICHD | The purpose of this Interdepartmental Delegations Authority (DDA) activity is to support a study to further understanding of an effective clinical intervention to help pregnant women quit smoking in the US. |
| Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | This working group discusses a range of issues relevant to the development of antiviral drugs for the treatment of influenza. |
| Clinical Islet Transplantation Consortium | Research Initiative | CMS, FDA | NIDDK, NIAID | The Clinical Islet Transplantation (CIT) Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in people with type 1 diabetes. Studies conducted by the CIT Consortium will focus on improving the safety and long-term success of methods for transplanting islets, the insulin-producing cells of the pancreas, in people whose own islets have been destroyed by the autoimmune process that characterizes type 1 diabetes. One clinical trial, in particular, is studying the efficacy of islet transplantation after kidney transplantation. Participants may include Medicare beneficiaries. This study was mandated in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. http://www.citisletstudy.org |
| Clinical Research Using Medicare Data from the Virtual Research Data Center (VRDC) | Research Initiative | CMS | NLM | NLM is working with CMS and other NIH ICs to demonstrate the value of the CMS Virtual Research Data Center (VRDC) as a source of Big Data. https://www.resdac.org/cms-data/request/cms-virtual-research-data-center |
| Clinical Trial Designs for Emerging Infectious Diseases | Meeting/ Workshop | CDC, FDA | NIAID | This workshop was hosted by the FDA in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), and the CDC.This workshop explored the ethical and methodological assumptions behind the choice of different trial designs, described different types of emerging infectious diseases of concern, and then explored several clinical trial designs for both vaccines and therapeutic products. Participants discussed the scientific, ethical, and practical issues considered in the choice of specific trial designs, and the generalizability of these designs for other types of emerging infectious diseases. http://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/AboutMCMi/ucm466153.htm |
| Clinical Utilization Plan for Anthrax Medical Countermeasure Use in a Mass Casualty Event (CUPAC) Medical Countermeasures Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | CC | The NIH Clinical Center is participating as a member of the Medical Countermeasures Work Group to provide clinical algorithms that will assist clinicians to evaluate, triage, diagnose and treat large number of patients presenting with symptoms of anthrax. It will also provide a clinical prioritization schema for the use of medical countermeasures specific to anthrax and outline unique critical care issues that may require special consideration. |
| Clinical Vocabulary and Standards Development for Meaningful Use of Electronic Medical Records | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, OS | NLM | NLM is collaborating with OS and HHS Office of the National Coordinator for Health Information Technology (ONC) on developing and disseminating regulatory language related to health information technology, meaningful use, and standards and certification criteria related to electronic health records and messaging. Collaboration includes serving as members of the Content Standards Workgroup, and Semantic Standards Workgroup of the Health IT (HIT) Standards Committee. The HIT Standards Committee is a Federal advisory committee that was created by the Health Information Technology for Economic and Clinical Health (HITECH) Act to provide input to HHS on the policies and technologies needed to improve health and care. http://www.nlm.nih.gov/healthit.html |
| ClinicalTrials.gov | Resource Development | FDA | NLM, CC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/OER, OD/OSP | ClinicalTrials.gov is an NLM-operated database containing summary protocol and results information from publicly and privately funded clinical research. As of December 2016, the database included summary protocol information on more than 230,000 clinical studies conducted in over 195 countries, with nearly 24,000 records displaying summary results. NLM originally collaborated with FDA on implementing Section 113 of the Food and Drug Administration Modernization Act of 1997. It subsequently collaborated with FDA and NIH OD to implement the statutory requirements of Section 801 of the Food and Drug Administration Amendments Act of 2007 through rulemaking. The final rule (42 CFR Part 11) was issued in September 2016. NLM is currently collaborating with FDA and other parts of NIH to implement the regulatory requirements of 42 CFR Part 11. https://www.clinicaltrials.gov/ |
| CMS End-stage Renal Disease (ESRD) Affinity Group | Committee, Work group, Advisory group, or Task Force | CMS | NIDDK | CMS has established a number of affinity groups to focus groups of individuals interested in and working on particular topics -- in this case, end-stage renal disease (ESRD). NIDDK Program staff have participated in meetings, bringing domain expertise and perspectives on current research findings. |
| CMS-FDA-NIH Trilateral Council | Committee, Work group, Advisory group, or Task Force | CMS, FDA | OD/OSP, NIA, OD/OER | The CMS-FDA-NIH Trilateral Council provides a forum for agency leaders to discuss policy issues, programs, and research initiatives of mutual interest and determine appropriate interfaces and collaborations that may inform NIH-funded research, FDA guidance and regulations, and CMS policies and programs. The Council formed in April 2016 and meets at the request of the Chairs: the NIH Director, FDA Commissioner, and CMS Administrator. |
| CMS-NIH Senior Leadership Council | Committee, Work group, Advisory group, or Task Force | CMS | OD/OSP, NIA, OD/OER | The CMS-NIH Senior Leadership Council provides a forum for agency leaders to discuss policy issues, programs, and research initiatives of mutual interest and determine appropriate interfaces and collaborations that may inform NIH-funded research and CMS policies and programs. The Leadership Council is co-chaired by the NIH Director and CMS Administrator, and meets at the request of the Chairs. |
| CMS/CDC/FDA/NIH Opioid Abuse Collaboration | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NIA, NIDA, NINDS | The purpose of this collaboration is to discuss agency activities surrounding the HHS Secretary’s opioid abuse initiatives. |
| Collaboration With Indian Health Service Institutional Review Board (IRB) In Training IRB Interns From Native Communities | Committee, Work group, Advisory group, or Task Force | IHS | CC, NHGRI | The Clinical Center’s Department of Bioethics, in collaboration with NHGRI, piloted an Institutional Review Board (IRB) internship program for Native Americans. http://www.ihs.gov/Research/index.cfm?module=hrpp_about |
| Collaborative Islet Transplant Registry Ad Hoc Scientific Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NIAID | This Advisory Committee provides scientific direction to the Collaborative Islet Transplant Registry on an ad hoc basis. |
| Collaborative on Healthy Parenting in Primary Care | Committee, Work group, Advisory group, or Task Force | CDC, SAMHSA | NICHD | The Collaborative on Healthy Parenting in Primary Care recognizes the accumulated evidence of the effectiveness of family-focused prevention programs that promote the physical and behavioral health and emotional well-being of children from before their birth through adolescence. Members of this collaborative have united around an initiative to support the integration of effective programs that promote healthy parenting into primary care settings in order to achieve optimal health for children. |
| Collaborative Use Repurposing Engine (CURE) | Research Initiative | FDA | NCATS | CURE is a new tool designed to centrally capture and organize real-world information about how healthcare practitioners use existing drugs in novel ways to treat patients with neglected tropical diseases (NTDs), emerging infections and drug-resistant infections when treatment options are limited or inadequate. It is currently publicly available in “beta” as an open-access website that enables healthcare practitioners throughout the world to contribute to the database by using a simple online form, a smartphone or other mobile device. In addition to submitting their own case reports, practitioners are also able to query and retrieve information from the database. Neglected Tropical Diseases (NTDs) are a group of parasitic and bacterial diseases that cause substantial illness for more than one billion people globally. Patients with NTDs, emerging or drug-resistant infections may lack adequate treatment options due to the limited number of drugs approved for these conditions. Out of necessity, healthcare practitioners try to use existing drugs in novel ways to treat these patients. At present, much of this clinical experience, regardless of whether the patient outcomes are positive or negative, is never reported or shared, and the knowledge is therefore lost. https://www.hhs.gov/idealab/projects-item/collaborative-use-repurposing-engine/ |
| Common Data Elements (CDE) for Patient-Centered Outcomes Research | Resource Development | OS | NLM, CC, CIT, NCATS, NCI, NEI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NIMH, NINDS, NINR, OD/OER | Led by NLM, a Task Force of the NIH Scientific Data Council and others are working to promote the use of common data elements in research, surveillance, and patient registries to facilitate data sharing and reuse. Work to date has produced a portal of NIH projects that use Common Data Elements (CDEs) and, with the assistance of funding to develop data infrastructure to promote patient-centered outcomes research (OS Patient-Centered Outcomes Research Trust Fund), will contribute to development of a search, retrieval, and repository mechanism that will support and reflect the standards work of the Standards & Interoperability (S&I) Framework Structured Data Capture Initiative. This project contributes to efforts to develop a repository and search tool for identification of CDEs for Patient-Centered Outcomes Research. Initially formed as a work-group of the Trans-NIH BioMedical Informatics Coordinating Committee (BMIC), and changed to SDC Task Force in 2016. https://www.nlm.nih.gov/cde/ |
| Community Guide Screen Time Team | Meeting/ Workshop | CDC | NHLBI | The goal of the workshop was to review the evidence related to screen time and its effects on obesity and health behaviors of youth. In 2016, a review was published: Reducing Recreational Sedentary Screen Time: A Community Guide Systematic Review. https://www.thecommunityguide.org/findings/obesity-behavioral-interventions-aim-reduce-recreational-sedentary-screen-time-among |
| Community Preventive Services Task Force (CPSTF) | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/ODP, OD/DPCPSI | The Community Preventive Services Task Force (CPSTF) is an independent, non-federal panel of prevention experts that conducts rigorous systematic reviews and provides public health recommendations to the CDC to inform decision-making about policy, practice, and research priorities for community preventive services. Recommendations from the CPSTF are published in The Guide to Community Preventive Services. The ODP represents NIH as an official liaison member and works with the CDC and CPSTF members to ensure that recommendations represent the views, concerns, and needs of the NIH and our constituents. ODP staff also serve on, or recommend NIH scientist to serve on, systematic review teams, and help translate CPSTF recommendations into actions. http://www.thecommunityguide.org |
| Computational Toxicology for NIH Medications Discovery | Research Initiative | FDA | NIDA | Through an inter-agency agreement, the FDA provides structure-activity, relationship-based toxicity predictions for compounds that are under evaluation in the NIDA Addiction Treatment Discovery Program. On a limited basis, other NIH ICs may utilize this resource by working through NIDA. |
| Computer-aided Diagnosis for Radiology Images | Research Initiative | FDA | CC | The collaboration focuses on the improvement of computer-aided diagnosis for radiology images. Specific applications include computer-aided polyp detection for CT colonography, improvements in the conduct and analysis of observer performance experiments using radiology images and the use and development of advanced machine learning and receiver operating characteristics methods with application to computer-aided diagnosis. |
| Conducting Comprehensive Toxicological Assessments | Research Initiative | FDA | NIEHS | The purpose of this Agreement is to conduct, at FDA/NCTR, comprehensive toxicological assessments on FDA priority chemicals/agents nominated to the National Toxicology Program. Studies can include range finding sub-chronic and chronic, compound-specific mechanistic studies, and consideration of the use of alternate test systems. This combination of studies is designed to facilitate the interpretation of study results in support of comprehensive quantitative human health risk assessments. The primary goal of this program is to develop a comprehensive scientific data base that can be utilized to reduce the uncertainty in risk assessment/risk benefit analysis for specific chemicals with high FDA impact. |
| Congenital Heart Public Health Consortium | Resource Development | AHRQ, CDC | NHLBI | The Congenital Heart Public Health Consortium (CHPHC) is a group of organizations uniting resources and efforts in public health activities. The mission of the CHPHC is to prevent congenital heart defects and improve outcomes for affected children and adults. The consortium achieves its mission by providing leadership and a unified voice for public health priorities, expanding opportunities for surveillance and public health research, and informing public policy priorities that benefit public health and affected persons. The CHPHC represents various federal, state, and community organizations, including those representing patient/family, clinical, and research interests. It is pooling expertise and experience and using a public health model to address Congenital Heart Disease (CHD) issues across the lifespan. https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/chphc/Pages/default.aspx |
| Consensus-Based Entity (CBE) Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA | NLM | The Consensus-Based Entity (CBE) Committee is a HHS-wide entity, chaired by ASPE, to provide oversight and input into the execution of ASPE’s legislation-mandated contract with the National Quality Forum (the Consensus-Based Entity) for establishing quality and performance measures. NLM participates as an invited member. |
| Consortium for TB Biomarkers (CTB2) | Resource Development | FDA | NIAID | The Consortium for TB Biomarkers (CTB2) seeks to establish a robust biorepository of well-documented clinical specimens to support the discovery and qualification of biomarkers of TB drug effect, especially surrogate markers for stable cure vs. relapse, and to facilitate development of rapid, reliable TB diagnostics, including tests for drug-susceptibility that would be practical for use in resource poor settings. |
| Contact Lens Safety Campaign | Public Education Campaign | CDC | NEI | The NEI helped CDC disseminate contact lens safety information via social media during its spring break campaign in March. Additionally, NEI added CDC resources to its Pinterest page. https://www.pinterest.com/neinih/contact-lens-safety |
| Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee | Committee, Work group, Advisory group, or Task Force | OS | NLM | The Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to ONC on standards, implementation specifications, and certification criteria for the electronic exchange and use of health information. http://www.healthit.gov/facas/health-it-standards-committee/hitsc-workgroups/content-standards-workgroup |
| Council on Emergency Medical Care | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, OS, SAMHSA | NIMH, NCATS, NHLBI, NICHD, NIGMS, NINDS, NLM | The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policy makers in emergency medical care from organizations across the Federal Government. The CEMC contributes to the development, advancement, and coordination of federal strategies, policies, and priorities relating to emergency medical care to improve the nation’s emergency care system. |
| Countering Biothreats IPC on Gene Editing and Synthesis (CBT IPC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | Coordinating group comprised of senior-level leadership from NIH, CDC, and OS that discuss policy options related to gene editing and synthesis. |
| Countering Biothreats sub-IPC on Gene Editing and Synthesis (CBT sub-IPC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | Coordinating group of staff from NIH, OS, and CDC that discuss policy options related to gene editing and synthesis. This sub-IPC supprts the Countering Biothreats IPC on Gene Editing and Synthesis (CBT IPC) group. |
| Countermeasures Against Chemical Threats (CounterACT) Research Network | Research Initiative | CDC, FDA, OS | NINDS, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NLM | The CounterACT program is a translational research program supporting basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic medical countermeasures and/or diagnostic technologies against chemical threat agents, and facilitates their movement through the regulatory process in collaboration with other federal departments and agencies, such as the Biomedical Advanced Research and Development Authority (HHS BARDA). The program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense. Among other activities, NINDS organizes an annual meeting of investigators supported by the program allowing researchers to share information, encourage collaboration, and enable NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard. |
| Country Work in Cancer Research and Cancer Control Planning Strengthening – Kenya | Other | CDC | NCI, FIC, NIAID | Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M. USAID invested $700 million in Kenya in FY2011. At least 6 NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment, to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH), in partnership with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. |
| Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone, National Hormone and Pituitary Program (NHPP) | Resource Development | CDC, FDA | NIDDK | From 1963 to 1985, the National Hormone and Pituitary Program (NHPP), funded by the U.S. Department of Health and Human Services (HHS), sent Human Growth Hormone (HGH) made from human pituitary glands to hundreds of doctors across the country. As a part of research studies, doctors used the hormone to treat nearly 7,700 children for failure to grow. In 1985, the HHS learned that three people treated with pituitary HGH died of Creutzfeldt-Jakob Disease (CJD), a rare, incurable brain disease. The HHS immediately stopped distributing the hormone and began a national study to learn more about how pituitary HGH treatment may have caused this problem. http://www.niddk.nih.gov/health-information/health-topics/endocrine/national-hormone-pituitary-program/Pages/national-hormone-pituitary-program-comprehensive-report.aspx |
| Critical Path to Tuberculosis (TB) Drug Regimens (CPTR) Rapid Drug Sensitivity Testing (DST) Consortium | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The purpose of the Critical Path to Tuberculosis (TB) Drug Regimens (CPTR) Rapid Drug Sensitivity Testing (DST) Consortium is to support and sustain discussion, share information, and to coordinate clinical trials of new TB drug combinations. The overall goal is to rapidly advance new cost-effective therapies while maintaining the highest standards of scientific rigor. The Consortium will work to coordinate planning among the major non-commercial sponsors and their research groups to ensure rapid and efficient Phase II evaluations of drug combinations. |
| Cross Agency Priority Goals-Service Members and Veterans Mental Health | Committee, Work group, Advisory group, or Task Force | OS | NIMH | In 2014, the White House and the Office of Management and Budget created a Cross Agency Priority Goal to improve mental health outcomes for Service Members, Veterans, and their families. The Domestic Policy Council, National Security Council, and Departments of Veterans Affairs (VA), Defense (DoD), and Health and Human Services (HHS) led and synchronized activities across agencies to improve access to care and support research. NIH, VA, and DoD are supporting research that will standardize and integrate measurements for traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and suicide prevention research funded by the agencies. Building on the foundation of common data elements for PTSD and suicide prevention research, efforts are underway to accelerate progress through data sharing, data harmonization, and the reporting of research results. The workgroup is tasked to develop and test suicide risk assessments and suicide prevention and treatment interventions for Service Members and Veterans. The agencies meet weekly and report quarterly on progress. . https://www.performance.gov/node/3405/view?view=public |
| DailyMed | Resource Development | FDA | NLM | DailyMed provides high quality information about marketed drugs, including FDA labels (package inserts). The Web site provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. NLM provides this DailyMed as a public service, free of advertising. http://www.dailymed.nlm.nih.gov |
| Data Access for Grantees | Resource Development | CMS | NIA | NIA has an Inter-Agency Agreement (IAA) to assist grantees with accessing Centers for Medicare & Medicaid Services (CMS) data. It is anticipated that this initiative will create a more user friendly and more cost efficient means for grantees to access CMS data especially the need to access Part D data. Specifically, this agrement gives CMS''s Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use. This includes activities for remote access data enclave. |
| Demand Reduction Interagency Working Groups | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS, SAMHSA | NIAAA, NIDA | These working groups aim to prevent substance abuse and related negative consequences by implementing a prevention framework to serve as a foundation for collaboration among Federal agencies in the development of joint initiatives that serve States and communities across the Nation. |
| Department of Defense Resuscitation and Transfusion Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee oversees DoD research in resuscitation and transfusion. |
| Developing Clinical Vocabulary Standards for Public Health Reporting | Resource Development | CDC | NLM | This collaboration between NLM and CDC is to develop Logical Observation Identifiers Names and Codes (LOINC) for use in public health reporting, including tumor registry reporting and reportable disease reporting. https://phinvads.cdc.gov/vads/SearchVocab.action |
| Development and Use of a Non-human Primate Model of Pertussis Disease and Transmission | Research Initiative | FDA | NIAID | NIH has been working with the FDA towards the development and use of a non-human primate model of pertussis disease and transmission. |
| DHHS Health Care Personnel Influenza Vaccination Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee is charged with developing strategies to increase the number of healthcare professionals who are vaccinated with the influenza vaccine. http://www.hhs.gov/ash/initiatives/hai/hcpflu.html |
| DHHS Healthcare Infection Control Practices Advisory Committee (HICPAC) | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee serves as the major policy advisory committee in the nation for healthcare epidemiology. |
| DHHS Medical Claims Review Panel | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | CC | The MCRP assists the DHHS in meeting its responsibility to provide quality health care in its facilities and by its practitioners. The MCRP reviews paid claims against DHHS facilities and providers to determine if the care provided met the standard of care and makes quality improvement recommendations to health care facilities and individual providers. The Panel meets monthly and includes two NIH representatives; the current Chair of the Panel is a NIH physician. |
| DHHS Steering Committee for the Prevention of Healthcare-Associated Infections | Committee, Work group, Advisory group, or Task Force | OS | CC | This steering committee is charged with developing a national action plan for addressing the important problem of healthcare-associated infections. https://health.gov/hcq/prevent-hai-action-plan.asp |
| Diabetes Mellitus Interagency Coordinating Committee (DMICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, IHS, OS | NIDDK, CSR, NCATS, NCCIH, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The DMICC facilitates cooperation, communication, and collaboration on diabetes among the participating government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate. http://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee/Pages/background.aspx |
| Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS) | Research Initiative | CDC, IHS | NIDDK, NCATS, NCI, NCMHD, NEI, NHLBI, NIA, NICHD | The Diabetes Prevention Program (DPP) showed that lifestyle change or metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP. https://dppos.bsc.gwu.edu/web/dppos/about |
| Diabetic Eye Disease Information Dissemination | Public Education Campaign | CDC | NEI | CDC''s National Diabetes Education Program is part of the National Eye Health Education Program Partnership. This past year, NEI and CDC worked outlets and conference calls, and circulated information in phConnect and among each other''s stakeholder groups. |
| Diabetic Retinopathy Clinical Research Network | Research Initiative | OS | NEI, NIDDK | The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the NEI, and co-funded by OS, through NIDDK, with the Special Funding Program for Type 1 Diabetes Research. http://drcrnet.jaeb.org/ViewPage.aspx?PageName=Home |
| Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population | Research Initiative | CMS | CC | Centers for Medicare and Medicaid Services (CMS) and NIH CC Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research, the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to the NIH Clinical Center, which will perform analyses that are agreed to by both parties. |
| Diet-Induced Hypomethylation in Preneoplastic Liver | Research Initiative | FDA | NCI | The Food and Drug Administration (FDA) National Center for Toxicological Research and the National Cancer Institute (NCI) Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that predetermine individual susceptibility to development of hepatocellular carcinoma and to provide evidence that epigenetic alterations may be used as markers of susceptibility to disease development and correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. |
| Dietary Supplements Ingredient Database (DSID) | Research Initiative | CDC, FDA | OD/DPCPSI/ODP, NCI, NHLBI, NIDDK, OD/DPCPSI/ODS | The NIH Office of Dietary Supplements (ODS) leads this program, which provides a database of basic information about the nutrient content of selected ingredients in dietary supplements, compared to label-reported ingredient levels. ODS, with collaboration from USDA, develops and maintains this database of statistical estimates—based on chemical analysis—of the nutrient content of selected ingredients in dietary supplements, compared with label-reported ingredient levels. Currently the Dietary Supplements Ingredient Database (DSID) provides estimated levels of 18 vitamin and mineral ingredients derived from analytical data for 115 representative unspecified adult multivitamin/multimineral supplements (MVMs). Additional dietary supplement ingredients will be included in future releases of the database. https://dietarysupplementdatabase.usda.nih.gov/ |
| Dietary Supplements Label Database (DSLD) | Resource Development | CDC, FDA | OD/DPCPSI/ODP, NLM, OD/DPCPSI/ODS | In response to congressional mandate, the NIH Office of Dietary Supplement (ODS), in collaboration with the National Library of Medicine, takes the lead on the development and maintenance of the DSLD. The database now contains over 65,000 labels, with new data accumulating at the rate of 1,000 labels per month. The DSLD will grow to include nearly all of the dietary supplement products in the U.S. All labels are verified yearly to ensure that they remain current. The DSLD provides product information that can be organized and searched by users. The primary users of this database are researchers who use the DSLD to help determine total nutrient intakes from food and supplements in populations they study. Health care providers use it to find the content of products their patients are taking. https://www.dsld.nlm.nih.gov/dsld/index.jsp |
| Digital Quantitation of Plasma Cells in Marrow Biopsies | Research Initiative | FDA | CC | This project is a collaboration between the NIH Clinical Center and the FDA that consists of developing software and establishing validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis and therapy monitoring of marrow disorders. |
| Disaster Research Response Project | Research Initiative | ATSDR, CDC, FDA, OS | NIEHS, NLM | The NIH Disaster Research Response (DR2) Project is a pilot project aimed at creating an environmental health disaster research system through platforms of ready-to-go research data collection tools and a network of specially trained research responders. This project was developed and will be administered by the NIEHS and NLM. Elements of the system include epidemiologic questionnaires and clinical protocols, specially trained disaster researchers, environmental health disaster research networks, a reach-back roster of subject matter experts, and a support infrastructure that can be activated and deployed during public health emergencies and declared disasters. This effort will not only serve as a model for enhancing environmental health research responses, but will also provide invaluable lessons and platforms for others interested in advancing timely post-disaster research activities. http://disasterinfo.nlm.nih.gov/ |
| Dominantly Inherited Alzheimer''s Network (DIAN): International Network for the Identification, Evaluation, and Follow up of Families with Early Onset of Dominantly Inherited Alzheimer''s Disease | Research Initiative | FDA | NIA | This collaboration aims to set up an international network consisting of a consortium of scientific investigators that will have the responsibility to identify, recruit, evaluate, and follow-up individuals from families with early onset dominantly inherited Alzheimer’s Disease [i.e., families with the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations or duplications or others still to be discovered]. http://www.dian-info.org/ |
| Drug Induced Liver Injury Network (DILIN) | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK | Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of FDA serve as ad hoc members on the committee overseeing the network activities. http://www.dilin.org/ |
| Early Hearing Detection and Intervention | Meeting/ Workshop | CDC | NIDCD | This collaboration focuses on a teleconference sponsored by CDC. http://www.cdc.gov/ncbddd/hearingloss/index.html |
| Early Learning Interagency Policy Board (IPB) | Committee, Work group, Advisory group, or Task Force | ACF | NICHD, NIDA | The purpose of this workgroup is to collaborate with the Administration for Children and Families (ACF) in order to coordinate efforts in the area of preschool education, including research. |
| East Asia Viral Hepatitis and Liver Cancer Consortium | Other | CDC | NCI, NIAID, NIDDK | The consortium aims to coordinate and share human, financial, and technical resources to effectively and efficiently address research and public health action needs in the prevention and control of viral hepatitis and liver cancer. This is a trans-HHS collaboration working with the World Health Organization Western Pacific Region Office WHO/WPRO and Ministries of Health of several partner countries. |
| Ebola Clinical Research Response in West Africa | Research Initiative | CDC, FDA | NIAID | This is a research collaboration between FDA, NIH, and CDC to respond to the Ebola emergency in West Africa. |
| Electronic Research Administration (eRA) | Resource Development | AHRQ, CDC, FDA, SAMHSA | NINR, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/OER | The Electronic Research Administration (eRA) provides information technology solutions and support for the full life cycle of grants administration functions for the NIH as well as the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Veterans Health Administration (VHA). eRA offers vital solutions to manage the receipt, processing, review, award and monitoring of over $30 billion in research and non¬research grants awarded annually by NIH and other grantor agencies in support of the collective mission of improving human health. eRA helps NIH meet a vital mission: the support of cutting¬ edge biomedical research via grants to scientists at universities and other research institutions. Over 4,100 NIH staff, 729 partner agency staff, and 171,083 active external users depend on eRA daily. Used by Federal staff and applicants at over 28,400 research institutions worldwide, eRA has helped eliminate the hundreds of millions of pieces of paper previously required to: • Record, review and process over 89,600 applications each year. • Support more than 3,960 review meetings held annually. • Administer more than 61,200 awarded competing and non¬competing grants. • Maintain patent and invention records for 32 Federal agencies (see the iEdison website). • Support thousands of applicant interactions with the Federal Government before and after the grant award, through the eRA online interface. eRA''s focus is on supporting the mission of serviced agencies by providing tools to electronically manage and report on grants in a way that maximizes efficiencies, provides a strong and scalable infrastructure, is responsive to evolving customer needs and employs sound management controls. eRA systems align with Grants.gov (the one¬ stop web portal for finding and applying for federal grants), allowing for full electronic processing of grant applications from application submission through closeout of the grant award and reporting thereafter. eRA operates as a fee for service activity to OPDivs and other federal agencies. http://era.nih.gov/ |
| Emergency Care Research Interagency Program Officer Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, FIC, NCI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NIDDK, NIGMS, NIMH, NINDS, NLM | This working group aims to share common challenges in conducting emergency care research; identify innovative solutions amongst the projects in NIH Institutes/Centers portfolios for common problems; discuss performance evaluation of emergency care networks; and discuss models for funding and evaluating data coordinating centers. https://www.nigms.nih.gov/About/Overview/OECR/Pages/NIH_emergencygroup.aspx |
| Emergency Preparedness, Medical Countermeasures | Resource Development | OS | NCI | NCI provides expertise in radiation biology and radiation oncology to help guide the research and development for medical countermeasures for radiation injury and for biomarkers for assessing injury, dose and who needs treatment. http://www.phe.gov/about/barda/Pages/default.aspx |
| End-stage Renal Disease (ESRD) Collaboration | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIDDK, NIBIB | Participating agencies and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed on phone calls and structured meetings. |
| Endocrinologic and Metabolic Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/default.htm |
| Enhanced NIH Reporting on Research Spending | Resource Development | CDC | OD/OSP, OD/OER | In early 2016, in response to a Congressional request from the FY16 Omnibus budget, NIH collaborated with the National Center for Health Statistics (NCHS) at the CDC to post federally sourced data on prevalence, from the National Health Interview Survey, and mortality, from the National Vital Statistics system, leveraging NCHS expertise to match these data sources to disease categories for which NIH reports spending totals. NIH intends to update these data on an annual basis, in regular consultation with NCHS, in order to maintain as accurate and comprehensive a dataset as possible. These data are posted alongside the RCDC spending categories on the NIH RePORT web site. NIH provided mortality data for 103 RCDC categories, and prevalence for 36, out of 265 total RCDC categories. https://report.nih.gov/categorical_spending.aspx |
| Ethical, Legal and Social Issues (ELSI) Sub-study in the Biospecimen Pre-Analytical Variables (BPV) Project | Research Initiative | OS | NCI, CC | Pre-Analytical Variables (BPV) Ethical Legal and Social Implications (ELSI) Substudy is a study of the ethical, legal and social implications related to the informed consent process for biobanking. The ELSI study is designed to address current issues related to informed consent for biobanking, particularly the issues of consent for broad future research use and return of research results. The objective of the ELSI Substudy is to assess research participant comprehension and concerns related to informed consent and data sharing for biobanking across the diverse patient populations included in the BPV program. The intent of this evaluation is to improve our understanding of the issues that impact donor participation in such programs and to identify factors that may result in decreased rates of donor participation. This study provides a unique and unprecedented opportunity to address these issues in a diverse patient population of actual biospecimen contributors approached for consent using a highly harmonized informed consent document. Each Biospecimen Source Site collecting tumor tissue from surgical procedures is participating in the ELSI study. To date, several hundred interviews with BPV participants have been submitted for analysis. Data collection concluded in May of 2015 and data analysis is in progress. |
| European-US Pediatric Formulations Excipients Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | Multinational academic, industry, and regulatory group convened to determine toxicity of excipients in pediatrics. Accomplishments include developing a database that is tested both in the EU and US. |
| Evaluation of Patient Reported Outcomes Following LASIK Surgery | Research Initiative | FDA | NEI | In October 2009, the FDA, the National Eye Institute (NEI), and the Department of Defense (DoD) launched the LASIK Quality of Life Collaboration Project (LQOLCP) to help better understand the potential risk of severe problems that can result from LASIK. The project published three manuscripts in 2016 on the new questionnaire developed by the group that can be used to assess the percent of patients who develop difficulties performing their usual activities following LASIK, and to identify predictors for those patients. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupport/LASIK/ucm190291.htm |
| Evaluation of the Association between Maté Consumption and urinary PAH in Brazil | Research Initiative | CDC | NCI | This collaboration between CDC and NCI will measure metabolites of polycyclic aromatc hydrocarbons (PAHs) in the urine samples from individuals with different amounts of daily maté drinking. |
| Evidence-Based Review & Report Program | Resource Development | AHRQ | OD/DPCPSI/ODP, NCCIH, OD/DPCPSI/ODS | This Congressionally mandated NIH Office of Dietary Supplements program reviews current scientific evidence on the efficacy and safety of dietary supplements; identifies research needs; and prepares reports of their findings. http://ods.od.nih.gov/Research/Evidence-Based_Review_Program.aspx |
| Exposure Science in the 21st Century (ES21) Working Group | Research Initiative | CDC, FDA | NIEHS, NCI | ES21 is a working group chartered by the Toxics and Risk subcommittee of the OSTP Committee on Environment, Natural Resources, and Sustainability. The group focuses on coordinating efforts to advance exposure science through research and development. The primary emphasis is on information sharing and cataloging federal activities on biomonitoring, community engagement, data management, environmental monitoring, modeling and the development of sensors and dosimeters. https://www.epa.gov/innovation/exposure-science-21st-century-federal-working-group |
| Extracellular Ribonucleic Acid (RNA) Communication | Research Initiative | FDA | OD/DPCPSI, NCATS, OD/DPCPSI/OSC | Recent advances have indicated that ribonucleic acids (RNAs) can play a role in a variety of complex cellular functions, including newly discovered mechanisms of cell-to-cell communication. RNA can be exported from cells in extracellular vesicles or bound to lipids or proteins, to circulate through the body and affect cells at a distance. However, the actual impact of the extracellular RNAs, or exRNAs, is currently unknown. NIH and FDA have coordinated efforts on the preclinical and clinical use of exRNAs to address human health and disease. To date, several PIs have had pre-pre-IND meetings with FDA/CBER. They have been provided information necessary to submit applications, for example a biomarkers device. http://commonfund.nih.gov/Exrna/index |
| Extracting Adverse Reactions and Indexing the Content of Structured Product Labels (SPLs) | Resource Development | FDA | NLM | The objective of this initiative is for NLM to assist the U.S. Food and Drug Administration (FDA) in indexing the content of structured product labels (SPL) for drugs. Natural language processing technology is used to extract drug-drug interaction information from SPLs which will be validated by FDA subject matter experts. Transforming the narrative text to structured information encoded in national standard terminologies is a prerequisite to the effective deployment of drug safety information in drug labels for clinical decision support. Starting in FY16, LHC and FDA/CDER collaborate on advancing automated extraction of Adverse Reactions (ARs) from drug listing information companies have submitted to FDA in the form of Structured Product Labels (SPLs). The goals of the initial agreement were to develop optimal MetaMap settings for extracting ARs from SPLs and provide FDA with the software necessary to replicate the results. To evaluate the extraction quality, LHC and FDA needed to develop a test collection of SPLs annotated with ARs. Working together, LHC and FDA have developed annotation guidelines. LHC have annotated 200 SPLs and coded the results to MedDRA, the official controlled vocabulary used by FDA to normalize the labeled ARs. In FY17, the collaboration continues with the goals to conduct a community wide evaluation of the available AR extraction tools. The evaluation venue is NIST Text Analysis Conference (TAC). http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm |
| Extreme Events and the Elderly: Scientific Evidence, Cultural Considerations and Sustainable Solutions | Meeting/ Workshop | CDC | NIEHS, NIA | The purpose of this workshop was to explore research, service, and policy needs of the elderly in the context of extreme events (natural and manmade catastrophes such as hurricanes floods oil spills fires). The workshop highlighted existing resources and sustainable solutions for the elderly within the context of specific cultural needs of a variety of elder populations (African American, Hispanic, native American, Asian and rural/remote and low SES elderly). |
| Eye Research Collaboration | Other | FDA | NEI | The National Eye Institute (NEI) is collaborating with the Food and Drug Administration (FDA) on uveitis research. Uveitis is an autoimmune disease that targets the eye. If left untreated the disease can cause permanent vision loss. Current treatments consist of steroids to suppress the immune system. However, chronic use of these drugs has many side-effects and complications. |
| Fast Track Action Committee on Biosafety and Biosecurity | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | This Committee examines relevant biosafety regulations and further explore other options for biosafety oversight |
| FastTrack Action Committee - Mapping the Microbiome (FTAC-MM) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/DPCPSI, NHGRI, OD/DPCPSI/OSC | The purpose of the FTAC-MM was to identify areas of current Federal investment, research needs, and resource gaps for the development of an integrated Federal plan for microbiome research, and to identify priority areas for Federal agency coordination and cooperation on achieving a predictive understanding of microbiomes and their functions. |
| FDA Cancer Imaging Program (CIP) Bi-annual Meeting | Meeting/ Workshop | FDA | NCI | This collaboration is a bi-annual meeting to enhance communication between the Cancer Imaging Program (CIP) and the Division of Medical Imaging Products of CDER in the FDA. This allows for a two-way exchange of information and discussion of issues that are important for each side. Topics that have been discussed include CIP''s standardization efforts of medical imaging scanners in NCI Cancer Centers, presentation and discussion of specific new molecular imaging modalities, and discussion of recent FDA decisions regarding new medical imaging innovations. |
| FDA Drug Safety Oversight Board | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | OD/OSP, NCI | The FDA Drug Safety Oversight Board (DSB), created in 2005 and mandated by law in the FDA Amendments Act of 2007, advises the FDA''s Center for Drug Evaluation and Research (CDER) Director on the handling and communicating of important and often emerging drug safety issues and regulatory science. The DSB is composed of representatives from two FDA Centers and eight other federal government agencies: the Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), Centers for Medicare and Medicaid Services (CMS), Department of Defense (DOD), Health Resources and Services Administration (HRSA), Indian Health Service (IHS), National Institutes of Health (NIH), and Department of Veterans Affairs (VA). An important role of the DSB is to help FDA assess the impact of their safety decisions on the healthcare systems of its Federal Partners. The Board, with its broad representation from federal healthcare organizations, can provide valuable input and allows FDA to hear other perspectives on drug safety issues. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm082129.htm |
| FDA Medical Countermeasures Initiative (MCMi) Regulatory Science Steering Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This committee provides guidance to the Medical Countermeasures Initiative (MCMi) stakeholders. |
| FDA Pediatric Advisory Committee (PAC) Neonatal Subcommittee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | This committee addresses the need to expand current pediatric science to include the neonatal population. The committee addresses the challenges and identifies different programmatic strategies for advancing the knowledge necessary to develop neonatal regulatory science. |
| FDA Substance Registry System Public Interface | Resource Development | FDA | NLM | The National Library of Medicine (NLM) and the Food and Drug Administration (FDA) established a collaborative effort to provide an interface for public access to the FDA’s Substance Registration System (SRS). The FDA SRS utilizes an existing NLM database backend architecture to provide public search capability for FDA substances and medicinal products. https://fdasis.nlm.nih.gov/srs/srs.jsp |
| FDA-NCI Every Other Month Meeting | Meeting/ Workshop | FDA | NCI | An every other month meeting to enhance communication between NCI and FDA, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure; as well as an understanding of the operations of the sister agencies. |
| FDA/NIH Interagency Clinical Outcomes Assessments Working Group Meeting | Committee, Work group, Advisory group, or Task Force | FDA | NIMH, NCCIH, NCI, NHLBI, NIAMS, NINDS | The FDA and Institute representatives from NIH meet periodically to discuss the development of valid patient-oriented treatment outcomes, and relative measurements, for use in clinical trials of therapeutic interventions. |
| Federal Breastfeeding Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OSG | NICHD | The purpose of this workgroup is to develop strategies to implement the Surgeon General’s call to action to support breastfeeding. |
| Federal Consortium on the Substance Abusing Offender | Committee, Work group, Advisory group, or Task Force | SAMHSA | NIDA | Coordination of agencies that work with substance abusing offenders. |
| Federal Dietary Reference Intakes Steering Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OS | NIDDK | This committee serves as an interagency forum to provide oversight on the process used to establish the Dietary Reference Intakes. These values serve as a basis for many federal nutrition programs and policies. |
| Federal Early Childhood Data Workgroup | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NICHD, NIDA | The National Center for Education Statistics (NCES) and other HHS agencies collaborate to exchange information and help develop common definitions and procedures for collection of early childhood data for research purposes. |
| Federal Education and Training Interdisciplinary Group (FETIG) National Center for Disaster Medicine and Public Health | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The Federal Education and Training Interagency Group for Public Health and Medical Disaster Preparedness and Response (FETIG) committee provides oversight and guidance to the National Center for Disaster Medicine and Public Health which is a center of the Uniformed Services University of the Health Sciences-the Nation’s only federal sciences university. |
| Federal Experts Security Advisory Panel (FESAP) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Addresses policy issues relevant to the security of biological select agents and toxins https://www.phe.gov/Preparedness/legal/boards/fesap/Pages/default.aspx |
| Federal HIV/AIDS Web Council (AIDS.gov) | Resource Development | CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR, NCI, NIAID, NIDA, NLM | AIDS.gov expands visibility of timely and relevant Federal HIV policies, programs, and resources to the American public. Increase use of new media tools by government, minority, and other community partners to extend the reach of HIV programs to communities at greatest risk. Increase knowledge about HIV and access to HIV services for people most at-risk for, or living with, HIV. http://aids.gov/ |
| Federal Interagency Forum on Aging Related Statistics | Resource Development | ACL, AHRQ, CDC, CMS, OS, SAMHSA | NIA | This Interagency Forum was formed with the goal of bringing together Federal agencies that share a common interest in improving aging-related data. The specific goals of the Forum are to improve both the quality and use of data on the aging population. https://agingstats.gov/about.html |
| Federal Interagency Health Equity Team (FIHET) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMHD, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NINR, OD/DPCPSI/ODP | Federal leadership for the National Partnership for Action to End Health Disparities (NPA) is provided by the Federal Interagency Health Equity Team (FIHET). The FIHET was established to foster communications and activities of the NPA within federal agencies and their partners; and to increase the efficiencies and effectiveness of related policies and programs at the national, state, tribal, and local levels. http://www.minorityhealth.hhs.gov/npa/ |
| Federal Interagency Health Equity Team (FIHET) - Maternal and Child Health | Committee, Work group, Advisory group, or Task Force | OS | NICHD | The purpose of this team is to serve on various committees to provide input/recommendations on maternal and child health equity. nonhttp://minorityhealth.hhs.gov/npa/templates/browse.aspx?lvl=1&lvlid=36e |
| Federal Interagency Healthy Homes Work Group (HHWG) | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The HHWG developed a Strategy for Action that will capitalize on the collective expertise within the HHWG and the Task Force to advance the policy established in the United States Housing Act: “…to assist States and political subdivisions of States to remedy the unsafe housing conditions and the acute shortage of decent and safe dwellings for low-income families [and] to assist States and political subdivision of States to address theshortage of housing affordable to low-income families.” https://portal.hud.gov/hudportal/HUD?src=/program_offices/healthy_homes/advhh |
| Federal Interagency Task Force on the Arts and Human Development | Research Initiative | ACF, ACL, SAMHSA | NIA, NCCIH, NCI, NICHD, NIMH, OD/DPCPSI/OBSSR | Beginning in 2011, the National Endowment for the Arts (NEA) has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life. Task force members represent multiple units across federal government, including the U.S. Department of Health and Human Services, the National Institutes of Health, the National Science Foundation, and the U.S. Department of Education, among others. To date, the Task Force has met quarterly to share ideas and information about research gaps and opportunities for understanding the arts'' role in improving health and educational outcomes throughout the lifespan. The Task Force has conducted a series of public webinars on compelling research and practices. Additionally, the group has begun a literature review of research on the arts and human development. In November 2012, four Task Force member agencies hosted a first-ever convening at the National Academy of Sciences to review the current state of research on the arts, health, and well-being in older Americans. http://www.nea.gov/national/TaskForce/index.html |
| Federal Interagency Traumatic Brain Injury Research (FITBIR) Working Group | Resource Development | AHRQ, CDC, HRSA, OS, SAMHSA | NINDS, CIT, NCATS, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIGMS, NIMH | The charge of the Interagency Committee includes promoting collaboration among federal agencies. A goal of this committee is to develop a national “Roadmap” for Traumatic Brain Injury (TBI). This strategic planning effort will represent the collective expertise of providers, educators, advocates, federal/state/national organizations, and individuals with TBI and their families and will result in a consensus document outlining the critical elements of a successful system of care for TBI service delivery. https://fitbir.nih.gov/ |
| Federal Interagency Working Group for Diabetes | Committee, Work group, Advisory group, or Task Force | FDA | NIA | One of three Federal Interagency Working Groups formed as part of the National Action Plan to Prevent Adverse Drug Events. https://health.gov/hcq/pdfs/ade-action-plan-508c.pdf |
| Federal Interagency Working Group on Improving Measurement of Sexual Orientation and Gender Identity in Federal Surveys | Committee, Work group, Advisory group, or Task Force | ACF, CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/DPSCSI/SGMRO, NICHD | The Working Group explores measurement of sexual orientation and gender identity (SOGI), considering multiple different dimensions of sex, gender, and sexuality. The Working Group examines variability in measurement by age, race, ethnicity, and cultural group. It prepares recommendations to OMB and other Federal agencies for the development, testing, and usage of SOGI measures to more accurately describe LGBT populations. |
| Federal Partners Committee on Women and Trauma | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, SAMHSA | NIDA, NIAID, NIMH, OD/DPCPSI/ORWH | Led by the Department of Labor (DOL) and Substance Abuse and Mental Health Services Administration (SAMHSA), the Women and Trauma workgroup includes more than three dozen federal agencies, departments, and offices one of the largest interagency collaborations in federal government history. https://www.nasmhpd.org/content/federal-partners-committee-women-and-trauma-report |
| Federal Partners in Bullying Prevention, Intervention, and Recovery | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, SAMHSA | NIMH, NIAAA, NICHD, NIDA | This workgroup meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning how to prevent or stop bullying in schools and communities. http://www.stopbullying.gov/ |
| Federal Partners in Chronic Obstructive Pulmonary Disease (COPD) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, CMS, HRSA, IHS, OSG | NIA, NCI, NHLBI, NIDA, NIEHS | This collaboration was created to share information about current activities related to COPD and discuss opportunities for further cooperation and enhanced effectiveness of the federal response to this serious public health problem. http://www.nhlbi.nih.gov/research/reports/2013-copd-workshop |
| Federal Partners Working Group - Admin for Community Living | Committee, Work group, Advisory group, or Task Force | ACL, CDC | NICHD | This group exchanges information among agencies that work with ACL. |
| Federal RePORTER | Resource Development | ACF, AHRQ, CDC, FDA | OD/OER | Federal RePORTER is a searchable public database of scientific awards from federal agencies, which allows for portfolio analysis and metrics development across scientific domains. The trans-federal agency consortium called STAR METRICS (Science and Technology for America’s Reinvestment Measuring the Effects of Research on Innovation, Competitiveness, and Science) designed, created, and maintained Federal RePORTER. https://www.starmetrics.nih.gov/ |
| Federal Supply and Demand of Isotopes | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, NCI | This workgroup was formed as follow-up to the Inaugural Workshop on Isotope Federal Supply and Demand, a workshop now held annually. The workgroup consists of representatives of Federal agencies with the aim of providing a forum for interaction between agencies and departments to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. DOE is charged with the production of isotopes that are not commercially available, and coordinates the informational and production efforts. Dr. Roderic Pettigrew, Director of NIBIB is the NIH point of contact on this topic. The workgroup holds an annual workshop that includes all Federal agencies that use isotopes; the workshop promotes discussion on the use, supply and demand of isotopes in various areas including homeland defense, medicine, agriculture, and basic and applied research. The fifth workshop was held in November 2016. A NIH representative participated as a panel member at a congressional briefing on this topic in December 2014. The event was co-sponsored by the American Chemical Society and Research America! http://science.energy.gov/np/community-resources/workshops/2015-workshop-on-isotope-federal-supply-and-demand/ |
| Federal Working Group on Bone Diseases | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA | NIAMS, CSR, NCCIH, NCI, NEI, NIA, NIAAA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH | An interagency committee focusing on osteoporosis, Paget''s disease, and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency''s mission |
| Federal Working Group on Dietary Supplements (FWGoDS) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | OD/DPCPSI/ODP, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS | The Office of Dietary Supplements (ODS) leads the Federal Working Group on Dietary Supplements (FWGoDS) which is comprised of individuals from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS facilitates communication and collaboration between NIH and its federal partners in several ways: co-funding research investigations within the NIH, expanding opportunities for research-investigator training, and strengthening collaborative efforts involving dietary supplement research, education, and communication. The FWGoDS meets twice a year and serves as a means of communication between ODS and its federal partners. |
| FedTel: Cross-Federal work group on telehealth | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIBIB, NLM, OD/DPCPSI/OBSSR | The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. Current topics of emphasis include Telehealth and Health Information Technology (HIT); Technology, Innovation and Standards; Public Education of Telehealth; and Access to Health Care. |
| FESAP Recommendation 1.2 Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The goal of this group is to develop an approach to require that all research institutions, in which human, plant, and/or animal infectious agents and toxins research is conducted, have an appropriate organizational and governance structure to ensure compliance with biosafety, biocontainment, and laboratory biosecurity regulations and guidelines https://www.phe.gov/Preparedness/legal/boards/fesap/Pages/default.aspx |
| Field Epidemiology Training Program (FETP) Tobacco Control Curriculum Training | Meeting/ Workshop | CDC | NCI | Cancer incidence and mortality are rising rapidly worldwide, particularly in low- and middle-income countries. There is an overwhelming need for countries to adopt and implement cancer control actions. Yet only 1 in 5 low- and middle-income countries have the necessary data to drive policy and reduce the burden and suffering due to cancer. The Global Initiative for Cancer Registry Development (GICR) is a coordinated, multi-partner approach to deliver the required change. It is time to make cancer data count. |
| Filovirus Animal Non-Clinical Group (FANG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories. |
| Fogarty HIV Research Training Program | Training Initiative | CDC | FIC, NIDA | The goal of the Fogarty HIV Research Training Program (AITRP) is to build multi-disciplinary bio-medical, behavioral, and social science research capacity for the prevention, care, and treatment of HIV/AIDS and HIV-related conditions in adults and children in low- and middle- income countries (LMIC). Research training will be provided to scientists at institutions in countries defined by the World Bank criteria as LMIC. In FY15, PEPFAR/CDCCOP funded one supplement to a parent AITRP award in Ukraine through SUNY Medical Center Downstate. Also, research training activities in Uganda continued to be supported in FY 15 through the FY2014 PEPFAR/CDC-COP funded supplement to the Fogarty HIV Research Training award at the University of California, Berkeley. http://www.fic.nih.gov/Programs/Pages/hiv-aids-research-training.aspx |
| Forum on Regenerative Medicine | Committee, Work group, Advisory group, or Task Force | FDA | NIDCR, NHLBI, NIAMS, NIBIB, NIDDK, NINDS | Six NIH institutes and FDA are participating in a multi-year National Academy of Medicine (NAM)-led activity entitled "Forum on Regenerative Medicine". The objective of the Forum is to engage key stakeholders of regenerative medicine in a dialogue about opportunities and challenges facing translation of regenerative medicine science and technologies to clinic. The setting of the NAM provides a neutral convening mechanism for interactions between academia, industry, government, regulators, patients’ organizations, foundations and others. In addition to science, ethical, legal and societal issues related to regenerative medicine are discussed. In October 2016 the Forum supported a highly successful interdisciplinary workshop that examined the current state of science in regenerative medicine. Further activities are currently being planned. http://www.nationalacademies.org/hmd/Activities/Research/RegenerativeMedicine.aspx |
| Full-text health-related documents at NLM (includes HSTAT) | Resource Development | AHRQ, ATSDR, CDC, CMS, FDA, OSG, SAMHSA | NLM | The National Library of Medicine of the National Institutes of Health provides a free, web-based resource of full-text documents that provide information on health-care decision making. https://www.ncbi.nlm.nih.gov/books/?term=intra_hhs_collaborations%5bfilter%5d |
| Funding Opportunity Announcement Module (FOAM) | Resource Development | ACF | OD/OER, NHLBI | The Funding Opportunity Announcement Module (FOAM) allows NIH Institutes and Centers and HHS Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. Furthermore, FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system. |
| Gene-Environment Interaction in Orofacial Clefting | Meeting/ Workshop | CDC | NIDCR, NIAAA, NICHD, NIDA, NIEHS | This workshop was held September 6-7, 2016, and brought together experts across multiple scientific disciplines to assess the current research into a role for gene-environment interactions in the etiology of orofacial clefting. At the conclusion of the workshop several strategies were put forward to speed the pace of discovery and reduce barriers to advancement in this field. |
| Genetic Studies in the National Birth Defects Prevention Study | Research Initiative | CDC | NHGRI | This study is a collaboration between CDC and NHGRI to carry out DNA sequencing and genotyping on samples collected as part of the National Birth Defects Prevention Study. |
| Global Environmental and Occupational Health (GEOHealth) | Research Initiative | CDC | FIC, NCI, NIEHS | FIC, NCI, NIEHS and NIOSH/CDC, Canada’s International Development Research Centre (IDRC), and the Global Alliance for Clean Cookstoves are supporting Global Environmental and Occupational Health (GEOHealth) Hubs, which are regional hubs based at low- or middle-income country (LMIC) institutions focused on collaborative research, data management, training, curriculum development and policy support around high-priority local, national and regional environmental and occupational health threats. The expectation is that GEOHealth Hubs will become the lead resources for environmental and occupational health, attract and retain the best talent in the region, and provide the scientific evidence for policy formulation. Together all regional hubs supported will form the GEOHealth Network, a platform for coordinated environmental and occupational health research and research training activities. FIC and its partners are supporting linked U2R and U01 awards to U.S. and LMIC institutions, respectively. All partners contribute funds to the program. http://www.fic.nih.gov/Programs/Pages/environmental-occupational.aspx |
| Global Health - Household Air Pollution Investigation Network (HAPIN) | Research Initiative | CDC | OD/DPCPSI, FIC, NCI, NHLBI, NICHD, NIEHS, OD/DPCPSI/OSC | The Household Air Pollution Investigation Network (HAPIN) is a large NIH initiative designed to tackle the challenge of reducing the burden of disease from household air pollution (HAP). Within HAPIN, an Implementation Science Network (ISN) was formed to advance the science of uptake and scale up of clean cooking technology in the developing world. The ISN steering committee is composed of HAP experts from across NIH and various government and non-government agencies. https://commonfund.nih.gov/globalhealth/HAPINresources |
| Global Health Security Advisory Group (GHSAG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID, NINDS | The Global Health Security Advisory Group (GHSAG) is a committee composed of high-level representatives of the national health authorities for the G-8 block of countries. The GHSAG was formed to develop and implement concrete actions to improve global health security and serve as a network for rapid response to biological, chemical, radio-nuclear terrorism (CBRN) crises. http://www.ghsi.ca/english/index.asp |
| Global Ingredient Archival System (GINAS) | Research Initiative | FDA | NCATS | The Global Ingredient Archival System is a project that aims to provide a common identifier for all of the substances used in medicinal products, utilizing a consistent definition of substances globally, including active substances under clinical investigation, consistent with the ISO 11238 standard. The FDA is utilizing software from this project to meet their obligations under the Identification of Medicinal Products (IDMP) global regulatory scheme. In 2016, the software was deployed onto FDA internal systems and FDA’s existing data was migrated into their instance (internally called Global Substance Registration Service (GSRS)). A public version of FDA’s substance definitions for use by researchers outside the agency were made available through NCATS’ website for the project. https://ncats.nih.gov/expertise/preclinical/ginas |
| Global Initiative for Cancer Registry Development | Other | CDC | NCI | Cancer incidence and mortality are rising rapidly worldwide, particularly in low- and middle-income countries. There is an overwhelming need for countries to adopt and implement cancer control actions. Yet only 1 in 5 low- and middle-income countries have the necessary data to drive policy and reduce the burden and suffering due to cancer. The Global Initiative for Cancer Registry Development (GICR) is a coordinated, multi-partner approach to deliver the required change. It is time to make cancer data count. http://gicr.iarc.fr/ |
| Global Strategic Plan to Prevent Harms Associated with Alcohol Misuse | Meeting/ Workshop | CDC, SAMHSA | NIAAA | NIAAA represented HHS at the World Health Organization, coordinating with officials at CDC and SAMHSA to review Global Strategies to Prevent Harms Associated with Alcohol Misuse. |
| Go4Life | Public Education Campaign | ACL, AHRQ, CDC, OS, OSG | NIA, NCCIH, NEI, NHLBI, NIAMS, NIDDK, NIMH, NINDS | Go4Life, is an exercise and physical activity campaign from the National Institute on Aging at the National Institutes of Health (NIH), and is designed to help individuals fit exercise and physical activity into their daily life. Motivating older adults to become physically active for the first time, return to exercise after a break in their routines, or build more exercise and physical activity into weekly routines are the essential elements of Go4Life. Go4Life offers exercises, motivational tips, and free resources to help individuals get ready, start exercising, and keep going. The Go4Life campaign includes an evidence-based exercise guide in both English and Spanish, an exercise video, an interactive website, and a national outreach campaign. http://www.nia.nih.gov/Go4Life |
| Harmonization of various Common Data Models and Open Standards for Evidence Generation | Resource Development | FDA | NCATS, NCI, NLM | The goal of this project is to build data infrastructure for conducting patient-centered outcomes research using data derived from the delivery of health care in routine clinical settings. These data are collectively referred to as observational data. The sources of these data may include, but are not limited to insurance billing claims, electronic health records (EHRs), and patient registries. The Common Data Model (CDM) organizes data into a standard structure, which may differ across networks. This project intends to harmonize several existing CDMs in order to support research and analyses across multiple data networks. The aim is to advance the utility of data and its interoperability across networks to facilitate patient-centered outcomes research. The enhanced data infrastructure created through this project will have the capacity to support evidence generation on patient-centered outcomes that can inform regulatory and clinical decision making within federal programs. |
| Health and Retirement Study (HRS) | Research Initiative | CDC, CMS | NIA | This study follows more than 20,000 men and women over 50, offering insight into the changing lives of the older U.S. population. Launched in 1992, this multidisciplinary, longitudinal study has become known as the Nation’s leading resource for data on the combined health and economic conditions of older Americans. |
| Health Economics | Research Initiative | AHRQ, CMS | OD/DPCPSI, NIA, NIDA, NIMH, OD/DPCPSI/OSC | The Health Economics program aims to support theoretical and applied research to understand how innovations in treatments, diagnosis, and preventive strategies can be most effectively deployed to improve health and wellbeing. Research supported by this program will identify factors determining optimal adoption of highly effective health technologies, innovations, and discoveries, so that past and future investments by NIH may have greater public health impact. The Health Economics program is collaborating with AHRQ and CMS to discuss ongoing efforts in this area of research. http://commonfund.nih.gov/Healtheconomics/index |
| Health Literacy Work Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG | NICHD, NCI, NEI, NHGRI, NHLBI, NIDA, NIDCR, NLM, OD/DPCPSI/OBSSR | This Workgroup is comprised of various HHS agencies that work towards meeting the Department’s prevention goals and to accomplish the National Action Plan and the Healthy People 2020 Objective: Improve the health literacy of persons with inadequate or marginal literacy skills. http://www.surgeongeneral.gov/topics/healthliteracy/appxc.htm |
| Health Services and Technology Assessment Text (HSTAT) | Resource Development | AHRQ, ATSDR, CDC, CMS, FDA, OSG, SAMHSA | NLM | The National Library of Medicine of the National Institutes of Health provides a free, web-based resource of full-text documents that provide information on health-care decision making. http://www.ncbi.nlm.nih.gov/books/NBK16710/ |
| Health Systems Research Workshop | Meeting/ Workshop | AHRQ, FDA, HRSA | NICHD, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAID, NIEHS, NIMH, NINDS, NLM | Health care systems are playing an increasingly prominent role in biomedical research. Increased adoption of health information technologies as well as imaging and genomics technologies are not only changing how care is delivered, but also providing opportunities for developing personalized medicine approaches to disease prevention, diagnosis, and treatment. These changes provide the potential to conduct research studies in real-world settings, on large numbers of participants, and enable studies that could not be addressed previously. This workshop aimed to identify key opportunities and strategies that will enable the NIH and health care systems to advance our mutual research priorities and to ultimately benefit the health of women, children, and people with disabilities and included leaders from health care systems, academic investigators, as well as government and policy representatives. |
| Healthcare Systems (HCS) Research Collaboratory | Research Initiative | AHRQ, CDC, FDA | NINR, NCATS, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, OD/DPCPSI/OSC | The overall goal of the Common Fund’s Health Care Systems (HCS) Research Collaboratory program is to strengthen the national capacity to implement cost-effective large-scale research studies that engage health care delivery organizations as research partners. The aim of the program is to provide a framework of implementation methods and best practices that will enable the participation of many health care systems in clinical research, not to support a defined health care research network. Research conducted in partnership with health care systems is essential to strengthen the relevance of research results to health practice. http://commonfund.nih.gov/hcscollaboratory/index.aspx |
| HealthMap: Knowledge Management for Emerging Infectious Disease Intelligence | Research Initiative | OS | NLM | Leveraging previous National Library of Medicine (NLM) funded work under the HealthMap project, the HHS Assistant Secretary for Preparedness and Response (ASPR) and OPEO co-funded an administrative supplement to an NLM/NIH grant to provide funding to Harvard University for a pilot project in which Harvard will develop real-time applications to collect, parse, analyze, and display open source data in order to address the national needs of emergency preparedness and response for hurricanes. http://www.healthmap.org |
| Healthy People 2020 | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/ODP, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS | Healthy People provides science-based, national goals and objectives with 10-year targets designed to guide national health promotion and disease prevention efforts to improve the health of all Americans. As part of its mission, Healthy People has established benchmarks and monitored progress over 3 decades in order to (1) engage multiple sectors to strengthen policies and improve practices that are driven by the best available evidence and to (2) increase public awareness of the determinants of health, disease, and disability and the opportunities for progress. https://www.healthypeople.gov/ |
| Healthy People 2020 - HHS Disability and Health Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The purpose of this workgroup is to discuss the measurement of health and the targets for persons with disabilities. |
| Healthy People 2020 - Kidney Disease | Public Education Campaign | CDC, CMS, FDA, HRSA, OS | NIDDK | The Office of the Secretary of HHS leads the Healthy People 2020 initiative. The lead agency for most data activities is the CDC. However, for the kidney area, most of the information is provided by NIDDK through the US Renal Data System. http://www.healthypeople.gov |
| Healthy People 2020 - Older Adults | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA | NIA | This Healthy People 2020 topic is designed to develop an understanding of the health and health care needs and implications for older adults. The objectives overall will promote healthy outcomes in this population. The goal of these objectives is to improve the health, function, and quality of life of older adults. http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=31 |
| Healthy People 2020 - Respiratory Diseases | Health Survey | CDC | NHLBI, NIAID, NIEHS | The purpose of the collaborative activity is to support development and implementation by the National Health Interview Survey (NHIS) of measures that could be used to assess progress towards achieving Healthy People 2020 respiratory/asthma objectives. The NHLBI and the National Center for Health Statistics collaborate on this activity. http://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=36 |
| Healthy People 2020 - Social Determinants of Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, OS, SAMHSA | NIMHD, NCI, NHLBI, NIAAA, NIAMS | The overarching goals for Healthy People 2020 incorporate a focus on social determinants of health as well as on health outcomes and risk factors. The Working Group intends to develop objectives for the social determinants and methods to ensure their integration across all Healthy People 2020 objectives. https://www.healthypeople.gov/2020/about/history-development/Federal-Interagency-Workgroup |
| Healthy People 2020 - Structured Evidence Queries (SEQs) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS, SAMHSA | NLM | NLM is collaborating with ODPHP to develop structured PubMed searches for the HP 2020 objectives. Each PubMed search (a SEQ or "seek") is developed by medical librarians and reviewed by members of the HP 2020 working groups. The canned PubMed searches enable the public health workforce to find evidence-based information related to a specific HP 2020 objective. The SEQs are accessible from the HP 2020 website as well as the PHPartners.org website. http://phpartners.org/hp2020/index.html |
| Healthy People 2020 - Visual Health | Health Survey | AHRQ, CDC | NEI | Healthy People 2020 is a collaboration with NIH, CDC, and AHRQ to survey and measure public health outcomes for a variety of common diseases over the current decade. NEI''s goal for this program is to Improve the visual health of the Nation through prevention, early detection, timely treatment, and rehabilitation. https://www.healthypeople.gov/ |
| Healthy People 2020 Adolescent Health Work Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OS, SAMHSA | NICHD | This work group addresses the goal of the Healthy People 2020 Adolescent Health which is to improve the healthy development, health, safety, and well-being of adolescents and young adults. |
| Healthy People 2020 Nutrition Working Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The purpose of this committee is to support the objectives of the Healthy People 2020 Nutrition goals. |
| Healthy People 2020 Working Group on Family Planning | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The purpose of this committee is to support Healthy People 2020''s objectives on Family Planning, which is to improve pregnancy planning and spacing, and prevent unintended pregnancy. |
| Healthy People 2020-Dementias, Including Alzheimer''s Disease | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA | NIA, NIMH, NINDS | This Healthy People 2020 topic will focus on increasing the awareness of the diagnosis of Alzheimer’s disease, and reducing the proportion of preventable hospitalizations in persons with diagnosed Alzheimer’s disease and other dementias. The goal is to reduce the morbidity and costs associated with, and maintain or enhance the quality of life for, persons with dementia, including Alzheimer’s disease. http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=7 |
| Healthy Vision Month | Public Education Campaign | CDC | NEI | Each May, the NEI sponsors Healthy Vision Month (HVM) which is a national observance designed to elevate eye health as a priority for Americans. NIH worked with CDC for the 2014 observance to disseminate disease information for CDC''s Vision Initiative website and provided online banners and buttons linking to the HVM site and to the NEI for additional information. http://www.nei.nih.gov/hvm/ |
| Hematopoietic Stem Cell Transplantation Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCI, CC, NHLBI, NIAID, NIDDK | This working group reviews matters associated with hematopoietic stem cell transplantation. |
| Hepatitis B Research Network | Research Initiative | CDC | NIDDK | The Hepatitis B Research Network (HBRN) was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brings together clinical centers from throughout the U.S. and Canada. This multi-center Network is enrolling patients in multiple clinical trials in both adults and children with hepatitis B. http://www.hepbnet.org/ |
| HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis Interagency Implementation Group (VHIG) | Research Initiative | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIDA, NIAID, NIDDK, NIMHD | HHS agencies review the Institute of Medicine (IOM) recommendations and develop a comprehensive strategic viral hepatitis action plan that would: address IOM recommendations for viral hepatitis prevention, care, and treatment; set forth actions to improve viral hepatitis prevention and ensure that infected persons are identified and provided care and treatment; and improve coordination of all activities related to viral hepatitis across HHS and promote collaborations with other government agencies and nongovernmental organizations. http://www.hhs.gov/ash/ohaidp/initiatives/ |
| HHS Adolescent Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NIDA, NIAAA, NICHD, NIMH | Interagency working group established in January 2010 within the Office of the Assistant Secretary for Health as a forum for HHS agencies to share updates on adolescent health activities and address cross-cutting issues. http://www.hhs.gov/ash/oah/news/e-updates/eupdate_evelyn.html |
| HHS Antimicrobial Resistance Challenge Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID, OD/DPCPSI | Development and management of the HHS Antimicrobial Resistance Rapid Point of Need Diagnostic prize competition http://www.cccinnovationcenter.com/challenges/antimicrobial-resistance-diagnostic-challenge/ |
| HHS Arctic Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, SAMHSA | NIMH, NIDA, NIEHS, NIGMS, NIMHD | The Department of Health and Human Services (HHS) Arctic Working Group was organized in March 2015 by the Office of Global Affairs, Office of the HHS Secretary. The purpose of the Working Group is to (1) ensure coordination of deliverables to the Arctic Executive Steering Committee (AESC), which was established by Executive Order and held its first meeting in February, 2015; (2) provide an opportunity for cross-agency learning and communication regarding activities and projects in Arctic regions; and, (3) facilitate future interagency collaborations. |
| HHS ASPR Obstetric-Pediatric and Chemical Integrated Program Teams (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD | This workgroup is a Public Health Energy Enterprise. The IPT working group provides an end-to-end vision of medical countermeasures needed for a particular threat type (e.g., anthrax, rad/nuc, etc.). The scope of their work includes setting requirements for the stockpiling of Medical Countermeasures (MCMs), MCM delivery, and dispensing and monitoring MCM development. The IPTs also advise the Enterprise Executive Committee as to threat- or capability-specific MCM priorities for improving preparedness, to inform leadership consideration of cross-threat prioritizations and strategic goal setting. |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Behavioral Health Quality Measures | Committee, Work group, Advisory group, or Task Force | CMS, SAMHSA | NIDA | A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the U.S. Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. This subcommittee addresses behavioral health quality measures. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Communications | Committee, Work group, Advisory group, or Task Force | ACL, OS | NIDA, NIMH | A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the U.S. Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. This subcommittee of communication professionals collaborates on inter-departmental behavioral health initiatives and promotional efforts. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Prescription Drug Abuse | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIDA | A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the U.S. Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. The National Institute of Drug Abuse (NIDA) Serves as Co-Chair with FDA on this inter-agency subcommittee addressing prescription drug abuse. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Committee (BHCC) Trauma and Early Intervention Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, SAMHSA | NIMH, NIAAA, NICHD, NIDA | The BHCC is tasked with assuring that agencies coordinate their activities related to addressing the needs of and services for persons with behavioral healthcare concerns, particularly but not exclusively those with serious mental illness (SMI). The new charge of the Trauma and Early Intervention Subcommittee is the creation of a Primer on Trauma-Informed Human Services that will summarize the practical implications of recent research about trauma, toxic stress, executive functioning, and related constructs for managers and administrators of HHS-supported human services programs. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Council (BHCC) Subcommittee on Marijuana | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | NIDA | The Behavioral Health Coordinating Council (BHCC) Subcommittee on Marijuana develops projects with clear goals, provides guidance to achieve steady progress, and measurable outcomes, and develop key policy messages on issues related to marijuana. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Council (BHCC) Subcommittee On Primary Care And Behavioral Health Integration | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIMH, NIAAA, NIDA | The BHCC is tasked with assuring that agencies coordinate their activities related to addressing the needs of and services for persons with behavioral healthcare concerns, particularly but not exclusively those with serious mental illness (SMI). The Behavioral Health/Primary Care Integration Subcommittee addresses the need to improve the integration of mental health and primary care services. This group convenes bi-monthly to share agency initiatives in this area and collaborate on new initiatives to promote this integration. http://www.samhsa.gov/about-us/interagency |
| HHS Biannual Dual Use Research of Concern (DURC) Inventory | Resource Development | CDC, FDA, OS | OD/OSP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | Development of the HHS Biannual Dual Use Research of Concern (DURC) inventory reports, as required by the USG Policy for Oversight of Dual Use Research of Concern. |
| HHS Biomedical Advanced Research and Development Authority (BARDA) Armed Forces-Radiobiology Research Institute (AFRRI) Good Laboratory Practices (GLP) Integrated Project Team | Committee, Work group, Advisory group, or Task Force | OS | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) participates on the HHS BARDA Armed Forces Radiobiology Research Institute (AFRRI) Good Laboratory Practices (GLP) Integrated Project Team to collaborate and provide subject matter expertise, advice, and guidance on establishing a quality assurance program at AFRRI for GLP compliance. |
| HHS Biomedical Advanced Research and Development Authority (BARDA) Radiological and Nuclear Threats Integrated Program Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This Interagency Working Group, established under the Biomedical Advanced Research and Development Authority (BARDA), determines overall radiation countermeasures strategy and priorities. The National Institute of Allergy and Infectious Diseases (NIAID) provides subject matter expertise, advice and guidance on medical countermeasure development, requirements, and preparedness/response. |
| HHS Biosafety and Biosecurity Coordinating Council (HHS BBCC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP | This Council serves as a high-level and formal mechanism to coordinate and collaborate on biosafety and biosecurity issues across the Department |
| HHS Biovigilance Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee develops systems for reporting adverse events resulting from blood transfusion or donation. |
| HHS Border Health Intra-agency Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, FDA, HRSA, IHS | NICHD, NIA, NIAID, NIDDK, NIMH, NIMHD | This intra-agency workgroup allows for exchange of information and cooperation among HHS agencies for issues related to border health. The purpose of this group is to convene HHS components that have a vested interest in US-Mexico border health issues to provide a platform for discussion, coordinate efforts, and potentially identify mutual areas of collaboration to improve the health and quality of life for border residents. |
| HHS Data Council | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OBSSR | Coordinates all health and human services data collection and analysis activities of the Department of Health and Human Services, including an integrated data collection strategy, coordination of health data standards and health and human services and privacy policy activities. https://aspe.hhs.gov/hhs-data-council-introduction#dcpurpose |
| HHS Day Planning Committee | Meeting/ Workshop | CDC, FDA, HRSA, OS, SAMHSA | NIAID, FIC | This Committee developed the program for the annual HHS meeting held with the PEPFAR Annual Meeting. This year''s theme was "HHS Day 2016: Leveraging Partnerships to Achieve an AIDS-free Generation." It was held in Durban on July 18, 2016. |
| HHS Dietary Guidance Review Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS | NIDDK | This committee reviews draft nutrition materials developed by all federal agencies and fulfills the legislative mandate (1990 NNMRRA) to ensure that Federal dietary guidance is consistent with the Dietary Guidelines for Americans and is scientifically accurate. |
| HHS ED Developmental and Behavioral Screening Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NICHD | This committee supports the objectives of improving developmental and behavior screening. |
| HHS Evidence & Evaluation Policy Council | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/OSP | The HHS Evidence & Evaluation Policy Council was instituted in 2016. The aims of the Council are to develop and coordinate a community within HHS that can advise and consult with their agencies on evaluation and evidence activities. The council works toward improving efficiency and effectiveness in planning, conducting, and disseminating evaluations and evidence throughout HHS, and ensuring the integrity, rigor, and relevance of the information collected, analyzed, and disseminated for evaluation purposes. Activities focus on coordination and collaboration, emphasizing areas of common interest. Example topics include staff development, emerging issues like using administrative data for evaluation purposes, working effectively with leadership and agency partners, and adopting common principles and practices. |
| HHS Global Health Collaborative | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMH | This interagency working group meets to provide a forum within the Department of Health and Human Services (HHS) that identifies Global Health issues relevant to the HHS Global mental health agenda. |
| HHS H5N1 Gain-of-Function Review Group (HHG Review Group) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The Framework for Guiding HHS Funding Decisions about Research Proposals with the Potential for Generating Highly Pathogenic Avian Influenza (HPAI) H5N1 Viruses that are Transmissible among Mammals by Respiratory Droplets requires that certain research proposals undergo additional review at both the funding agency and Departmental (HHS) levels prior to funding. The HHS Department-level review is performed by the HHG Review Group, which brings to bear multidisciplinary interagency expertise in science, countermeasure development and availability, national security, law, public health preparedness and response, biodefense, select agent regulations, and science and public health policy. The purpose of the HHS Department-level review includes review of the funding agency''s risk assessment, consideration of whether additional factors may alter assessment of whether the research can be funded, determination of which measures are needed to mitigate risks, consideration of the overall HHS influenza research portfolio, and determination of whether the proposal is acceptable for HHS funding. |
| HHS Healthy Weight, Nutrition and Physical Activity Work Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIDDK, NCI, NHLBI, NICHD, OD/DPCPSI/ODP | The Department of Health and Human Services (HHS) Healthy Weight, Nutrition and Physical Activity Work Group aims to improve dietary and physical activity behaviors through targeted sector initiatives. |
| HHS LGBT Policies Coordinating Committee | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | OD/DPSCSI/SGMRO, NCCIH, NICHD, NIMH, NIMHD | The HHS LGBT Policy Coordinating Committee is comprised of senior representatives from each division of HHS. This committee coordinates LGBT-related policies across the department and recommends future actions that HHS can take to improve the health and well-being of LGBT individuals. https://www.hhs.gov/programs/topic-sites/lgbt/reports/index.html |
| HHS Measurement Policy Council | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NLM | The HHS Measurement Policy Council was convened in early 2012 to begin the work of aligning measures across HHS. Composed of senior-level representatives from Agencies and operating divisions across HHS, the group also addresses new measure development and implementation, and measurement policy. The Council has so far reviewed nine topics to date: hypertension control, hospital-acquired conditions/patient safety, HCAHPs, smoking cessation, depression screening and care coordination, HIV/AIDS, perinatal, and obesity/BMI. While these measures are used for Federal programs, the Measurement Policy Council supports State and private-sector efforts to adopt core measure sets for further harmonization and alignment across the health and health care community. NLM serves on this council. http://www.ahrq.gov/workingforquality/about.htm |
| HHS National HIV/AIDS Strategy Implementation Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | OD/DPCPSI/OAR | Trans Department of Health and Human Services (DHHS) Committee charged with addressing issues of and/or related to AIDS. |
| HHS Nutrition Policy Board | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS, SAMHSA | NIDDK | This Board coordinates the Department''s nutrition policy development and program implementation and is the principle point of contact with USDA for nutrition policy. |
| HHS Secretary''s Initiative on Serious Mental Illness (SMI) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMH | The Department of Health and Human Services (HHS) Action Plan includes activities addressing the needs of individuals with serious mental illness (SMI) as well as those at high risk for developing SMI. This plan targets three goals: reducing the duration of untreated SMI through early engagement in care; improving the quality of care through stronger measurement and accountability; and, increasing access to community-based treatment and support services. |
| HHS Tobacco Control Implementation Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, SAMHSA | NIDA, NCI | Comprising senior HHS leaders and tobacco control experts, the committee monitors the overall implementation of the Tobacco Control Strategic Action Plan to ensure effective coordination and collaboration across the Department and with other federal agencies and to provide support to the Food and Drug Administration’s role of regulating tobacco products. The Steering Committee meets regularly to set priorities, develop plans for cross-agency implementation of strategic actions, and promote information exchange and collaboration. |
| HHS Viral Hepatitis Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIDDK, CC, NCCIH, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIMHD, OD/DPCPSI/OAR | The HHS Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. The working group is developing a 2017-2020 National Viral Hepatitis Action Plan. http://www.hhs.gov/hepatitis/action-plan/u-s-viral-hepatitis-action-plan-overview/index.html |
| HHS Working Group on the Epilepsies | Committee, Work group, Advisory group, or Task Force | ACL, CDC, CMS, FDA, HRSA, OS | NIA, NICHD, NIMH, NINDS | The purpose of this group, which is led by the Office of the Assistant Secretary for Health, Department of Health and Human Services (HHS), is to increase communication among agencies sponsoring epilepsy-related activities and explore opportunities for increased coordination. The National Institute of Neurological Disorders and Stroke (NINDS) is the lead Institute representing the National Institutes of Health on the Working Group. |
| HHS- Office of the Assistant Secretary for Preparedness and Response (ASPR) | Committee, Work group, Advisory group, or Task Force | OS | NCI, NIAID | NCI and NIAID participate in ASPR''s chemical, biological, radiological and nuclear defense team and Senior Medical Advisor to ASPR https://www.phe.gov/about/aspr/Pages/default.aspx |
| HHS/USAID/OMB Zika Coordination Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD, NIAID, NIEHS | This is a collaborative effort by the Department of Health and Human Services, the United States Agency for International Development, and office of Management and Budget to address issues regarding Zika virus. The goal of this group is to develop a coordinated US government strategy. |
| HIV/AIDS Cancer Match Study | Research Initiative | CDC | NCI | Investigators use data from the NCI HIV/AIDS Cancer Match Study, in conjunction with data from the CDC HIV surveillance program, to estimate the burden of cancer in HIV-infected people in the United States. http://hivmatch.cancer.gov/ |
| HOPE Act Research Criteria Workshop | Meeting/ Workshop | CDC, CMS, FDA | NIAID, NIDDK | The goal of this workshop was to educate the transplant community about implementation of the Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV, published in the Federal Register on 11/25/2015. |
| HPV Working Group for the Advisory Committee on Immunization Practices (ACIP) | Committee, Work group, Advisory group, or Task Force | CDC | NCI | HPV Working Group for the Advisory Committee on Immunization Practices ACIP Work Groups (WGs) serve in a key scientific role in support of vaccine policy development by the ACIP. ACIP WGs conduct extensive background reviews of relevant research data to develop options for recommendations for use of vaccines in the civilian population of the United States. WGs are convened solely to gather scientific information related to vaccines and the diseases they prevent, to analyze relevant issues and data, and to draft policies or options for review, deliberation and vote by the ACIP. |
| HRSA Interagency Committee On Emergency Medical Services For Children Research | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD, NIGMS | This committee supports improving emergency medical services for child research. |
| HRSA/NIH Joint Technical Expert Consultation on Trauma and HIV Care | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIMH, NIAID, NIDA | The Health Resources and Services Administration (HRSA) and the National Institutes of Health (NIH) held a one-day meeting with experts on trauma treatment and research to review the evidence for implementing care practices that address trauma in HRSA’s Ryan White HIV/AIDS Program (RWHAP). HRSA and NIH led the meeting, which included representatives from the White House Office on National AIDS Policy, National Institute of Mental Health (NIMH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), Kaiser Permanente, and academic experts. |
| Human Immunology Project Consortium Collaboration on Mechanism Studies of Influenza Vaccination | Research Initiative | FDA | NIAID | The NIAID-funded Human Immunology Project Consortium (HIPC) supports an Infrastructure/Opportunity Fund to create a shared research infrastructure for ongoing development of the immune profiling network, support collaborative projects, pilot projects, and new research opportunities for the HIPC investigators. |
| I-Corps @ NIH | Training Initiative | CDC | NCI, NCATS, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS | The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. https://sbir.cancer.gov/programseducation/icorps |
| ICARE: Interagency Collaborative to Advance Research in Epilepsy | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NINDS, FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIMH | The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the NIH ICs involved in epilepsy-related research, as well as across HHS and other Federal agencies and multiple epilepsy research and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals. http://www.ninds.nih.gov/research/epilepsyweb/researchers/ICARE/index.htm |
| Identifying Early Psychosis in Primary Care and Connecting to Care | Research Initiative | HRSA | NIMH | The Health Resources and Services Administration (HRSA) and National Institute of Mental Health (NIMH) are supporting developmental of testing of a brief early psychosis screening instrument. This instrument may be used in a primary care setting to identify people with psychosis at the earliest possible opportunity and connect them to an early psychosis treatment program. |
| Image-guided Interventional Therapeutics | Research Initiative | FDA | CC, NCI | This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the FDA Center for Devices and Radiological Health''s preclinical review of device applications while meeting the primary research goal of optimizing image guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies. |
| Immunology Interest Group | Meeting/ Workshop | FDA | NCI, CC, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, OD/OIR | The NIH Immunology Interest Group brings together immunologists from across all NIH institutes as well as the FDA .The two major activities of the IG are a Wednesday afternoon lecture series highlighting world class immunologists and intramural immunologists and an annual workshop where up to 350 NIH/FDA immunologists get together to present their work to the community. https://ecollab.niaid.nih.gov/sites/IIG/_layouts/15/start.aspx#/SitePages/Welcome%20to%20the%20NIH%20Immunology%20Interest%20Group.aspx |
| Immunotoxicity of Workplace Xenobiotics | Research Initiative | CDC | NIEHS | The Immunotoxicity of Workplace Xenobiotics interagency agreement functions to enhance the immunotoxicological evaluations of humans exposed to quantifiable levels of xenobiotics in the environment and workplace. To date work funded by this IAG has examined immune responses in diverse worker populations including farmers, health care and hospital workers, firefighters, manufacturing workers (nano materials, lead batteries), etc. A variety of occupational populations in the agriculture, forestry, service, and manufacturing sectors are at elevated risk of fungal exposures due to workers handling contaminated cellulose-based materials. The current projects focus on the growing concern of personal exposure to fungal bioaerosols and the potential toxicity of mold and mold-related related xenobiotics from contaminated materials. |
| Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group | Research Initiative | CDC, FDA, OS | NCCIH, NCI, NHGRI, NIDA, NLM | The overarching workgroup effort is to enhance research initiatives/resource development as IAA workgroup members committed to sustain and accelerate translatability of validation analytics and reference datasets using omic and other multi-omic substitutable [SMART] tools, devices, and HL-7 FHIR technologies to support rapid and efficient interoperability with electronic health records and clinical decision support systems. A second goal is to coordinate and plan trans-NIH and Inter-agency meetings, workshops and initiatives with greater efficiency of ICO resources and expertise between agencies. Innovative technologies like HL-7 SMART on FHIR have been demonstrated to enhance health information exchange, affordably and accurately. Novel device monitoring using reference standards including, FDA Precision and NIST nanofabrication, multi-omics and modeling strategies can be integrated to improve validation and standards biosafety, risk monitoring of adverse drug events, food safety, overuse and resistance to antibiotics, and emerging infection. The intent originated in April 2016 with an Initiative planning meeting that are now ongoing for IAA partnered PCORI; other IAA collaboratives in progress. |
| Influenza Risk Management Meeting | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Risk Management Meetings provide members (including ASPR/BARDA, CDC, FDA, and NIH) with a venue to discuss issues relating to the U.S. Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. |
| Influenza Vaccine Manufacturing Improvement Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Vaccine Manufacturing Improvement Group aims to optimize donor strains, improve sterility assays, and develop alternative potency assays. |
| Innovation in Organ Transplantation | Meeting/ Workshop | HRSA | NIAID | This HRSA-led, multi-agency workshop addressed issues that present real or potential barriers to progress in clinical research in organ transplantation, including structural impediments to research innovation; special considerations in assessing transplant outcomes; and establishing review processes for research deserving special consideration. |
| Institute of Medicine Consensus Study on Accessible and Affordable Hearing Health Care for Adults | Other | CDC, FDA | NIDCD, NIA | This study provides background on the importance of hearing to individual and societal health including issues such as isolation, social connectivity, well-being, and economic productivity. It will examine federal regulations for non-surgical hearing aid dispensing by asking if current regulations provide a clinically meaningful benefit to adults with hearing loss and what the required federal regulatory paradigm should be. The study will also address the affordability of non-surgical devices and services. It will look at how affordability can be improved, how current approaches can be used or modified to increase access, how new and innovative approaches (such as telehealth, mobile health, and team-based care) can be used to increase access and affordability, and will discuss challenges for select populations such as older adults and transitioning young adults. The committee will provide short- and long-term recommendations for solutions to these questions. http://iom.nationalacademies.org/Activities/HealthServices/HearingHealthCareForAdults.aspx |
| Integrating Prevention Science and Public Policy | Meeting/ Workshop | ACF, CDC | NIAAA, NCI, NHLBI, NICHD, NIDA, NIMH, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP, OD/DPCPSI/ORWH | The Society for Prevention Research (SPR) envisions a wellness-oriented society in which evidenced-based programs and policies are continuously applied to improve the health and wellbeing of its citizens. The SPR Annual Meeting provides unique opportunities to advance this vision by providing an integrated forum for the exchange of new concepts, methods, and results from prevention and public health-related research, and communication between scientists, public policy leaders and practitioners concerning the implementation of evidence-based preventive interventions. http://www.preventionresearch.org/2012-annual-meeting/ |
| Inter-agency Adult Literacy Research Group | Committee, Work group, Advisory group, or Task Force | ACF | NICHD | The purpose of this group is to address the research needs and future directions in adult and family literacy. The Department of Education is a partner with this endeavor. |
| Inter-Agency Working Group on Technology Transfer | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OIR/OTT, OD/OER, OD/OSP | This working group recommends opportunities for improving technology transfer (TT) from Federal laboratories, including: (i) current technology transfer programs and standards for assessing the effectiveness of these programs; (ii) new or creative approaches to technology transfer that might serve as model programs for Federal laboratories; (iii) criteria to assess the effectiveness and impact on the Nation''s economy of planned or future technology transfer efforts; (iv) an assessment of cooperative research and development venture programs; and (v) policy and guidance statements to support all Federal Agencies'' TT programs. |
| Inter-Agency Working Group on the National Healthcare Quality and Disparities Report | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, OS | NIMHD, NCI, NHLBI, OD/DPCPSI | This working group provides expert scientific guidance for the National Healthcare Quality and Disparities Report. These annual reports measure trends in effectiveness of care, patient safety, timeliness of care, patient centeredness, and efficiency of care. The reports present, in chart form, the latest available findings on quality of and access to health care. https://www.ahrq.gov/research/findings/nhqrdr/index.html |
| Inter-Society Coordinating Committee (ISCC) for Practitioner Education in Genomics | Committee, Work group, Advisory group, or Task Force | CMS, HRSA | NHGRI, NCI, NEI, NHLBI, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIGMS, NIMH, NINDS, NINR, NLM | This education collaborative facilitates sharing interactions among professional societies, agencies, and health systems. It intends to enhance the accrual of knowledge and skill among practitioners applying genomic results to clinical care. In its start-up phase, the ISCC focused primarily on physicians and dentists. It has since expanded to engage and collaborate with allied practitioner groups such as nurse practitioners, physician assistants, pharmacists, genetic counselors, and nurses comprising integrated health care teams. It will continue to add other relevant professions and add to the reviewed and searchable educational resources on its website. http://www.genome.gov/27554614 |
| Interagency Agreement for Communications on Prevention of Underage Tobacco Use | Public Education Campaign | FDA | NCI | The FDA Center for Tobacco Products (CTP) and the NCI Office of Communications and Education are collaborating on an Interagency Agreement in which CTP will provide funds to NCI to provide planning, formative research, target messaging, creative content, outreach strategies, and communications support for a campaign to prevent underage tobacco use as it relates to FDA’s authorities under the Tobacco Control Act. Primary focus areas include multi-ethnic journalist training and outreach; development of a partnership strategy, digital strategy, and social marketing tools; digital gaming best practices; and formation of a CTP communications workgroup comprised of subject matter experts. |
| Interagency Artificial Pancreas Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NIBIB, NICHD | The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the Food and Drug Administration (FDA) and the NIH to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. |
| Interagency Autism Coordinating Committee (IACC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA | NIMH, NICHD, NIDCD, NIEHS, NINDS | The Interagency Autism Coordinating Committee (IACC) is a Federal advisory committee that coordinates all efforts within the Department of Health and Human Services (HHS) concerning autism spectrum disorder (ASD). Through its inclusion of both Federal and public members, the IACC helps to ensure that a wide range of ideas and perspectives are represented and discussed in a public forum. The committee reconvened in November 2015 to begin a new session under the Autism CARES Act. http://iacc.hhs.gov |
| Interagency Biorisk Management Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | This working group coordinates and collaborates on mechanisms to strengthen research laboratory biorisk management and to promote outreach and education programs that inform scientists, biosafety professionals, institutional officials and the public on biorisk management. |
| Interagency Chemical Risk Assessment Working Group | Committee, Work group, Advisory group, or Task Force | OS | NINDS, NIAID | This working group is a Department of Homeland Security led effort to determine chemical hazards and develop Chemical Risk Threat Assessment list of priority chemicals. |
| Interagency Collaborative Animal Research Education (ICARE) Training Project | Training Initiative | FDA | OD/OER | The Interagency Collaborative Animal Research Education (ICARE) Academies and Train the Trainer Institutes use active learning to train participants to meet their responsibilities for animal welfare oversight. The program empowers accountability for facts and conceptual understanding of Federal standards through the study of realistic problems encountered in animal care and use programs. Faculty includes subject matter experts from biomedical research institutions and federal agencies, including NIH and USDA. Institutional Animal Care and Use Committee members, staff, institutional officials, veterinarians, animal facility personnel, administrators, consultants, as well as compliance and regulatory personnel involved in the humane use of animals in research all may participate in the ICARE program. https://grants.nih.gov/grants/olaw/interagency_icare.htm |
| Interagency Committee on Assistive Technology (ICAT) | Committee, Work group, Advisory group, or Task Force | ACL | NICHD | This committee seeks to improve research on assistive technology. |
| Interagency Committee on Disability and Rehabilitation | Committee, Work group, Advisory group, or Task Force | ACL | NICHD | This committee was established to promote coordination and cooperation among federal departments and agencies conducting disability, independent living, and rehabilitation research programs—including those that relate to assistive technology research, and research that incorporates the principles of universal design. |
| Interagency Committee on Disability Employment and Education Working Group (ICEE/ICDR) | Committee, Work group, Advisory group, or Task Force | ACL | NICHD | The Employment and Education working group scope includes policy, systems, and services research related to employment and self-sufficiency of people with disabilities, and youth transition to work. http://www.icdr.acl.gov/committee/employment-education |
| Interagency Committee on Disability Health and Health Disparities (ICHD/ICDR) | Committee, Work group, Advisory group, or Task Force | ACL | NICHD | The Interagency Committee on Health and Health Disparities of the ICDR provided a series of webinars to promote awareness of current research related to the biological, sociocultural, environmental, and behavioral determinants of health disparities for people with disabilities. |
| Interagency Committee on Disability Research (ICDR) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIDCD | The Interagency Committee on Disability Research (ICDR) was established to promote coordination and collaboration among federal departments and agencies conducting disability, independent living, and rehabilitation research programs—including programs related to assistive technology research, and research that incorporates the principles of universal design. http://www.icdr.us/ |
| Interagency Committee on Disability Research: Working Group on Assistive Technology | Committee, Work group, Advisory group, or Task Force | ACL | NICHD | The Assistive Technology and Universal Design working group scope includes design, development, policy, systems, and services research related to AT; accessibility of electronic information and technology, products, and environments. http://www.icdr.acl.gov/committee/assistive-technology-universal-design |
| Interagency Committee on Medical Rehabilitation (ISMR) | Committee, Work group, Advisory group, or Task Force | ACL | NICHD | The Committee shall identify, assess, and seek to coordinate all Federal programs, activities, and projects, and plans for such programs, activities, and projects with respect to the conduct of research (including assistive technology research and research that incorporates the principles of universal design) related to rehabilitation of individuals with disabilities. |
| Interagency Coordinating Committee for Newborn Screening | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD | This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions. |
| Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, SAMHSA | NIAAA, NICHD, NIDA | The Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences; the most recent was Oct. 31-Nov. 2, 2011 on Recognizing Alcohol-related neurodevelopmental disorder (ARND) in Primary Health Care of Children. http://www.niaaa.nih.gov/ICCFASD |
| Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK, NICHD, NINDS | Coordinates federal efforts to understand how pituitary human growth hormone may have led to the development of Creutzfeldt - Jakob disease in participants of the National Hormone and Pituitary Program. http://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/public-health-service/Pages/public-health-service-interagency-coordinating-committee-human-growth-hormone-creutzfeldt-jacob-disease.aspx |
| Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, IHS, OS, OSG, SAMHSA | NIDA, NIAAA | The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency. https://www.stopalcoholabuse.gov/default.aspx |
| Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) | Research Initiative | ATSDR, CDC, FDA | NIEHS, NCI, NEI, NIAID, NLM | The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS. NICEATM in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientific valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting it. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints. http://ntp.niehs.nih.gov/?objectid=61BA4EF0-C880-CB0E-6C33B90B6612ABCF |
| Interagency Dual Use Outreach Working Group (IDOWG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | This working group develops strategies to educate the research community about Dual Use Research of Concern (DURC) and the DURC-related USG policies http://www.phe.gov/s3/Pages/default.aspx |
| Interagency Epilepsy Working Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA | NICHD, NIA, NIMH, NINDS | This group seeks to improve research about epilepsy. |
| Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA | NIA | This interagency group was established by HHS in response to the Congressional directive to address Alzheimer disease. Under the National Alzheimer’s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran’s Administration, National Science Foundation, and Department of Defense are also involved in this effort. http://aspe.hhs.gov/daltcp/napa/ |
| Interagency Midazolam Product Coordination Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS | A collaboration led by the Department of Health and Human Services (HHS) to facilitate activities, both research and regulatory, related to the Food and Drug Administration (FDA) approval of midazolam for use in treating nerve agent exposure. |
| Interagency Modeling and Analysis Group (IMAG) | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, CSR, NCI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR | The Inter-agency Modeling and Analysis Group (IMAG) is comprised of program directors from nine government agencies in the U.S. including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and continued on by various IMAG agencies through other funding opportunity announcements. The most recent multi-agency funding opportunity was issued in 2015 and expires in 2018. IMAG is planning a tenth anniversary consortium meeting in March 2017. http://www.nibib.nih.gov/research/featured-programs/interagency-modeling-and-analysis-group-imag |
| Interagency Pain Research Coordinating Committee (IPRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | NINDS, NCCIH, NIDA, NIDCR, NINR | The Interagency Pain Research Coordination Committee is an Affordable Care Act mandated committee to coordinate pain research activities across the government. http://iprcc.nih.gov/ |
| Interagency Precision Medicine Initiative Working Group (IPMI WG) | Committee, Work group, Advisory group, or Task Force | FDA, OS | OD/OSP | The IPMI WG coordinates activities across the Federal government to enhance innovation in precision medicine, with the ultimate goal of moving the United States into an era where medical care can be more precisely tailored to each patient and the best outcomes can be achieved for all. |
| Interagency Select Agent Review Group (ISARG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID, OD/OM/OB, OD/OSP | The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the NIH-OD and BARDA, advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed. |
| Interagency Task Force on Military and Veterans Mental Health (ITF) | Committee, Work group, Advisory group, or Task Force | ACL, OS, SAMHSA | NIMH | Executive Order 13625, Improving Access to Mental Health Services for Veterans, Service Members, and Military Families, was released on August 31, 2012, and directed the Departments of Defense (DoD), Veterans Affairs (VA), and Health and Human Services (HHS) to ensure that Veterans, Service Members, and their families have access to needed mental health services and support. The Executive Order also established the Interagency Task Force on Military and Veterans Mental Health (ITF) and directed it to provide an annual review of agency actions, to define specific goals and metrics to aid in measuring progress, and make additional recommendations as appropriate to the President to improve mental health and substance use disorder treatment services for Veterans, Service Members, and their families. The ITF, co-chaired by the DoD Assistant Secretary for Health Affairs, the VA Under Secretary for Health, and the HHS Administrator for the Substance Abuse and Mental Health Services Administration, tracks and reports progress in executing all activities resulting from recommendations made pursuant to the Executive Order. |
| Interagency Workgroup on Child Abuse and Neglect | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CDC, IHS, SAMHSA | NICHD, CSR, NIAAA, NIDA, NIMH, NINDS, OD/DPCPSI/OBSSR | The Federal Interagency Workgroup on Child Abuse and Neglect meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning the prevention of child maltreatment and other related issues. http://www.acf.hhs.gov/cb/resource/fediawg |
| Interagency Workgroup on Technology to Facilitate Aging in Place | Research Initiative | ACL, CMS, FDA | NIA, NCI, NHLBI, NIBIB, NINDS, NINR | The purpose of this Trans-NIH/Inter-Agency group is to develop new platforms for everyday life technology that will enhance the common goals of multiple NIH institutes and other federal government agencies by improving the capability to rapidly conduct peer-reviewed technology research to facilitate aging in place, with a special emphasis on people from underrepresented groups. A platform is a group of technologies that are used as a base upon which other applications, processes or technologies are developed. http://silvrnetwork.org/ |
| Interagency Working Group in the Glycosciences | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI, NICHD, NIDCR, NIDDK | This group meets annually to identify synergies, discuss progress on the development of national standards for carbohydrates and exchanges information on the glycosciences being pursued at each agency |
| Interagency Working Group on Neuroscience | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIMH, NIA, NIDA, NINDS, NINR, OD/DPCPSI/OBSSR | By Executive Order, the White House Office of Science and Technology Policy established the Interagency Working Group on Neuroscience (IWGN) by action of the National Science and Technology Council. The purpose of the group is to foster collaboration across agencies and to coordinate federal investments in neuroscience research. The IWGN coordinates activities in neuroscience research across the Federal Government with a focus on the fundamental understanding of learning, brain development and plasticity, and brain health and recovery. The IWGN enhances federal efforts related to: improving our understanding of learning and cognition, and applying this understanding to improvements in education and other areas; improving our understanding of a variety of neurological conditions and injuries; and developing appropriate resources, tools, techniques, interventions, and therapies to assist in research, treatment, and recovery. The IWGN includes members from the Departments of Agriculture, Defense, Education, Energy, Health and Human Services, Homeland Security, Justice, and Veterans Affairs, as well as the Central Intelligence Agency, Environmental Protection Agency, National Aeronautics and Space Administration, the National Science Foundation, and the Office of the Director of National Intelligence. https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/NSTC/charter_2015_nstc_cos_working_group_on_neuroscience.pdf |
| Interagency Working Group on Open Science | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, OS | OD/OSP, OD/OER | On February 22, 2013, the Director of the White House Office of Science and Technology Policy (OSTP), Dr. John Holdren, issued a memorandum to all agency and department heads entitled, “Increasing Access to the Results of Federally Funded Scientific Research.” The memo directed federal agencies with more than $100 million in annual conduct of research and development to develop plans for increasing public access to peer-reviewed scientific publications and digital data resulting from federally funded research investments. Within HHS, six operating divisions and the Office of the Secretary meet this threshold. The HHS operating divisions have aligned their work through a common set of guiding principles and a framework around which they could develop implementation plans tailored to the needs of their research communities, taking into account their unique missions and legal authorities. OSTP also maintains federal-wide interagency working group. http://www.hhs.gov/open/publicaccess/index.html |
| International Cancer Control Partnership | Other | CDC | NCI | The National Cancer Institute and the Union for International Cancer Control convened global partners including CDC to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners will assist countries by: creating a searchable database of current cancer control plans from around the globe; performing analysis of gaps and highlighting priority areas for inclusion in plans; training appropriate personnel to develop plans with targets and evaluation strategies; providing planners with relevant existing materials and tools; and offering technical assistance. ICCP partners will use their collective state, country and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets. http://www.iccp-portal.org/ |
| International Conference on Betel Quid and Areca Nut | Meeting/ Workshop | CDC | NCI, NIAID, NIDCR | This conference, held in April 2016, focused on understanding the impact of use of areca nut and betel quid, both with and without tobacco, and all its variants, addiction issues, and the associated cancers and other oral health issues, specifically cancers of the lip, mouth, tongue, pharynx, and esophagus. http://umconference.um.edu.my/ICBA2016 |
| International Consortium for Emergency Contraception Technical Advisory Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | International Consortium for Emergency Contraception (ICEC) Technical Advisory Group (TAG) brings together experienced scientists, researchers, and other thinkers not currently affiliated with an ICEC member organization. These experts provide technical advice and input to the Consortium and serve as individuals, not as representatives of their organization. http://www.cecinfo.org/about/technical-advisory-group/ |
| International Select Agent Review Group (ISARG) | Committee, Work group, Advisory group, or Task Force | CDC | OD/OSP, NIAID | Provides advice to NIAID on projects it intends to fund that involve the use of Select Agents and Toxins overseas. |
| International TB Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Subgroup of the Federal TB Task Force - Int. TB WG chaired and organized by USAID. Monthly meetings and coordination of international TB support. |
| Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee | Committee, Work group, Advisory group, or Task Force | OS | NLM | The Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to ONC on standards and implementation specifications to promote interoperability of computer systems and health information. https://www.healthit.gov/facas/calendar/2017/01/17/standards-2017-interoperability-standards-advisory-task-force |
| Intradepartmental Council for Native American Affairs (ICNAA) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIMHD | The purpose of this collaborative activity is to support activities of the Intradepartmental Council for Native American Affairs (ICNAA), including tribal consultation sessions and development of the annual tribal consultation report. https://www.hhs.gov/about/agencies/iea/tribal-affairs/about-icnaa/index.html |
| Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NIAID | The Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) makes technically based recommendations to the APHIS/CDC Select Agent and Toxin Program on restricted experiments of Select Agents and Toxins and the exclusion and exemption of attenuated strains. The Committee also conducts a biennial review of the Select Agents and Toxins list for HHS and overlap agents and toxins. http://www.nicbr.mil/ |
| Investigations of Early Life Determinants of Pediatric and Adult Malignancies in a Population | Research Initiative | CDC | NCI | In collaboration with investigators from the U.S. Centers for Disease Control and Prevention (CDC) and the China CDC, the National Cancer Institute (NCI) is assessing risk of pediatric leukemia and other pediatric cancers in a large population of offspring of mothers enrolled in a community intervention program of peri-conception folic acid supplementation in China. Pediatric cancer risks will be compared in offspring of mothers treated vs offspring of mothers not treated with folic acid supplements. |
| IOM Consensus Study: Public Health Approaches to Reduce Vision Impairment and Promote Eye Health. | Other | CDC | NEI | The Institute of Medicine conducted a consensus study to examine the core principles and public health strategies to reduce visual impairment and promote eye health in the United States. The study described limitations and opportunities to improve vision and eye health surveillance; reduce vision and eye health disparities; promote evidence-based strategies to improve knowledge, access and utilization to eye care; identify comorbid conditions and characterize their impact; and, promote health for people with vision impairment. The study also examined the potential for public and private collaborations at the community, state, and national levels to elevate vision and eye health as a public health issue. http://iom.nationalacademies.org/Activities/PublicHealth/ReduceVisionImpairment.aspx |
| It’s a Noisy Planet. Protect Their Hearing® Public Education campaign | Public Education Campaign | CDC | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) sponsors, It’s a Noisy Planet Protect Their Hearing®, a national public education campaign to increase awareness among parents of children ages 8 to 12 about the causes and prevention of noise-induced hearing loss (NIHL). The campaign disseminates messages through print and digital materials, community-based events, school presentations, and other methods. The campaign launched in October 2008 as a follow up to the NIDCD''''s Wise Ears! campaign, which increased awareness about preventing NIHL among workers, employers, and Americans of all ages from 1999 to 2008. The CDC’s National Institute for Occupational Safety and Health (NIOSH) has actively collaborated with the NIDCD for both campaigns. https://www.noisyplanet.nidcd.nih.gov |
| Joint Agency Microbiome (JAM) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, CC, CIT, CSR, FIC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/OAR, OD/DPCPSI/ODS | The Joint Agency Microbiome (JAM) Working Group provides an interagency forum for discussion of microbiome-related topics and research. The working group includes members from various NIH Institutes and Centers and the FDA. |
| Joint Agency Nutrition (JAN) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NICHD, OD/DPCPSI/ODP, OD/DPCPSI/ODS | This Working Group was established to address gaps and opportunities in the areas of dietary supplements and nutrition research related to pregnant women and children and chronic diseases. |
| Joint Committee and Joint Commission Meetings | Meeting/ Workshop | CDC, FDA, OS | NCI, FIC, NIAID | US State Department establishes collaborative agreements with foreign governments in fields of science and technology. These Joint Committee and Joint Commission Meetings (JCMs) facilitate discussion on selected topics creating cross-talk among the equivalent government agencies leading towards future collaborations. The Office of the HHS Secretary (OS), through the Office of Global Affairs (OGA), organizes the operational divisions of the Department of Health and Humans Services (HHS); The Fogarty International Center (FIC) facilitates the participation of NIH Institutes and Centers. For FY2011, JCMs were convened for Brazil, Colombia, and Mexico. |
| Joint Fellowship Program | Training Initiative | FDA | NCI | The objective of the NCI-FDA Joint Fellowship Training Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set that bridge the two disparate processes. Fellows will learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review. http://iotftraining.nci.nih.gov/ |
| Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations | Research Initiative | CDC | NCI | Epidemiological studies are being conducted to assess small-area variation of HHV8 and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda. |
| Kidney, Urologic, & Hematologic Diseases Interagency Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIDDK, NCCIH, NCI, NHLBI, NIA, NICHD, NINDS | The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. Public Law 99-158 created the KUHICC in 1987 and emphasized the importance of interagency coordinating meetings. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and to form partnerships among agencies. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/kidney-urologic-hematologic-diseases-interagency-coordinating-committee/Pages/default.aspx |
| Laboratory-Developed Tests (LDT) Interagency Task Force | Other | CDC, CMS, FDA | OD/OSP, NLM | The Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) put together an interagency task force to expand their collaboration around oversight of laboratory-developed tests (LDTs). FDA issued draft guidance in October 2014 for overseeing the quality of LDTs, proposing that the FDA oversee the tests alongside CMS, which regulates labs through the Clinical Laboratory Improvement Amendments (CLIA). |
| Leadership Forums in Cancer Control Planning | Meeting/ Workshop | CDC | NCI | The goal of the Cancer Control Leadership Forum Program is to increase the capacity of participating countries from target regions to initiate or enhance cancer control planning and implementation through a multi-sectoral approach. The three-day Forum is the focal point of a three-part process spanning approximately 18 months and is an opportunity for each country to develop an action plan to move their cancer control planning efforts forward and to exchange experiences about creating and implementing comprehensive cancer control plans with other countries in the region. https://www.cancer.gov/about-nci/organization/cgh/research/cancer-control-leadership-forums |
| Leprosy Research Support in Armadillos (Dasypus Novemcinctus) | Other | HRSA | NIAID | The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers. |
| Library of Integrated Network-based Cellular Signatures (LINCS) | Research Initiative | FDA | OD/DPCPSI, NHGRI, NHLBI, OD/DPCPSI/OSC | The Library of Integrated Network-based Cellular Signatures (LINCS) program is developing a library of data at the cellular level that describes how different types of cells respond to a variety of agents that disrupt normal cellular functions, called “perturbagens.” This library may help us better understand normal and diseased conditions in cells and how to alter them. In FY2016, the LINCS program discussed with the Food and Drug Administration (FDA) how LINCS data may be used to predict the toxicity of drugs in cardiac (heart) cells. https://commonfund.nih.gov/LINCS/index |
| Linkage to Care Committee for Adolescents with HIV/AIDS | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The purpose of this committee is to collaborate with other HHS agencies to improve the outcome of adolescents with HIV/AIDS. |
| Logical Observation Identifiers Names and Codes (LOINC) | Resource Development | AHRQ, CDC, CMS, HRSA, IHS, OS | NLM | This activity supports the maintenance, distribution, and continued development of LOINC®, a set of universal codes and names to identify laboratory and other clinical observations which facilitates the exchange and pooling of clinical results for clinical care, outcomes management, public health and research. The Regenstrief Institute, Inc., an internationally renowned healthcare and informatics research organization, maintains the LOINC database and supporting documentation, and the RELMA mapping program. http://www.nlm.nih.gov/research/umls/loinc_main.html |
| Long-term Oxygen Treatment Trial | Research Initiative | CMS | NHLBI | The Long-term Oxygen Treatment Trial (LOTT) is a randomized controlled clinical trial to assess the efficacy of around-the-clock, supplemental oxygen therapy in subjects with chronic obstructive pulmonary disease and moderately severe hypoxemia. NHLBI administered and oversaw the study, and Medicare covered the costs of items and medical services that are generally available through that program to beneficiaries enrolled in the trial. https://jhuccs1.us/lott/Default.asp |
| Lupus Federal Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NIAMS, NCCIH, NEI, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The Lupus Federal Working Group, established on behalf of the HHS Secretary by the NIH, facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus. http://www.niams.nih.gov/About_Us/Committees/lupus_fwg.asp |
| Lyme and Tick-borne Diseases Work Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This work group involves members from agencies including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and the NIH with the purpose of continued coordination and communication of activities, policy updates, events, agency highlights, and other shared interests relating to Lyme disease and other tick-borne diseases. |
| Mapping of the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) and International Classification of Disease (ICD) Clinical Terminology | Resource Development | CDC, OS | NLM | The U.S. Department of Health and Human Services (HHS) has set a goal for the nationwide implementation of an interoperable health information technology infrastructure to improve the quality and efficiency of health care. Achieving this goal will require that key clinical data elements are captured or recorded in detailed, standardized form (using standard vocabularies, codes, and formats) as close to their original sources (patients, health care providers, laboratories, diagnostic devices, etc.) as possible. If these standardized clinical data can also be used to generate HIPAA- compliant billing transactions automatically, this will provide another incentive for adoption of clinical data standards. For automated generation of bills from clinical data to become a reality, robust mappings from standard clinical terminologies to the HIPAA code sets must be created. To support the transition to ICD-10-CM in 2015, a map from SNOMED CT to ICD-10-CM is being created. https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd10cm.html |
| Medical Countermeasures Surveillance Integrated Program Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This team was created to identify the regulatory science research required for real‐time tracking and evaluation of medical countermeasures (MCMs) during public health emergencies. The team is developing a comprehensive Action Plan to identify and facilitate the development of systems that can be used to monitor MCM safety and clinical benefit during an event. |
| Medical Device Research Interest Group | Other | FDA | NICHD | The purpose of the group is to increase collaboration and communication regarding specific initiatives or policies that affect medical device development, regulatory approval, and commercialization. |
| Medical Education Partnership Initiative (MEPI) | Training Initiative | CDC, HRSA | FIC, NCI, NHGRI, NHLBI, NIMH, NINDS, NINR, OD/DPCPSI/OAR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC | The Medical Education Partnership Initiative (MEPI) builds human capacity for health in Africa by strengthening the medical education system in an environment that values and nurtures research in President’s Emergency Plan for AIDS Relief (PEPFAR)-funded countries. MEPI aims to advance PEPFAR''s goal of increasing the number of new health care workers by 140,000; strengthen in-country medical education systems; and build clinical and research capacity in Africa as part of a retention strategy for faculty of medical schools and clinical professors. The 13 awards administered by FIC/NIH are either in a no-cost extension to complete their activities or they have completed. MEPI recently began a stage 2 and NIH is working with PEPFAR on two new program concepts that build on the success of the first stage. The first would support a governing body to continue networking activities among health educators in Africa and the second would fund efforts to strengthen training and retention of health care professionals; encourage research to improve and evaluate educational practices; and enhance capacity to develop, implement and evaluate evidence-based services with an emphasis on HIV/AIDS. NIH/MEPI works in collaboration with OGAC and HRSA. http://www.fic.nih.gov/Programs/Pages/medical-education-africa.aspx |
| Medical Expenditure Panel Survey (MEPS) | Health Survey | AHRQ | NCI | The Medical Expenditure Panel Survey (MEPS) is a set of large-scale surveys of families and individuals, their medical providers, and employers across the United States. MEPS is the most complete source of data on the cost and use of health care and health insurance coverage. http://meps.ahrq.gov/mepsweb/ |
| Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS | Other | FDA | NINDS | This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and FDA approval. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm446756.htm |
| Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS | Other | FDA | NINDS | This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and FDA approval and licensure. http://www.fda.gov/aboutfda/partnershipscollaborations/memorandaofunderstandingmous/domesticmous/ucm397727.htm |
| Memorandum of Understanding Between National Toxicology Program (NTP) and NIH/NIEHS, FDA, and CDC/NIOSH | Other | CDC, FDA | NIEHS | The interagency NTP, established in 1978 and administratively headquartered at NIH/NIEHS, is an ongoing cooperative effort to evaluate substances of public health concern, develop improved methods, strengthen the science base in toxicology, and provide information important for decisions to safeguard public health. This MOU between FDA, NIH/NIEHS, CDC/NIOSH and NTP affirms a commitment to provide resources dedicated toward carrying out NTP’s mission and outlines various administrative and managerial actions the agencies will take to support NTP’s activities. http://ntp.niehs.nih.gov |
| Metabolomic Characterization of Fungi | Research Initiative | CDC | NIEHS, NIAID | The NIEHS and CDC''s National Institute for Occupational Safety and Health are jointly interested in examining the feasibility of using nuclear magnetic resonance to characterize air samples of fungi. |
| Microbiological Testing of Live Biotherapeutic Products | Resource Development | FDA | NIAID | The research and manufacturing community has a need for regulatory tools to determine the identity, potency, and purity of new probiotic products currently under development. This project will develop tools for identifying these products, therefore satisfying one of the regulatory requirements for product characterization needed by the FDA for evaluation. |
| Microbiome Interagency Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/DPCPSI, NHGRI, OD/DPCPSI/OSC | The purpose of the Microbiome Interagency Working Group (MIWG) is to develop a Federal Strategic Plan for microbiome research. The Plan should use the needs, gaps, and Report’s recommendations as a foundation, taking into account how future Federal actions could benefit from an understanding of and engagement with current international activities. The Plan should provide recommendations for improving coordination of microbiome research among Federal agencies and also between Federal agencies and non-Federal domestic and international microbiome research efforts. The MIWG will also strive to enhance the Federal R&D enterprise by embracing diversity, recognizing that inclusion of a broad range of backgrounds and perspectives is critical to achieving robust intellectual dialogue. https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/NSTC/charter_-_microbiomes_wg_signed_2.pdf |
| Microphysiological Systems for Drug Efficacy and Toxicity Testing | Research Initiative | FDA | NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI, OD/DPCPSI/ORWH | The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the U.S. Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans. http://www.ncats.nih.gov/research/reengineering/tissue-chip/tissue-chip.html |
| Microsystems Team | Research Initiative | FDA | NIDDK, NCATS, NCI, NIBIB, NICHD, NIEHS, NINDS | The NIH has identified a critical need for improved model systems to predict efficacy, safety, bioavailability, and toxicology outcomes for candidate therapeutics. This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund and participating NIH IC''s, invites applications for projects that will develop accurate cellular and organ microsystems representative of human physiology for the evaluation of drug efficacy and toxicity. By definition, these cellular and organ microsystems will have a multicellular architecture representing the characteristics and functions of the tissue of origin and will demonstrate a reproducible and viable operation under physiological conditions over a long culture period. It is anticipated that these bio-engineered human tissue models could lead to the development and commercialization of microsystems that will enable rapid and high fidelity evaluation of safety and efficacy for candidate therapeutics. http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-11-022.html |
| Mind Your Risks | Public Education Campaign | CDC, CMS | NINDS | The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia. http://www.mindyourrisks.nih.gov/ |
| Models of Infectious Disease Agent Study (MIDAS) | Research Initiative | CDC | NIGMS, FIC, NIAID | Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models will be useful to public health workers and researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid in our understanding of the disease and its spread. http://www.nigms.nih.gov/Research/SpecificAreas/MIDAS/Pages/default.aspx |
| Monthly NHLBI/BARDA/DoD Meeting | Meeting/ Workshop | OS | NHLBI | BARDA is funding pathogen reduction in response to the ebola epidemic and meets monthly with the DoD and NHLBI to discuss. |
| Mortality Disparities of American Communities | Health Survey | CDC | NIA, NCI, NHLBI | A national, longitudinal, mortality study to study the effects of differentials in demographic and socio-economic characteristics on mortality. http://www.census.gov/did/www/nlms/ |
| mPOWER mHealth Group | Research Initiative | CDC, CMS, FDA, HRSA, IHS | NINR, CIT, FIC, NCCIH, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI/OBSSR | Mobilizing Research supports the development, promotion, and dissemination of a wireless health research recruitment and data platform. In addition to being a primary data collection mechanism, the platform would be a data repository for both basic and applied health science, making validation and standardization of mobile health tools accessible. |
| Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | ACL, CMS, FDA | NIBIB, NCI, NHLBI, NIA, NIAMS, NICHD, NIDCD, NIDCR, NINDS | The Multi-Agency Tissue Engineering Science (MATES) Interagency Working Group (IWG), originally organized under the auspices of the Subcommittee on Biotechnology of the National Science and Technology Council (NSTC), was established in 2000 to provide a forum for federal agencies involved in tissue science and engineering to stay informed of each other’s activities and coordinate research efforts. Its five-year plan was renewed in 2002 and new Terms of Reference were introduced in 2007. Since early 2009, the MATES group has worked independently of NSTC but is in the process of being charted under the NSTC''s Subcommittee on Technology to reflect an emerging focus on translation. This process is ongoing as of December 2016. . The principal purpose of the MATES IWG is to provide a platform across which the many member agencies can interact and exchange information on tissue engineering efficiently and effectively. The group played a role in responded to a GAO review of regenerative medicine in 2015. The MATES IWG regularly organizes and co-chairs workshops at the annual premier meeting in the field, the Tissue Engineering and Regenerative Medicine International Society (TERMIS), held this past year December 11-14, 2016. |
| Multinational Influenza Seasonal Mortality Study (MISMS) Research | Research Initiative | FDA, OS | FIC, NHLBI, NIAID, NLM | The Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses, including natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed by MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. Our research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications. http://misms.net |
| Muscular Dystrophy Coordinating Committee (MDCC) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, FDA, HRSA | NINDS, NHLBI, NIAMS, NICHD | This Committee coordinates activities across NIH and with other Federal health programs and activities relevant to the various forms of muscular dystrophy. http://www.ninds.nih.gov/about_ninds/groups/mdcc/ |
| My Family Health Portrait | Resource Development | CDC, HRSA, OSG | NHGRI, NCI, NICHD, NLM | My Family Health Portrait (MFHP) is a web-based tool from NHGRI and the U.S. Surgeon General’s Family History Initiative that helps individuals track their family health history. Using any computer, an Internet connection and an up-to-date Web browser, individuals add health information to build a drawing of their family tree and a chart of their family health history while exploring disease calculators. The tool is designed to keep all data on the client side to maximize privacy using HTML, CSS, and client-side JavaScript as its principal platforms. Users interact with the tool in a browser to build family health history generating an XML data file (HL7v3 standard) that users store locally or in the cloud. Both the family tree and the chart can be printed and shared with family members and an individual’s doctor. https://familyhistory.hhs.gov/FHH/html/index.html |
| Naloxone Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDA | The goal of this Workgroup is to discuss ways to implement the use of naloxone as emergency treatment for opioid overdose. |
| Nanomaterial Registry | Resource Development | CDC, FDA | NCI, NIBIB, NIEHS | The Nanomaterial Registry is an authoritative, fully curated resource available to the public that archives research data on nanomaterials and their biological and environmental implications. https://www.nanomaterialregistry.org/ |
| Nanotechnology Characterization Laboratory | Research Initiative | FDA | NCI, NIEHS | The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications. http://ncl.cancer.gov/ |
| National Academies of Sciences Issues in Organ Donor Intervention Research Study | Other | HRSA | NHLBI, NIAID, NIDDK | The Committee on Issues in Organ Donor Intervention Research is examining the ethical, policy, regulatory, and operational issues relevant to the conduct of research involving deceased organ donors (for purposes of the study, the concept excludes interventional research preceding declaration of death by neurologic or cardiopulmonary criteria among potential organ donors). The committee will examine the gaps, barriers, and opportunities for clinical research involving deceased donors that aims to increase the quality and quantity of donated organs available for transplantation, with particular attention to interventions administered to the donor and thus potentially affecting all of the donor''s organs. Specifically, the report will delineate the issues pertinent to organ donor intervention research and make recommendations to maximize public and professional trust in the organ donation process and ethical conduct of organ donor intervention research. http://www.nationalacademies.org/hmd/Activities/Research/IssuesinOrganDonorInterventionResearch.aspx |
| National Academy of Sciences "Investing in Young Children Globally" | Other | CDC | NICHD, FIC, NIMH | The NAS forum on "Investing in Young Children Globally" sponsors conferences, supports discussion papers, and engenders discussion among NAS/NAM members, federal partners, and international experts on children''s health and well being around the world. For example, a March 2016 meeting of the forum brought together two communities—early childhood development and peacebuilding—to promote knowledge exchange and identification of opportunities to leverage investments in early childhood development to promote peace. USAID, the World Bank, CDC, and ASPE along with NIH support this forum. http://nationalacademies.org/hmd/activities/children/investingyoungchildrenglobally.aspx |
| National Action Alliance for Suicide Prevention (NAASP) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, HRSA, IHS, OS, OSG, SAMHSA | NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | Founded in September 2010, the NAASP is a public-private partnership designed to advance the National Strategy for Suicide Prevention in the United States. The NAASP''s Research Priority Task Force (RPTF) is charged with developing a process to prioritize suicide prevention research efforts and consider ways to integrate science and service to ensure that suicide deaths decrease significantly within the next decade. The RPTF released the Nation''s first suicide research agenda, “A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives.” The research agenda includes an overarching goal to advance suicide prevention research more rapidly, seeking ways to reduce suicide deaths and attempts by 20% in five years and by 40% or greater in ten years. In 2015, the RPTF produced the "U.S. National Suicide Prevention Research Efforts: 2008-2013 Portfolio Analyses." The analyses revealed that investments in suicide research are severely lagging, but there is a growing knowledge base of intervention research. In 2016, the National Institutes of Health, Office of Disease Prevention supported the “Pathways to Prevention Workshop, Advancing Research to Prevent Youth Suicide in 2016,” which further refined methodological challenges and data linkage needs relevant to multiple NIH Institutes. The National Institute of Mental Health (NIMH) developed a request for information relevant to this workshop, and a federal partners meeting in the spring of 2017 will consider additional actions in response to the workshop recommendations. http://actionallianceforsuicideprevention.org/ |
| National Action Plan for the Elimination of MDR TB | Other | CDC | NIAID | Federal agenciees involved in the National Action Plan for the Elimination of MDR -TB - coordination of reporting across agencies. Annual reporting and regular updates on opportunities for cross-agency collaboration and information sharing. https://www.usaid.gov/what-we-do/global-health/tuberculosis/resources/news-and-updates/national-action-plan-combating-mdr |
| National Advisory Board for Medical Rehabilitation Research | Committee, Work group, Advisory group, or Task Force | CDC, CMS | NICHD, CSR, NCATS, NCI, NHLBI, NIA, NIAMS, NIBIB, NIDCR, NINDS, NINR | The National Advisory Board for Medical Rehabilitation Research (NABMRR) is a Federal Advisory Committee that is composed of researchers, clinicians, and members of the public that advise the Directors of the National Center for Medical Rehabilitation Research, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institutes of Health on issues related to research in medical rehabilitation. The Board includes Ex Officio members from various Federal Departments and Agencies (VA, DoD, NSF, NIDILRR, AHRQ, FDA) to aid in the coordination of Federal programs, activities, projects, and plans for the same with respect to the conduct of research related to rehabilitation of individuals with disabilities. In 2015, the Board provided advice and consultation on: the development of a NIH Rehabilitation Research Plan, the review and marketing of a Medical Rehabilitation Research Infrastructure Network, the structure and funding of training opportunities for rehabilitation scientists, and concept approval for programs planned by the NCMRR. http://www.nichd.nih.gov/about/advisory/nabmrr/pages/index.aspx |
| National Advisory Committee on Children and Disasters | Committee, Work group, Advisory group, or Task Force | OS | NICHD | The National Advisory Committee on Children and Disasters provides expert advice and consultation to the HHS Secretary on comprehensive planning and policies to meet the needs of children before, during, and after a disaster or other public health emergency. |
| National Ambulatory Medical Care Survey (NAMCS) Asthma Supplement - Interagency agreement with CDC/NCHS | Health Survey | AHRQ, CDC | NIEHS, NHLBI, NIAID, NICHD | Developed a survey of a national sample of primary care health providers and specialists likely to see asthma patients to gauge implementation of the NHLBI Guidelines for the Diagnosis and Management of Asthma. http://www.cdc.gov/namcs/ |
| National Amyotrophic Lateral Sclerosis (ALS) Registry | Resource Development | ATSDR, CDC | NINDS | The National ALS Registry is a congressionally mandated registry for persons in the U.S. with ALS. It is the only population-based registry in the U.S. that collects information to help scientists learn more about who gets ALS and its causes. http://wwwn.cdc.gov/als/ |
| National Biomonitoring Network Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The National Biomonitoring Network is an effort coordinated by the Association of Public Health Laboratories (APHL) to formally link national, regional, state and local laboratories conducting the analysis of environmental exposures in biological samples to ensure high quality data for use in public health practice. The effort is led by a Steering Committee of experts from the public health laboratories and federal agencies supporting biomonitoring efforts and research, including NIEHS. https://www.aphl.org/aboutAPHL/publications/action/Pages/APHL-in-Action-Fall-2016-NBN.aspx |
| National Center for Injury Prevention and Control Board of Scientific Counselors | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, SAMHSA | NICHD, NIA, NIDA, NIMH | The Board of Scientific Counselors (BSC) advises the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCIPC regarding surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence. The Board makes recommendations regarding policies, strategies, objectives, projects, and priorities, and reviews progress toward injury and violence prevention. https://www.cdc.gov/injury/bsc/ |
| National Clinical Trials Network (NCTN) Scientific Steering Committees (SSCs) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to: (1) increase the transparency and openness of the trial design and prioritization process; (2) enhance patient advocate and community oncologist involvement in clinical trial design and prioritization; (3) convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies. http://www.cancer.gov/about-nci/organization/ccct/steering-committees |
| National Coalition for Oversite of Assisted Reproductive Technologies (NCOART) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The National Coalition for Oversight of Assisted Reproductive Technologies (NCOART) has become a successful forum for discussion of issues by organizations involved in the assisted reproductive technologies (ART) in the United States. |
| National Collaborative on Childhood Obesity Research (NCCOR) | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCI, NHLBI, NIDDK, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The National Collaborative on Childhood Obesity Research (NCCOR) brings together four of the nation’s leading research funders – the Centers for Disease Control and Prevention, the National Institutes of Health, the Robert Wood Johnson Foundation, and the U. S. Department of Agriculture – to address the problem of childhood obesity in America. NCCOR focuses on efforts that have the potential to benefit children, teens, their families, and the communities in which they live. A special emphasis is put on the populations and communities in which obesity rates are highest and rising the fastest. NCCOR''''s goals are to identify intervention needs, improve child obesity surveillance, improve research and evaluation methodologies, and provide national leadership to implement evidence-based practice and policy. NCCOR also works with many non-health partners to develop sustainable environmental design and food systems strategies to reach high risk populations and communities. http://www.nccor.org/ |
| National Committee on Vital and Health Statistics | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, OS | OD/DPCPSI/OBSSR | The National Committee on Vital and Health Statistics (NCVHS) is the statutory public advisory body to the Secretary of Health and Human Services on health information policy. Established in 1949, NCVHS provides advice and assistance on key health data issues related to community and population health, standards, privacy and confidentiality, quality, and data access and use. It reports regularly to Congress on HIPAA implementation, and serves as a forum for interaction between HHS and interested private sector groups. Members have distinction in such fields as public health, education, informatics, law, economics, and medicine. http://www.ncvhs.hhs.gov/ |
| National Coordinated Child Safety Initiative Steering Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA | NICHD | The Child Safety Network is supported by the National Coordinated Child Safety Initiative Steering Committee which will work to create new synergy among public and private stakeholders and to support the activities of the Child Safety Collaborative Innovation and Improvement Network (CoIIN) strategy teams. The Steering Committee will provide advice to the Child Safety CoIIN and help communicate the lessons and accomplishments of the Child Safety CoIIN to a broad national audience that will include public health professionals, policymakers, funders, and families. https://www.childrenssafetynetwork.org/national-coordinated-child-safety-initiative |
| National Database for Antibacterial Resistance | Resource Development | CDC | NIAID, NHGRI | The objective of this collaboration is to produce a collection of high quality genome sequences from antibiotic resistance strains and to create and maintain a publicly accessible database, National Database for AR, developed and housed at NCBI/NLM. |
| National Diabetes Education Program (NDEP) | Public Education Campaign | AHRQ, CDC, HRSA, IHS | NIDDK | Established in 1997, the National Diabetes Education Program (NDEP) is a federally-funded program sponsored by NIH and CDC and includes more than 200 partners at the federal, state and local levels that work together to improve the treatment and outcomes for people with diabetes, promote early diagnosis, and prevent or delay the onset of type 2 diabetes. http://www.ndep.nih.gov |
| National Drug Facts Chat Day | Public Education Campaign | CMS | NIDA, NIAAA, NIMH | The National Institute on Drug Abuse (NIDA) and several partner U.S. Department of Health and Human Services agencies and National Institutes of Health Institutes "Chat" in real time with high school students across the country. The students ask questions (anonymously) on drugs and get research-based responses directly from NIDA and other government scientists. http://drugfactsweek.drugabuse.gov/chat/ |
| National Family Health History Group | Public Education Campaign | CDC, HRSA, OS, OSG | NHGRI, NICHD, NLM, OD/OSP | Federal, state, and other stakeholders focus on increasing awareness of the value of family health history in managing health risks. National Family History Day is designated by the Surgeon General for increasing awareness of the above. Members of this group coordinate public communications and resource development. |
| National Food and Nutrient Analysis Program (NFNAP) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, IHS | NCI, NEI, NHLBI, NIA, NICHD, NIDDK, OD/DPCPSI/ODS, OD/DPCPSI/ORWH | The generation of original analytical data for foods at the U.S. Department of Agriculture (USDA) is conducted through the National Food and Nutrient Analysis Program (NFNAP) in collaboration with multiple groups including the Department of Health and Human Services (HHS) and other federal agencies. NFNAP includes statistically based sampling plans for Key Foods, and analysis of foods by qualified laboratories. The five Specific Aims of the NFNAP are to: 1) establish a monitoring program for Key Foods and critical nutrients. Key Foods are frequently consumed foods and ingredients, which contributed, collectively, more than 75% of the intake of any specific nutrient for the U.S. population; 2) conduct comprehensive analyses of selected Key Foods; 3) develop databases for high priority foods consumed by U.S. ethnic subpopulations; 4) develop databases for new bioactive components; and 5) develop a validated database for ingredients in dietary supplements. Analytical data generated through the NFNAP are compiled and released in annual updates of the USDA National Nutrient Database for Standard Reference (SR). They are also used to calculate estimates for related foods not analyzed, to assess nutrient variability, and to evaluate methods for estimating the nutrient content of multi-ingredient foods. These values will be used by the Food Surveys Research Group (FSRG), Agricultural Research Service (ARS) to develop the Food and Nutrient Dataset for Dietary Surveys used in the “What We Eat in America” (WWEIA) component of NHANES. http://www.ars.usda.gov/SP2UserFiles/Place/12354500/FactSheets/NDL_FactSheet_NFNAP.pdf |
| National Glycohemoglobin Standardization Program (NGSP) | Public Education Campaign | CDC | NIDDK | The purpose of the NGSP (originally the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. http://www.ngsp.org/ |
| National Health and Aging Trends Study (NHATS) | Health Survey | CMS, OS | NIA | The National Health and Aging Trends Study (NHATS) will examine how the daily lives of older adults change as they age. This research will help scientists understand the social and economic consequences of late-life disability for individuals, families, and society. http://www.nhats.org/ |
| National Health and Nutrition Examination Survey (NHANES) | Health Survey | CDC, FDA, OS | OD/DPCPSI/ODP, NCI, NHLBI, NIA, NIDDK, OD/DPCPSI/ODS | A program of studies designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews and physical examinations. ODS uses this survey mechanism to collect data on dietary supplement use and data on biomarkers of nutritional status. http://www.cdc.gov/nchs/nhanes.htm |
| National Health and Nutrition Examination Survey (NHANES) - Audiometric Exams and Hearing-Related Questions | Health Survey | CDC | NIDCD | To provide support to the National Center for Health Statistics (NCHS), CDC for audiometry testing and related questions on hearing loss and noise exposure in adults ages 20 to 69 years in the National Health and Nutrition Examination Survey (NHANES) for data collection years 2015–2016. The study collects pure-tone, air conduction hearing thresholds at .5, 1, 2, 3, 4, 6, and 8 kHz in each ear separately, as well as otoscopic exams, tympanometry, and acoustic reflexes on representative samples of the non-institutionalized U.S. population in sound-treated booths meeting recommended ANSI standards. Questionnaire information about tinnitus (frequency and degree of burden), use of hearing aids and other assistive devices, as well as exposure to firearms or other sources of loud noise are collected in home interviews prior to the subjects’ visit to the mobile exam centers (MECs) for audiometric exams. A similar hearing component was part of earlier NHANES, 1999–2004, and NHANES 2011–2012 conducted on a representative samples of U.S. adults, ages 20 to 69 years. One of the Healthy People 2010 goals is to assess (with the goal of reducing) noise-induced hearing loss in adults. For this purpose, audiograms are examined and “notches” identified in the higher frequency ranges at 3, 4, or 6 kHz as a surrogate marker of noise exposure. Computer algorithms to identify the notches have been developed. The NHANES, 1999–2004, data serve as a baseline, but to assess progress on this goal in Healthy People 2020, hearing thresholds of U.S. adults must be measured again in NHANES. NCHS directs the data collection contractor (i.e., WESTAT) in establishing and revising protocols for the hearing component and in preparing training and field manuals. NCHS provides NIDCD with an opportunity to collaboratively review summary data for purposes of quality control during the data collection period and, also, provides NIDCD with a data file for quality review approximately three months before the Public Use data release. http://www.cdc.gov/nchs/nhanes.htm |
| National Health and Nutrition Examination Survey (NHANES) - Physical Activity and Muscle Strength Components | Research Initiative | CDC | NCI, NHLBI, NIA, NIDDK, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | For the National Health and Nutrition Examination Survey (NHANES) 2011-14, the National Cancer Institute proposed and coordinated funding from multiple NIH Institutes and the Department of Defense for two components: a new technology physical activity monitor to be worn on the wrist and a measurement of muscle strength using a hand-grip dynamometer. The wrist-worn accelerometer will provide the first objective measurement of sleep duration in a nationally representative sample, in addition to measuring physical activity movement. The muscle-strength measure will provide an indicator of total body strength for children, adults, and older adults who are NHANES participants. |
| National Health and Nutrition Examination Survey (NHANES) Oral Health Component | Health Survey | CDC | NIDCR | The periodic oral health component of the National Health and Nutrition Examination Survey (NHANES); included enamel fluorosis imaging study for inclusion in future NHANES. http://www.cdc.gov/nchs/nhanes.htm |
| National Health and Nutrition Examination Survey 2005-2006, Allergy Component, Interagency Agreement with CDC/NCHS | Health Survey | CDC | NIEHS, NIAID | This collaborative project developed and implemented an allergy/asthma focused component for the National Health and Nutrition Examination Survey (NHANES). The allergy component, included in NHANES 2005-2006, enabled a more robust and generalizable investigation of the role of allergen/endotoxin exposures and IgE-mediated sensitization in allergic diseases than previously possible, increasing the knowledge of complex relationships between allergen and endotoxin exposures, allergic sensitization and allergic diseases, including asthma. This survey component queried on allergy and asthma prevalence and symptoms, measured levels of common indoor allergens and endotoxin in household dust, and quantified total and 19 allergen-specific immunoglobulin E levels in serum of study participants. "http://wwwn.cdc.gov/nchs/nhanes/2005-2006/AGQ_D.htm |
| National Health and Nutritional Examinations Surveys Interest Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NIDCR | The National Health and Nutrition Examination Survey (NHANES) is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews and physical examinations. |
| National Health Interview Survey (NHIS) | Health Survey | CDC | NCI, NCCIH, NIDDK | The National Health Interview Survey (NHIS) - started in 1957 - is a continuous, nationwide in-person survey of approximately 35,000 households, or about 87,500 persons, in the civilian non-institutionalized population. The NHIS over samples African-American and Hispanic respondents. NCI periodically sponsors a Cancer Control Supplement (CCS) which is administered to a randomly selected sample of 39,000 adults. http://www.cdc.gov/nchs/nhis.htm |
| National Health Interview Survey (NHIS): 2013 Respiratory/Asthma Questions | Health Survey | CDC | NHLBI | The purpose of the collaborative activity is support development and implementation by the National Health Interview Survey (NHIS) of measures that could be used to assess progress towards achieving Healthy People 2020 respiratory/asthma objectives. The National Heart, Lung and Blood Institute and the National Center for Health Statistics collaborate on this activity. http://www.cdc.gov/nchs/nhis.htm |
| National Healthcare Quality Data Report Interagency Working Group (QDRIWG) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, HRSA, SAMHSA | OD/DPCPSI/OAR | AHRQ convenes this trans-DHHS working group to ensure that the quality and data reporting is accurate, reflects the state of the science and translates findings into utilizable reports for health care watchers, providers and consumers. http://www.ahrq.gov/research/findings/nhqrdr/chartbooks/index.html. |
| National Hispanic Science Network (NHSN) | Meeting/ Workshop | AHRQ, CDC, SAMHSA | NIDA, NIAAA, NIMH | The National Hispanic Science Network is dedicated to improving the health equity of Hispanics. It has broad representation from academic and government agencies, including several National Institutes of Health Institutes and Centers, the Centers for Disease Control and Prevention, the Substance Abuse and Health Services Administration, and the Agency for Healthcare Research and Quality. http://nhsn.med.miami.edu/ |
| National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations | Resource Development | AHRQ, CDC, CMS | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations is designed to help patients, health consumers, providers, and others find agencies and organizations with an interest in the diseases and disorders of human communication. The directory is maintained as an online database accessible to the public from the NIDCD website. Several U.S. Department of Health and Human Services agencies are included. https://www.nidcd.nih.gov/directory/ |
| National Interagency Confederation for Biological Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIAID | The mission of the National Interagency Confederation for Biological Research is to develop unique knowledge, tools, and products by leveraging advanced technologies and innovative discoveries to secure and defend the health of the American people. http://www.nicbr.mil/ |
| National Kidney Disease Education Program (NKDEP) | Public Education Campaign | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NIDDK, NHLBI | The National Kidney Disease Education Program (NKDEP) is an initiative of the National Institutes of Health, designed to reduce the morbidity and mortality caused by kidney disease and its complications. NKDEP aims to improve early detection of chronic kidney disease (CKD), facilitate identification of patients at greatest risk for progression to kidney failure, promote evidence-based interventions to slow progression of CKD, and support the coordination of Federal responses to CKD. http://www.nkdep.nih.gov |
| National Kidney Disease Education Program Health Information Technology Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | NIDDK, NIA | The NKDEP HITWG is collaborating with the Office of the National Coordinator for HIT on a CKD Care Plan,the CKD-related elements that should be included in a comprehensive electronic care plan template. The template elements will enable patients and clinicians to access, create, record, change, and receive key patient information and goals across multiple conditions. https://www.niddk.nih.gov/health-information/health-communication-programs/nkdep/working-groups/health-information-technology-working-group/Pages/default.aspx |
| National Mental Health Study Field Test | Other | SAMHSA | NIMH | The National Institute of Mental Health (NIMH) is collaborating with the Substance Abuse and Mental Health Services Administration (SAMHSA) to develop a cross-sectional national mental health study designed to (1) estimate the prevalence of a number of specific mental disorders, (2) investigate disorder correlates and patterns of care, and (3) provide a platform for follow-up studies on subgroups of interest. The initial, currently funded, project will execute the steps necessary to build the instrument, obtain Office of Management and Budget clearance, and field test all procedures prior to launching the main study. |
| National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology for Sensors and Sensors for Nanotechnology: Improving and Protecting Health, Safety, and the Environment | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB | Interagency effort to coordinate and stimulate creation of the knowledge, tools, and methods necessary to develop and test nanosensors and to track the fate of engineered nanomaterials in the body, consumer products, the workplace, and the environment. http://www.nano.gov/SensorsNSIPortal |
| National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology Knowledge Infrastructure: Enabling National Leadership in Sustainable Design | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB | Interagency effort to provide a community-based, solutions-oriented knowledge infrastructure to accelerate nanotechnology discovery and innovation. http://www.nano.gov/NKIPortal |
| National Ocean Council | Committee, Work group, Advisory group, or Task Force | OS | NIEHS | As part of President Obama''s National Policy for the Stewardship of the Ocean, Our Coasts, and the Great Lakes, the National Ocean Council has released the Implementation Plan to address some of the most pressing challenges facing the ocean, our coasts, and the Great Lakes. It describes the actions the Federal Government will take to improve the health of the ocean, coasts, and Great Lakes, which support tens of millions of jobs, contribute trillions of dollars a year to the national economy, and are essential to public health and national security. |
| National Quality Measures Clearinghouse | Resource Development | AHRQ | NCI | The NQMC is a database and Web site for information on specific evidence-based health care quality measures and measure sets. The NQMC is sponsored by AHRQ to promote widespread access to quality measures by the health care community and other interested individuals. http://www.ahrq.gov/cpi/about/otherwebsites/qualitymeasures.ahrq.gov/index.html |
| National Research Action Plan (NRAP) | Research Initiative | CDC | NIDA, NIAAA, NIMH, NINDS | This Executive Order directed the Department of Defense, Veterans Affairs, Health and Human Services, and Department of Education to develop a National Research Action Plan on post-traumatic stress disorder, other mental health conditions, and traumatic brain injury to improve the coordination of agency research into these conditions and reduce the number of affected men and women through better prevention, diagnosis, and treatment. https://www.researchgate.net/publication/268102333_The_National_Research_Action_Plan_NRAP |
| National Robotics Initiative | Research Initiative | FDA | NIBIB, NEI, NIA, NICHD, NIDCD, NINDS, NINR, OD/DPCPSI/OBSSR | Although the National Robotics Initiative MOU has ended, NIH continues to engage and participate with colleagues in other agencies to promote this work. The robotics group engages program officers across NIH and other agencies with an interest in promoting robotics to address health needs. Discussions address topics related to planning trans-NIH initiatives, co-funding grants and contracts, and participating in joint site visits to mutually funded investigators. This working group is also linked to the efforts of the National Robotics Initiative that held a Principal Investigators meeting in November 2016. http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=503641&org=CISE |
| National Science Advisory Board for Biosecurity | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OSP, NIAID | NSABB is a Federal Advisory Committee established in 2004 to provide advice to the USG and leadership on biosecurity and issues related to dual use research. The NSABB is an influential committee and its reports and recommendations have shaped policy development. The NSABB also undertakes domestic and international outreach and education efforts to raise awareness of issues related to biosecurity. Currently the NSABB is part of a White House-initiated deliberative process to evaluate the risks and benefits associated with certain studies that could generate pathogens with pandemic potential. http://osp.od.nih.gov/office-biotechnology-activities/biosecurity/nsabb |
| National Science and Technology Council Committee on Science | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP | The NSTC Committee on Science (CoS), operated out of OSTP, aims to coordinate all Federal efforts in science by establishing a structure to improve Federal government planning and coordination of R&D and by ensuring that Federal R&D efforts are balanced, integrated, and comprehensive. One of the goals of CoS is to ensure that science is considered in development and implementation of Federal policies and programs. CoS membership includes : USDA, DoC, DoD, ED, HHS, DHS, DOI, DOJ, DOL, State, DoT, Treasury, VA, EPA, NASA, NSF, and the Smithsonian, as well as OSTP and OMB. In addition to the activities of the main committee, CoS oversees about a dozen interagency subcommittees and working groups on topics ranging from the microbiome to research business models. These subgroups often involve staff from other NIH ICs that have the appropriate subject matter expertise. https://www.whitehouse.gov/administration/eop/ostp/nstc/committees/cos |
| National Security Staff Combatting Antibiotic-Resistant Bacteria sub-Interagency Policy Committee (NSS CARB sub-IPC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID, NLM | This Sub-Interagency Policy Committee develops policy options for U.S. government oversight of dual use research of concern (DURC) and serves under the NSS DURC IPC |
| National Security Staff Dual Use Research of Concern Interagency Policy Committee (NSS DURC IPC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP, NIAID | This interagency Committee develops policy options for U.S. government oversight of dual use research of concern (DURC). |
| National Security Staff Dual Use Research of Concern Sub-Interagency Policy Committee (NSS DURC Sub-IPC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP, NIAID | Develops policy options for U.S. government oversight of dual use research of concern (DURC). |
| National Survey of Family Growth | Health Survey | ACF, CDC | NICHD | The purpose of this Interagency Agreement is to provide funds to the NCHS to continue support of the National Survey of Family Growth. The NICHD contribution will supplement the collection of data on contraceptive practices, fertility, and background factors among women and men 15-44 years of age. This will support continuous interviewing for a cumulative data file. The National Survey of Family Growth (NSFG) gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men’s and women’s health. The survey results are used by the U.S. Department of Health and Human Services and others to plan health services and education programs, and to do statistical studies of families, fertility, and health. http://www.cdc.gov/nchs/nsfg.htm |
| National Toxicology Program (NTP) Executive Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NIEHS, NCI | The National Toxicology Program (NTP) was established as a department-wide effort within the Public Health Service (PHS) on November 15, 1978. The program is comprised of the relevant PHS activities within the U.S. Food and Drug Administration, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention, and the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health. The NIEHS Director serves as NTP Director and reports to the Assistant Secretary for Health. The NTP Executive Committee reviews progress on NTP activities directed toward carrying out its mission. http://ntp.niehs.nih.gov/about/org/ec/index.html |
| Native American Research Center for Health (NARCH) | Research Initiative | AHRQ, HRSA, IHS, OS | OD/DPCPSI/OBSSR, CSR, NCI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NIMH | This NIH-wide program supports partnerships between American Indian (AI), Alaska Native (AN), and Tribally based organizations and institutions that conduct intensive academic-level biomedical research. This program supports research by and in the AI/AN communities by developing research infrastructure and a cadre of AI/AN scientists and health research professionals, with the goal of reducing health disparities in the Ai/An communities. Y1-MH-8221 https://www.nigms.nih.gov/Research/CRCB/NARCH/Pages/default.aspx |
| Natural Compounds to Reduce Nitrate in Meat Products: Phytome | Research Initiative | CDC | NCI | NCI and the CDC are collaborating on a longitudinal human feeding study of processed meats and drinking water nitrate conducted by Maastricht University. CDC researchers are measuring volatile nitrosamines (NOCs) and nitrate concentrations in urine samples taken before and after consumption different types of processed meats with and without intake of nitrate in drinking water. NCI will also evaluate nitrate and nitrosamine excretion levels in relation to the the oral microbiome. Results from this study will characterize NOC formed from water nitrate and processed meat ingestion. |
| Natural Experiments and Effectiveness Studies in the Prevention and Control of Diabetes | Research Initiative | CDC | NIDDK | This project will focus on population-targeted interventions that health systems, communities, and governments can undertake to reduce the incidence of diabetes and its complications. This project will also strengthen the capacity of CDC and NIDDK to conduct vital health services and health policy research related to diabetes prevention and care. |
| NCI Clinical Trials and Translational Research Advisory Committee (CTAC) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm |
| NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NHLBI, NIBIB, NIEHS | The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government and industry with diverse interests. https://nciphub.org/groups/nanowg |
| NCI/CCR-FDA Clinical Investigator Program | Research Initiative | FDA | NCI | Create Multilateral Benefit in a Joint Program to Recruit Combined FDA and NCI/CCR Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind https://deainfo.nci.nih.gov/advisory/joint/0615/03%20Pazdur.pdf |
| NCI/CDC Cooperative Agreements for Cancer Control Activities in Low and Middle Income Countries | Other | CDC | NCI | NCI is partnering with CDC in Kenya and Indonesia to fund cancer control activities through the CDC cooperative agreement, via an interagency agreement between NCI/CGH and CDC. The activities that will take place under this agreement include cancer registry strengthening and related cancer control activities. |
| NCI/FDA Memorandum of Understanding for Drug Related Information | Resource Development | FDA | NCI | The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the U.S. Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 10,000 FDA terms and codes are stored in the NCI Thesaurus. http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fda |
| NCI/FDA Memorandum of Understanding for Proteomics | Research Initiative | FDA | NCI | This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between the NCI (Office of Cancer Clinical Proteomics Research) and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development. http://proteomics.cancer.gov/aboutoccpr/partners/fedinternational |
| NEI/FDA Symposium – Retina Outcome Variables | Meeting/ Workshop | FDA | NEI | This was a meeting held by FDA and NEI to develop outcome variables for use in clinical trials of drugs in retina diseases. |
| Nested Case-Controlled Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners | Research Initiative | CDC | NCI | A retrospective cohort mortality and nested case-control study of about 12,315 non-metal miners (278,041 person-years) to investigate risk of lung cancer in relation to quantitative measures of exposure to diesel exhaust. |
| Network Executive Committee for the NIAID Centers of Excellence for Influenza Research and Surveillance | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID | The Network Executive Committee is an advisory group to the NIAID/NIH on the management, integration and analysis of the Centers of Excellence for Influenza Research and Surveillance program. The Network Executive Committee consists of approximately 18 individuals including the contract Principle Investigators, NIAID staff and other federal and non-federal experts. |
| Networking and Information Technology Research and Development (NITRD) | Research Initiative | AHRQ | NIGMS | The NITRD Program provides a framework in which many Federal agencies come together to coordinate their networking and information technology (IT) research and development (R&D) efforts. https://www.nitrd.gov/Index.aspx |
| Newborn Screening Coding and Terminology Guide | Resource Development | CDC, HRSA, OS | NLM, NHGRI, NHLBI, NICHD | This ongoing collaboration develops, supplements and publicizes a free online resource with guidance to help promote efficient electronic exchange of standardized newborn screening data. Related efforts include studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. https://newbornscreeningcodes.nlm.nih.gov/ |
| Newborn Screening Federal Partners Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD, NHLBI, NLM | The National Institutes of Health, Health Resources and Services Administration, Centers for Disease Control and Prevention (CDC), the American College of Medical Genetics and the Genetic Alliance meet monthly, in person or online, to discuss and coordinate current activities and initiatives in newborn screening. Topics include the activities of the Newborn Screening Translational Research Network Coordinating Center, the Clearinghouse of Newborn Screening Information, Sickle Cell Screening Programs, the CDC Newborn Screening Quality Assurance Program, and the Regional Newborn Screening Collaboratives. |
| Newborn Screening Pompe Pilot Study | Research Initiative | CDC, FDA, HRSA | NICHD | The purpose of this research initiative is establishing a resource to be used to support the development and rapid data collection of Pompe Disease to be added to the Recommended Uniform Screening Panel (RUSP) and to pilot the development and rapid data collection of a Pompe Disease newborn screening assay. This project supports the development of a Pompe Disease screening method in the newborn screening environment by establishing a pool of high throughput newborn screening laboratories (state and private) with the capacity to screen a large number of newborns in relatively short periods of time (12-18 months). These groups address follow-up and educational needs stemming from pilot studies for the newborn screening system. |
| Newborn Screening Quality Improvement Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD | This committee seeks to improve the quality of newborn screening. |
| Newborn Screening Technical Assistance and Evaluation Program (NewSTEPs) Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD | Steering committee for the Newborn Screening Technical Assistance and Evaluation Program (NEWSteps). NEWSteps is a cooperative agreement related to newborn screening that the Health Resources and Services Administration funds. |
| NEWSteps Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD | This steering committee supports the mission of NEWSteps which is to achieve the highest quality for newborn screening systems by providing relevant, accurate tools and resources and to facilitate collaboration between state programs and other newborn screening partners. |
| NEXT Longitudinal Study 2009-2013: Health Behavior in School-Age Children | Health Survey | HRSA | NIAAA, NCI, NHLBI, NICHD | NEXT is a four-year longitudinal assessment of a representative sample of U.S. school children starting at grade 10. The goals of the U.S. NEXT longitudinal study include: to identify the trajectory of adolescent health status and health behaviors from mid-adolescence through the post high school year; to examine individual predictors of the onset of key adolescent risk behaviors and risk indicators during this period; to identify family, school, and social/environmental factors that promote or sustain positive health behaviors; and to identify transition points in health risk and risk behaviors and changes in family, school, and social/environmental precursors to these transitions. http://clinicaltrials.gov/ct2/show/NCT01031160 |
| NHLBI Federal COPD Workshop | Committee, Work group, Advisory group, or Task Force | ACL, CDC, CMS, FDA, HRSA, IHS | NHLBI, NCCIH | The Senate Appropriations Committee in FY2012 encouraged the National Heart, Lung and Blood Institute (NHLBI) "to work with community stake-holders and other Federal Agencies, including CDC, to develop a national action plan to respond to the growing burden of this disease." In response to this congressional encouragement, NHLBI hosted in Bethesda, Maryland, on May 3, 2013, a forum of representatives from Federal Agencies and Institutes to share information about current activities related to Chronic Obstructive Pulmonary Disease (COPD) and discuss opportunities for further cooperation and enhanced effectiveness of the Federal response to this serious public health problem. https://www.nhlbi.nih.gov/research/reports/third-federal-copd-workshop |
| NHLBI Workshop on Implementation Science in Critical Care | Meeting/ Workshop | AHRQ | NHLBI, CSR, NICHD, NIGMS | NHLBI convened a workshop (April 6-7, 2016) to discuss opportunities and needs for implementation science research in critical care. Data show that evidence-based practices in critical care known to improve patient outcomes often are not implemented in clinical practice. Implementation science is a growing field that can enhance the translation of evidence into practice. The goal of this workshop was to examine gaps and opportunities for implementation science research in critical care. https://www.nhlbi.nih.gov/research/reports/nhlbi-workshop-implementation-science-critical-care |
| NIAID Universal Influenza Vaccine Working Group | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID | HHS working group established to facilitate the development of universal influenza vaccines and move them toward clinical trials. |
| NIAID-CDC Joint U.S. Partnership Implementing TB Elimination Research (JUPITER) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Through weekly teleconferences, the Joint U.S. Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate. |
| NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews | Other | CDC | NIAID | The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database. |
| NICHD Data Archiving and Specimen Hub (DASH) Committee | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The NICHD Director will consult the NICHD DASH Committee composed of NICHD staff with the appropriate policy knowledge. The Committee will provide oversight over the management and performance of NICHD DASH. Specialized sub-committees related to data submission, data access (such as the Data Access Committee), and quality control will report to the DASH Committee. In order to maintain policies consistent with evolving technological and ethical considerations, the NICHD Director will solicit, on an as needed basis, recommendations on the NICHD DASH Policy Statement from external experts representing public and scientific stakeholders through the NICHD Council. The NICHD DASH Committee will establish and maintain operating policies and procedures for NICHD DASH to address issues including, but not limited to: privacy and confidentiality of research participants, interests of individuals and groups, data submission procedures, data access and use procedures, and data security mechanisms based on the content and level of risk. |
| Nicotine Research Cigarettes (SPECTRUM) | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | This partnership with the Food and Drug Administration (FDA) is for the production of produce research cigarettes. |
| NIH Biomarkers Consortium | Research Initiative | CMS, FDA | NIMH, NCATS, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NINDS | The National Institutes of Health (NIH) Biomarkers Consortium develops, validates, and qualifies biological markers (biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis, and treatment of disease and to improve patient care. The Foundation for the National Institutes of Health (FNIH) coordinates and manages NIH participation in the consortium. The consortium encompasses research projects, ongoing working groups, as well as occasional workshops and conferences. http://biomarkersconsortium.org |
| NIH Gabriella Miller Kids First Common Fund Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NINDS, OD/DPCPSI/ORIP, OD/DPCPSI/OSC | The NIH Gabriella Miller Kids First Common Fund Working Group supports the goals and initiatives of the NIH Gabriella Miller First Common Fund Pediatric Research Program. In fiscal year 2015, in accordance with the Gabriella Miller Kids First Research Act, Congress appropriated $12.6 million to the NIH Common Fund to support pediatric research. The Common Fund’s Gabriella Miller Kids First Pediatric Research program (Kids First) is developing a data resource for the pediatric research community of well-curated clinical and genetic sequence data that will allow scientists to identify genetic pathways that underlie specific pediatric conditions but that may also be shared between apparently disparate conditions. |
| NIH Guide for Grants and Contracts | Resource Development | AHRQ, CDC, FDA | OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other U. S. Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 58,000 subscribers. http://grants.nih.gov/grants/guide/index.html |
| NIH Precision Medicine Initiative (PMI) Policy group | Committee, Work group, Advisory group, or Task Force | FDA, OS | OD/OSP, NCI, NHGRI, NIDA | This group was initially established in order to address policy recommendations in the report of the PMI Working Group of the Advisory Committee to the NIH Director. The group also met to identify and propose potential solutions to policy issues as they arose in the early course of the Precision Medicine Initiative Cohort Program (since renamed All of Us Research Program). The activities of this group were subsumed by the governance structure of the All of Us Research Program when it was established in mid-2016. |
| NIH Recombinant DNA Advisory Committee (RAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NHGRI, NIAID, NINDS | The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant DNA. It reviews protocols and provides recommendations for each protocol to enhance the scientific and ethical design. The RAC also discusses safety data and other emerging issues for the field of gene therapy. This year the RAC hosted a meeting to develop biosafety guidelines for gain-of-function research with H5N1 which led to the amendment of the NIH Guidelines for Research with Synthetic and Recombinant Research. The RAC also hosted a meeting of mid-level investigators to examine the scientific and other challenges that gene therapy will face in the next decade and a meeting to discuss optimization of the design of clinical trials using gene modified T cells in order to realize the potential of this immunotherapy while minimizing the risk to subjects. http://oba.od.nih.gov/rdna_rac/rac_about.html |
| NIH Translational Research Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, CC, CIT, CSR, NCATS, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER, OD/OIR, OD/OSP | As Chair of the National Institutes of Health (NIH) Translational Research Interest Group (TRIG), the National Cancer Institute (NCI) staff has coordinated Forums, Workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggestions of topics and speakers for the Annual NIH Research Festivals; and nominations of speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. NCI staff has informed TRIG members of scientific events coordinated with other NIH Scientific Interest Groups and Working Groups. http://sigs.nih.gov/trig/ |
| NIH-CDC Meeting on Molecular and Phylodynamic Approaches to HIV Prevention | Meeting/ Workshop | CDC | NIAID | Attendees at the NIH-CDC meeting on molecular and phylodynamic approaches to HIV prevention discussed joint NIH-interests in HIV phylodynamic analysis of transmission networks. Emphasis on scientific gaps and opportunities for both agencies. Discussions on continued communication towards future collaborations. |
| NIH-CDC-IDSA Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents | Committee, Work group, Advisory group, or Task Force | CDC | CC, OD/DPCPSI/OAR | The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm |
| NIH-FDA Clinical Trial Protocol Template Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The NIH-FDA Clinical Trial Protocol Template Working Group was established to facilitate collaboration and cooperation between NIH research program directors and FDA, to help develop protocol templates to facilitate transfer of NIH-supported research into FDA''s regulatory processes. |
| NIH-FDA Communications Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The NIH-FDA communications working group was established to facilitate collaboration and cooperation between NIH research program directors and FDA, to help ensure that NIH grantees will produce evidence that will meet FDA specifications for regulatory action and/or approval for drugs and medical devices. |
| NIH-FDA Interagency Clinical Outcome Assessments (ICOA) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research. Leveraging the unique strengths, knowledge, and resources at both the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), the objectives of the ICOA WG are: 1) To increase communication between the relevant groups at FDA and the many separate efforts at NIH to advance measurement science by exchanging information about specific COA projects of common interest, thereby improving the knowledge base for COA development; 2) To clarify and disseminate information about the regulatory processes for evaluation of medical product development tools; 3) To foster appropriate interagency scientific efforts to generate evidence toward the development and potential qualification of novel COAs; and 4) To leverage public and private efforts toward consensus and standards development in this area. The ICOA WG is composed of representatives and selected senior staff of each agency |
| NIH-FDA Joint Leadership Council | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP, NCATS, NCCIH, NCI, NHLBI, NIAID, NIDDK, NIMH, NINDS | The NIH-FDA Joint Leadership Council work together to help ensure that regulatory considerations form an integral component of biomedical research planning and the latest science is integrated into the regulatory review process. Such collaboration and integration will advance the development of new products for the treatment, diagnosis and prevention of common and rare diseases and enhance the safety, quality, and efficiency of the clinical research and medical product approval enterprise. The formation of the Leadership Council represents a commitment on the part of both agencies to forge a strong partnership and to leverage the strengths of each agency toward this common goal. http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm201654.htm |
| NIH/President''s Emergency Plan for AIDS Relief (PEPFAR) Prevention of Maternal Child HIV Transmission (PMTCT) Implementation Science Alliance | Other | CDC | FIC, NIAID, NICHD, NIMH, OD/DPCPSI/OAR, OD/DPCPSI/ORWH | Using the NIH/President’s Emergency Plan for AIDS Relief (PEPFAR) Collaboration for Advancing Implementation Science in Prevention of Maternal Child HIV Transmission (PMTCT) request for applications (RFA) as a platform, the NIH-PEPFAR PMTCT Implementation Science Alliance promoted collaboration between implementation science researchers and program implementers and policy makers on the ground. Basing this work on actual implementation research issues rather than hypothetical examples, this project provided a unique function, serving as the “connective tissue” over 2 years for the PIs and collaborators and program implementers on the ground. In this capacity, the Alliance created a forum for the network of grantees, PMTCT implementers, and policymakers on a regular basis enabling cross-fertilization of ideas, insights and experiences as the research and the field progress.The Alliance has successfully enabled cross-fertilization of ideas, insights and experiences as the research progressed and was able to bridge the gap between PMTCT research and program/policy. The Alliance produced six publications, including a supplement entitled, "Advancing Implementation Science in Prevention of Maternal-Child HIV Transmission" published in JAIDS. https://www.fic.nih.gov/About/center-global-health-studies/Pages/pmtct-prevent-mother-child-transmission-hiv.aspx |
| Northwest Portland Tribal Registry Project | Resource Development | IHS | NCI | Over the past 10 years, health care delivery for Northwest American Indians and Alaska Natives has evolved from a centralized system maintained by the Indian Health Service (IHS) to a diverse and complex environment. The Northwest Tribal Registry Project was developed in January 1999 by the Northwest Tribal Epidemiology Center, a tribally operated program located at the Northwest Portland Area Indian Health Board (NPAIHB) in Portland, Oregon. http://surveillance.cancer.gov/disparities/native/portland.html |
| Nutrition Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS | NIDDK, CC, CIT, CSR, FIC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/ODP, OD/DPCPSI/ODS | Nutrition Research Coordinating Committee (NRCC) operates as an NIH-wide forum to review, stimulate, and encourage the support of nutrition research and training to better define the role of nutrition in the promotion and maintenance of health and in the prevention and treatment of disease. The NRCC also plays a key role in the development of nutrition research policy at the NIH. The goal of the NRCC is to review, stimulate, and encourage the necessary support of nutrition research and training and to define the role of nutrition in health promotion and disease prevention and management. NCC membership includes a representative and alternate from the 20 NIH Institutes and 7 Centers. In addition, offices and agencies within the Department of Health and Human Services (HHS), U.S. Department of Agriculture (USDA), and the Department of Defense (DOD) have also appointed liaison representatives to the Committee. The NRCC meets monthly to provide an open forum for members to report on current and future nutrition research, policy activities, and research funding and training opportunities. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/nutrition-research-coordinating-committee/Pages/default.aspx |
| Office for Human Research Protections/Office of Extramural Research Training Initiative | Meeting/ Workshop | OS | OD/OER | The National Institutes of Health collaborated with the Office for Human Research Protections to provide comprehensive training at both NIH Regional Meetings for the extramural community. |
| Office of AIDS Research Advisory Council (OARAC) | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/OAR, NIAID | The Office of AIDS Research Advisory Council provides advice to the Director of the Office of AIDS Research (OAR) on the planning, coordination, and evaluation of research and other activities in respect to AIDS conducted or supported by the NIH. OARAC also advises the Secretary of Health and Human Services and the Director of NIH, on AIDS research programs, the development and annual review of the comprehensive plan for the conduct and support of all HIV/AIDS activities of the agencies of NIH, including research policies and priorities, and the coordination of domestic and international NIH AIDS efforts. http://www.oar.nih.gov/oarac/ |
| Office of Science and Technology Mo99 Stakeholders Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA, OSG | NIBIB, NCI | The purpose of this working group is to oordinate the efforts of multiple stakeholders (Department of State, Department of Energy, Department of Homeland Security, Department of Health and Human Services, private sector) to establish a stable, long-term domestic supply of Mo99 (molybdenum-99) for medical purposes. Such a supply needs to be consistent with current international goals (to which the US is an active participant) of reduction in the use of high-enriched uranium in all reactors, including Mo99 production facilities, as well as full cost recovery solutions. |
| Opioid Use in Pregnancy and Neonatal Abstinence Syndrome | Meeting/ Workshop | CDC, FDA, SAMHSA | NICHD, NIDA, NINDS | This workshop will be of high impact in addressing critical gaps in research, including (1) Screening for opioid use in pregnancy (2) Complications of pregnancy associated with opioid use (3) Most appropriate treatment of pregnant women with opioid use disorders given risks and benefits (4) Treatment and management of infants with neonatal abstinence syndrome; and (5) long-term effects of prenatal opioid exposure on children and the role of preventive interventions to improve childhood outcomes for this high risk population. |
| Oral Health, Cancer Care, and You | Public Education Campaign | CDC | NIDCR, NCI, NINR | A series of publications to inform health care providers and patients about steps they can take to reduce the risk and impact of oral complications of cancer treatment. http://www.nidcr.nih.gov/OralHealth/Topics/CancerTreatment/ |
| OS PCORTF Leadership Council | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | OD/OSP, NCCIH, OD/DPCPSI/ODP, OD/OER | The Patient Protection and Affordable Care Act of 2010 created the Patient-Centered Outcomes Research Trust Fund (PCORTF) to help build the national capacity and infrastructure needed to conduct patient-centered outcomes research (PCOR), and to enable PCOR findings to be integrated into clinical practice. The Office of the Secretary (OS) of the U.S. Department of Health and Human Services (HHS) receives 4% of the PCORTF to build data capacity for PCOR. ASPE convenes a Leadership Council of HHS principals or their designees to develop a strategy for use of these funds and to determine yearly investments https://aspe.hhs.gov/patient-centered-outcomes-research-trust-fund |
| Osteoporosis and Related Bone Diseases—National Resource Center | Resource Development | OS | NIAMS, NIA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH | Provides patients, health professionals and the public with an important link to resources and information on metabolic bone diseases, including osteoporosis, Paget’s disease of the bone and osteogenesis imperfecta. http://www.bones.nih.gov |
| OSTP Interagency Working Group on Medical Imaging | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NCI, NIAMS, NICHD, NIDDK | The IWMI is co-chaired by NIH and NIST and is working to identify gaps and develop a roadmap to accelerate technology development that is more effective, improves patient care, and has the potential to lower cost. The working group, which includes twelve federal agencies, has determined key strategic directions through a series of stakeholder meetings. Areas identified as important for joint focus include deep/machine learning, quantitative and high-value imaging, and inter-agency collaboration to accelerate translation. |
| P63, P13K and RAS oncogenes in tumorigenesis, immune deregulation and therapy of squamous cell carcinoma | Research Initiative | FDA | NIDCD | At the FDA, Dr. Weinberg is transducing murine keratinocytes with combinations of oncogenes found in human squamous cell carcinomas to determine if they generate transformation and tumors in laboratory environment conditions. Dr. Van Waes’ laboratory at NIDCD will study how these oncogene driven tumors in mice deregulate keratinocytes and host immune responses, as well as response to various standard, molecular and immune therapies. |
| Palliative Care: Maximizing Patient Preferences and Cost Savings | Research Initiative | AHRQ | CC | The goal of the study is to provide rational, patient-defined, evidence-based recommendations to inform the redesign of the Medicare hospice benefit, transitioning policy from the current hospice benefit to a more patient-centered palliative care model. http://grantome.com/grant/NIH/R01-HS018360-01 |
| Partners in Information Access for the Public Health Workforce | Resource Development | AHRQ, CDC, HRSA, OS | NLM | Partners in Information Access for the Public Health Workforce is a collaboration of U.S. government agencies, public health organizations, and health sciences libraries which provides timely, convenient access to selected public health resources on the Internet. http://phpartners.org/ |
| Partnership for Tuberculosis (TB) and TB/HIV Research -2 | Resource Development | CDC | NIAID | Support for whole genome sequencing (WGS) of isolates and bioinformatics/analytic support for WGS to characterize TB drug resistance mutations. This is a joint CDC/NIAID effort to develop a comprehensive database of resistance polymorphisms and phenotypic correlations from clinical samples from various sites worldwide. |
| Partnerships for Accelerating Cancer Therapies (PACT) | Other | FDA | OD/OSP, NCI | The Partnership for Accelerating Cancer Therapies (PACT) is a public-private partnership between NIH, FDA, the private sector, foundations, and cancer advocacy organizations to accelerate progress in cancer research and bring cancer therapies to patients in less time as part of the Cancer Moonshot. Following in the models of successful existing partnerships, PACT will support jointly funded research through a collaborative decision making structure and ensure open data sharing with partners and the public. |
| Pathogen Detection Project | Resource Development | CDC, FDA | NLM | The Pathogen Detection Project is a multi-agency collaboration that is combining data from pathogen outbreaks with other information to determine the major source of contamination. The project is conducted via a centralized system that integrates sequence data for bacterial pathogens obtained from food, the environment, and human patients. A number of public health agencies in the US and internationally are collecting samples from these sources to facilitate active, real-time surveillance of pathogens and foodborne disease. The agencies sequence the samples and submit the data to NCBI/NLM/NIH, which analyzes the sequences against others in its database to identify closely related sequences. The aim is to uncover potential sources of contamination by linking isolates from food or the environment to human illness and to quickly report the sequence relationships to public health scientists in order to aid trace back investigations and outbreak response. Collaborating agencies include FDA, CDC, USDA-Food Safety and Inspection Service, and Public Health England. http://www.ncbi.nlm.nih.gov/pathogens/ |
| Pathways to Prevention (P2P) | Meeting/ Workshop | AHRQ | OD/DPCPSI/ODP | The Pathways to Prevention (P2P) program is a workshop series hosted by the Office of Disease Prevention to identify research gaps in a selected scientific area, identify methodological and scientific weaknesses in that scientific area, suggest research needs, and move the field forward through an unbiased, evidence-based assessment of a complex public health issue. P2P workshops are designed for topics that have incomplete or underdeveloped research and for which it is difficult to produce a report synthesizing published literature. https://prevention.nih.gov/programs-events/pathways-to-prevention/ |
| Patient-Centered Outcomes Research Clinical Decision Support Learning Network (PCOR CDS-LN) Advisory Council | Committee, Work group, Advisory group, or Task Force | AHRQ, OS | NLM | Provide forum for stakeholders to assess both barriers and facilitators to implementing PCOR findings in CDS and make recommendations for optimizing PCOR-enabled CDS to facilitate improvements in care and outcomes.The PCOR CDS-LN is funded through a cooperative agreement with the Agency for Healthcare Research and Quality https://www.pcorcds-ln.org/about |
| Pediatric-PMTCT PEPFAR Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | The Pediatric-PMTCT PEPFAR working group supports the objectives of the U.S. President''s Emergency Plan for AIDS Relief (PEPFAR) and prevention of mother-to-child transmission (PMTCT). Beginning with the President''s Mother and Child HIV Transmission Initiative in 2002, and then expanding with the launch of the U.S. President''s Emergency Plan for AIDS Relief (PEPFAR) in 2003, prevention of mother-to-child transmission (PMTCT) has been a central focus of U.S. Government global HIV/AIDS efforts. Congress established the Expert Panel on Prevention of Mother-to-Child Transmission of HIV in Section 309 of H.R. 5501, the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008. Its purposes are to provide an objective review of PEPFAR''s PMTCT activities, and provide recommendations to the U.S. Global AIDS Coordinator and the appropriate Congressional committees for further scale-up of services to achieve the ambitious target of reaching 80 percent of pregnant women in countries most affected by HIV/AIDS in which the U.S. has HIV/AIDS programs. |
| Pertussis Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The objective of the Pertussis Working Group is to share information and promote collaborations among U.S. Department of Health and Human Services (HHS) agencies in order to better understand the recent resurgence of pertussis in the U. S. and identify potential strategies to address the problem. |
| PhenX Tobacco Regulatory Research (TRR) Working Groups | Committee, Work group, Advisory group, or Task Force | FDA | NIDA, OD/DPCPSI/ODP | The FDA and the NIH Tobacco Regulatory Science Program (TRSP) are seeking to expand the depth and breadth of tobacco-related measures that can enhance cross-study analysis in large-scale research. Use of the selected consensus measures will facilitate the comparison of results from different studies and the combination of studies to create larger sample sizes, increasing statistical power and the ability to detect more subtle and complex associations. The measures will be housed within the PhenX Toolkit (https://www.phenxtoolkit.org/). PhenX is a repository for measures identified as central in a field, developed with funding from the NHGRI. https://www.phenx.org/Default.aspx?tabid=814 |
| PhysicalAactivity and Healthcare Utilization and Costs in Older Adults | Research Initiative | CDC | NCI | Through this initiative, CDC and NCI plan to investigate the association between physical activity over the life-course on later life health care utilization and costs in Medicare recipeients in the AARP Cohort. |
| Pink Ribbon Red Ribbon | Meeting/ Workshop | CDC | NCI | Pink Ribbon Red Ribbon (PRRR) is a partnership to leverage public and private sector investments to address breast and cervical cancers in developing countries. It is being implemented in several countries in sub-Saharan Africa. The National Cancer Institute and Centers for Disease Control and Prevention provide technical assistance in implementation strategies to the PRRR countries. This assistance involves drafting guidelines for monitoring and evaluation of prevention and treatment services as well as developing communication strategies. http://www.ncbi.nlm.nih.gov/pubmed/24101785 |
| Planning and Design for Post-Acute Care Assessment Instruments and Data Elements | Resource Development | CMS | NLM | The ultimate goal of this work is to improve quality of care and interoperability of computerized data in acute hospitals and post-acute care (PAC) settings through use of health informatics and real-time transfer of patient information. The National Library of Medicine (NLM) and Centers for Medicare & Medicaid Services (CMS) collaborate on planning and design for the Continuity Assessment Record & Evaluation (CARE) instrument and its data elements, and those of other CMS post-acute care assessment tools; develop logical data model and software applications that promote compliance and compatibility with Federal Health Architecture consolidated health informatics (CHI) standards; adopt Federal government-wide health information interoperability standards associated with Meaningful Use; and improve data and messaging for the Medicare program. This collaboration benefits from NLM''s role as central U.S. Department of Health and Human Services (HHS) coordinating body for clinical terminology standards, and provides NLM specific and usage-based feedback on the utility of such standards in this environment. |
| Polyhalogenated Aromatic Hydrocarbons (PHAH) and Thyroid Cancer | Research Initiative | CDC | NCI | Polyhalogenated aromatic hydrocarbons are being measured in banked serum/plasma samples from cohort studies to evaluate the association with thyroid cancer incidence. |
| Population Assessment of Tobacco and Health (PATH) Study | Health Survey | FDA | NIDA | The Population Assessment of Tobacco and Health (PATH) Study is the first large-scale National Institutes of Health (NIH)/U.S. Food and Drug Administration (FDA) collaboration since Congress granted FDA the authority to regulate tobacco products in the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009. The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 U.S. household residents ages 12 years and older for at least three years. Objectives are to assess initiation and use patterns; to study trends in tobacco-product use cessation and relapse; to monitor behavioral and health impacts, including in risk perceptions and other tobacco-related attitudes; and to assess differences in tobacco-related attitudes, behaviors, and health outcomes among racial/ethnic, gender, and age subgroups. The PATH Study will also collect biospecimens from adults to analyze biomarkers of tobacco use and related health outcomes. By measuring and accurately reporting on the social, behavioral, and health effects associated with tobacco-product use in the U.S., the PATH Study will provide an empirical evidence base to help inform FDA’s decisions about changes in tobacco products in meeting the objectives of the 2009 FSPTCA. http://www.PATHStudyInfo.nih.gov |
| Post-Traumatic Stress Disorder (PTSD)/Trauma Brain Injury (TBI), Suicide Prevention National Research Action Plan (NRAP) Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIMH, NIAAA, NIDA, NINDS | A 2012 White House Executive Order, emphasizing support of Service Members, Veterans, and their families as a top priority, called for an urgent increase in the Departments of Health and Human Services (HHS), Defense (DoD), and Veterans Affairs (VA) research coordination to address the problems of PTSD, TBI, and suicide. Section 5 of this Executive Order requested a National Research Action Plan (NRAP) to develop biomarkers, define the pathophysiology, and develop new treatments for PTSD. HHS charged the National Institute of Mental Health (NIMH) to lead this effort along with a parallel effort for TBI led by National Institute of Neurological Disorders and Stroke (NINDS), with both Institutes working closely with VA and DoD. The NRAP was published in 2013. Prior investments integrating the molecular, genomic, and brain circuitry changes that give rise to PTSD in the context of environmental factors provide the requisite foundation to respond to this White House request for biomarkers for risk prediction, as well as new targets for medications, and other therapies to treat PTSD. This investment has the potential to revolutionize the care for individuals at high risk for PTSD and prevent the development of chronic, complex treatment-resistant PTSD. The agencies meet weekly and produce quarterly progress reports. http://www.whitehouse.gov/the-press-office/2012/08/31/executive-order-improving-access-mental-health-services-veterans-service |
| Practical Oral Care for People with Developmental Disabilities | Public Education Campaign | CDC | NIDCR, NICHD | A series of publications designed to equip dental professionals in the community with the information they need to deliver quality oral health care to people with special needs. http://www.nidcr.nih.gov/OralHealth/Topics/DevelopmentalDisabilities |
| Preclinical Assessment of Phage Therapy for Pathogen Decolonization | Research Initiative | FDA | NIAID | This project addresses key regulatory considerations relevant to using bacteriophages for decolonization of the drug-resistant nosocomial pathogens, vancomycin-resistant enterococci (VRE) and methicillin-resistant staphylococcus aureus (MRSA). These include characterizing pathogen resistance to phage, defining phage mixtures ("cocktails") to circumvent resistance, optimizing mouse models to evaluate pathogen decolonization and identifying endpoints that support claims for clinical benefit (e.g., reduced risk of disease transmission). |
| PregSource Management Team | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA | NICHD, NCCIH, NHLBI, NIDCR, NIEHS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | In consultation with the PregSource Partners, the PregSource Management Team: •Finalizes selection of topics for inquiry •Works closely with PregSource contractor to develop site •Assures compliance with applicable NIH policies and procedures, including IRB approval •Develops content for online and app-based versions •Oversees outreach efforts to bolster participation •Monitors overall function and usage of PregSource •Participates in analysis and interpretation of data •Reports results in publications and presentations |
| Preparing for the Next Outbreak of Ebola Virus Infection: Working Group Meeting | Meeting/ Workshop | CDC, FDA, OS | NIAID | The goal of this workshop was to plan the next iteration of a medical countermeasures research protocol against Ebola virus infection. |
| President''s Commission on the Study of Bioethical Issues | Committee, Work group, Advisory group, or Task Force | OS | CC | The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research, health care delivery, and technological innovation are conducted in a socially and ethically responsible manner. The Commission undertakes study of issues presented to them by the President and the Secretary of Health and Human Services. |
| President''s Task Force on Environmental Health Risks and Safety Risks to Children | Committee, Work group, Advisory group, or Task Force | FDA, OSG | NIEHS, NCI, NHLBI, NIAID, NICHD | The Secretary of the Department of Health and Human Services and the Administrator of the Environmental Protection Agency co-chair the Task Force, which is focused on coordinating Federal actions in this area, and which comprises representatives of 17 federal departments and White House offices. The Task Force currently focuses on priority areas including climate change, asthma disparities, healthy homes, chemical exposures, and lead. NIEHS staff co-chair the climate change, chemical exposures, and lead subcommittees. The Task Force released an inventory of federal activities to reduce children''s lead exposure in October 2016: https://ptfceh.niehs.nih.gov/features/assets/files/key_federal_programs… |
| Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NIAID | In March 2015, HHS announced the establishment of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (Advisory Council). The Advisory Council provides advice, information, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of Executive Order 13676, including the National Strategy for CARB and the National Action Plan for CARB. https://www.hhs.gov/ash/advisory-committees/paccarb/index.html |
| President’s Emergency Plan for AIDS Relief (PEPFAR) Implementation Science/Combination Prevention | Research Initiative | CDC | NIAID, FIC, NCI, NIAAA, NIDA, NIMH, OD/DPCPSI/OAR | This President’s Emergency Plan for AIDS Relief (PEPFAR) activity focuses on testing treatment as prevention on the population level in South Africa and Zambia. This activity was initiated through the HIV Prevention Trials Network (HPTN), with support of multiple National Institutes of Health (NIH) Institutes and Centers, PEFPAR, and the Bill & Melinda Gates Foundation. The Requests for Application (RFA) was issued concurrently with a Centers for Disease Control and Prevention (CDC) RFA for combination prevention, and the agencies have worked together to ensure that the studies are complementary and do not overlap. http://www.pepfar.gov/ |
| Preventing HIV in Adolescent Girls and Young Women Taskforce | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | In August 2014, the “Preventing HIV in Adolescent Girls and Young Women Task Force” was formed in response to a request from the Office of the Global AIDS Coordinator (OGAC) to articulate PEPFAR/South Africa’s strategy to address the high rates of HIV incidence and infection in 15-24 year old females. Despite slight HIV prevalence declines over the past decade young South African women continue to experience rapid increases in HIV infection rates beginning in late adolescence. Declining HIV knowledge and increased risk behavior, despite significant treatment scale up and the availability of new prevention tools, are concerning trends among young women. Representatives from NICHD, CDC and other government agencies joined the OGAC-led task force to develop the strategy and implementation plan. In December 2014, PEPFAR launched the DREAMS initiative: DREAMS is an ambitious partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored and Safe women. |
| Prevention Research Centers | Research Initiative | CDC | NCI | The Prevention Research Centers program funds community-based research projects at 37 academic research centers across the U.S.; 5 developmental and 32 comprehensive centers. These centers: Conduct research projects that promote health and prevent disease; Build research teams of multidisciplinary faculty; Seek solutions, strategies, and policies that address public health problems; Participate in research networks that address priority health issues, such as healthy aging, cancer prevention & control, and obesity prevention; Build long-term relationships for engaging communities as partners in research; Conduct research in directions guided by advisory boards of community leaders; Develop and deliver trainings that enhance the public health workforce; and Conduct additional research funded by other federal agencies, foundations, and nonprofit organizations. http://www.cdc.gov/prc/ |
| Prevention Research Coordinating Committee (PRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, OS | OD/DPCPSI/ODP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH, OD/OLPA | The NIH Prevention Research Coordinating Committee (PRCC) serves as a venue for exchanging programmatic and scientific information of interest to the NIH, as well as for planning and implementation of collaborative activities. As a trans-NIH committee, the PRCC provides a broad perspective on the current state-of-the-science, and disseminates to NIH Institutes and Centers information about prevention-related activities sponsored by Federal and non-Federal organizations. The PRCC also serves as an advisory body to the Director of ODP and makes recommendations regarding scientific, programmatic, and policy issues. ODP coordinates the activities of the PRCC. https://prevention.nih.gov/prevention-research/prcc |
| Prevention with Positives Intervention HIV Clinics (Y01-MH-1318) | Research Initiative | CDC | NIMH, NIAID | The Prevention with Positives Intervention HIV Clinics is a collaboration between the National Institute of Mental Health (NIMH) and the Centers for Disease Control and Prevention (CDC) to conduct an HIV clinic-based comparison of a comprehensive prevention program for people living with HIV, targeting multiple health behaviors (sexual risk, medication adherence, clinic attendance) and health outcomes (viral load, retention in care). In fiscal year 2016, data collection at six HIV clinics in the U.S. was completed, and the data will be analyzed for publication. |
| Priorities for National HIV/AIDS Strategy 2020 Research and Programmatic Agenda for Mental Health and Substance Use Concerns | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIMH, NIAID, NIDA | The Department of Health and Human Services (HHS) Interagency HIV, Mental Health, and Substance Use Concerns Work Group, which grew out of the National HIV/AIDS Strategy (NHAS), updated to 2020, includes participation from the Centers for Disease Control and Prevention (CDC), Health Services Resources Administration (HRSA), Substance Abuse and Mental Health Services Administration (SAMHSA), and National Institutes of Health (NIH). The work group identified priorities within four themes: (1) Screening; (2) Integrated Care and Prevention Services; (3) Anti-Stigma/Anti-Discrimination; and, (4) Addressing the Special Needs of Key Populations and Other Populations Heavily Affected by HIV. Priorities were written broadly to allow assessment, assurance, policy, and research strategies to be developed as needed or prioritized by each agency. Improving prevention and treatment outcomes for HIV, mental and substance use disorders, co-occurring disorders, and other problems is inherent in all priorities, as well. HIV prevention is focused on communities and populations with increased HIV incidence and prevalence, and HIV care and treatment is aimed at the HIV care continuum from testing to viral suppression, and continued care. Research goals include developing and testing novel and innovative interventions. Another focus is delivery of evidence-based services and practices to the relevant communities and populations. |
| Promoting Semantic Interoperability of Laboratory Data Test Results | Resource Development | CDC, FDA | NLM | CDC and NLM encourage considering ways that FDA could accelerate specifications of LOINC codes that apply to each test result that a lab/test instrument or kit can generate. Availability of the right LOINC codes with each instrument test kit will greatly simplify the correct assignment of codes by laboratory for sending to clinician''s medical record system. http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm453897.htm |
| Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, OS, SAMHSA | NIAID, NIAMS, NICHD, NINDS, NLM | The PHEMCE advances national preparedness for natural, accidental, and intentional threats by coordinating medical countermeasure-related efforts within HHS and in cooperation with PHEMCE interagency partners. NIAID has representatives on many groups within PHEMCE. http://www.phe.gov/Preparedness/mcm/phemce/Pages/mission.aspx |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Integrated Product Development Team (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NINDS, NIAID | The U.S. Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats. https://www.medicalcountermeasures.gov/ |
| Quantitative Data Mining for Drug-Adverse Event Safety Signal Detection Using MEDLINE | Research Initiative | FDA | NLM | The objective of this initiative between the National Library of Medicine (NLM) Cognitive Science Branch and the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA) is to develop a mutually beneficial automated data mining analytical tool in which NLM’s electronic databases and resources (including MEDLINE) are utilized to support the FDA’s mission related to enhancing postmarket drug safety surveillance and safe use. http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162057.htm |
| Racial Disparities in Prostate Cancer Incidence Rates by Census Division in the United States, 1999-2008 | Research Initiative | CDC | NCI | An analysis of the National Program of Cancer Registries database to assess census division differences by race (white, black) in trends of prostate cancer. |
| Radiation Biodosimetry Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry. |
| Radiation Emergency Medical Management (REMM) | Resource Development | CDC, OS | NLM, NCI | This activity is to develop a comprehensive web resource. Radiation Emergency Medical Management (REMM) is a mechanism to collect, evaluate, collate, store and make available electronically to health care professionals immediate, up-to-date, evidence-based clinical information they would use to treat civilian patients and others affected by radiation incidents. http://www.remm.nlm.gov/ |
| Radiation/Nuclear Biodosimetry Team | Committee, Work group, Advisory group, or Task Force | OS | NIAID | Team members participate in the review of white papers as well as proposals and progress reviews for Biomedical Advanced Research and Development Authority (BARDA)-funded contracts supporting the development of novel biodosimetry platforms. |
| Radiation/Nuclear Technical Evaluation Review Panel | Committee, Work group, Advisory group, or Task Force | OS | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) participates on the Radiation/Nuclear Technical Evaluation Review Panel to review white papers and proposals received by the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) for the development of radiation and nuclear medical countermeasures. NIAID provides scientific and programmatic critiques and reviews of selected submissions. |
| Radiobiology Bioterrorism Research and Training Group (RABRAT) | Meeting/ Workshop | FDA, OS | NCI | This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications and other events and information related to preparing the U.S. Government to respond to nuclear terrorism. https://rrp.cancer.gov/programsResources/program_collaborations.htm |
| Reciprocal Educational and Training Partnerships between FDA/CDER and the NIH Clinical Center | Training Initiative | FDA | CC, NCI, NIAID, NIDCR, NIDDK, NIMH, NINDS | This activity is sponsored by the Clinical Pharmacology Program, Office of Clinical Research Training and Medical Education (OCRTME) at The National Institutes of Health (NIH) Clinical Center (CC) and it consists of elective rotations at the Office of Clinical Pharmacology (OCP) and the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research for NIH staff with a primary focus on clinical fellows and research fellows who expressed an interest in learning more about FDA regulatory sciences applicable to drug development research. Rotating fellows are mentored by FDA staff on the required elements of an Investigational New Drug (IND) application and the key elements of the FDA review process from a regulatory perspective. This program also established a mechanism for FDA scientific reviewers at the OCP to rotate at the NIH CC and to interact with members of a clinical research team, thus acquiring a better perspective on clinical research protocol implementation and the requirements of an Institutional Review Board (IRB) at the NIH. |
| Recruiting Older Adults into Research (ROAR) Tookit | Research Initiative | ACL, CDC | NIA | The National Institute on Aging (NIA) at NIH, the Centers for Disease Control and Prevention (CDC), and the Administration for Community Living (ACL) are collaborating on the Recruiting Older Adults into Research (ROAR) project to encourage older adults and their family caregivers, including underrepresented populations, to consider participating in research. https://www.nia.nih.gov/health/publication/roar-toolkit |
| Reentry Research Network | Committee, Work group, Advisory group, or Task Force | ACF, SAMHSA | NIDA, OD/DPCPSI/OBSSR | This is a subgroup that reports to the Federal Interagency Reentry Council. The purpose of this group is to bring together numerous federal agencies to make communities safer, assist those returning from prison and jail to becoming productive, tax-paying citizens, and save taxpayer dollars by lowering the direct and collateral costs of incarceration. |
| Regional Grant Writing and Scientific Peer Review Workshop | Meeting/ Workshop | CDC | NCI, CSR, FIC, NHLBI, NIAID, NICHD, NIDA, NIMH, NINDS, OD/DPCPSI/OAR, OD/DPCPSI/ODP | The Center for Global Health of the U.S. National Cancer Institute (NCI) in collaboration with the South African Medical Research Council (SAMRC) holds regional grant writing and peer review workshops to encourage investigators to address public health issues through research. The objectives of the workshops are to (1) increase the participation of scientists from mid- to low-resource countries in the research grant process; (2) develop strategies for sustainable research support and collaborations, and; (3) use competitive research as a tool to address global health issues. |
| Registry of Patient Registries (RoPR) Project | Committee, Work group, Advisory group, or Task Force | AHRQ | NIDDK, NLM | The Agency for Healthcare Research and Quality (AHRQ) is working to design and deploy Registry of Patient Registries (RoPR), which will create a searchable central listing of patient registries in the United States that will be integrated with ClinicalTrials.gov. As part of this project, broad consultations were carried out with relevant groups. Staff of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) participated extensively in these consultations. |
| Rehabilitation Research: Moving the Field Forward | Meeting/ Workshop | ACL, FDA | NICHD, NIBIB, NINDS, NINR | The meeting was an opportunity to highlight the field, identify gaps and possibilities in rehabilitation research, discuss infrastructure needs, and highlight training and career development opportunities. During the meeting, input was solicited from the audience, including scientists, clinicians, policy makers, professional groups and public advocates, in order to further refine the recommendations and identify potential activities to advance the NIH Rehabilitation Research Plan. https://www.nichd.nih.gov/about/meetings/2016/Pages/052516.aspx |
| Research and Surveillance Working Group of the HHS LGBT Policies Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, IHS, OS, SAMHSA | OD/DPSCSI/SGMRO | The Working Group is a cross-Departmental group that initiates dialogue to help harmonize efforts and prevent duplication with respect to LGBT/SGM research. |
| Research in Diabetes Mellitus, Its Complications, and Obesity | Research Initiative | IHS | NIDDK | The objectives are to identify the determinants and understand the progression of type 2 diabetes, obesity, and other chronic diseases in Pima Indians. |
| Research to Guide Practice Enhancing HIV/AIDS Platforms to Address Non- Communicable Diseases in Low Resource Settings (PEPFAR-NCD) | Research Initiative | CDC | FIC, NCI, NHLBI, NIAID, NICHD, NIDDK, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/OAR | Research to guide practice: Enhancing HIV/AIDS platforms to address NCDs in low-resource settings (the PEPFAR-NCD Project) aims to bring together researchers, implementers and government representatives to articulate practical goals, approaches and a related research agenda to incorporate prevention, care and treatment for non-communicable diseases (NCDs) into HIV/AIDS platforms in sub-Saharan Africa. The PEPFAR-NCD project focuses on people living with HIV (PLWH), many of whom are being treated successfully for HIV, but who are increasingly experiencing co-morbid diseases or conditions such as cardiovascular disease, diabetes, cancer, and depression. This project has produce landscape analyses and is establishing research agendas, priorities, and products, including modeled data, to enhance NCD services through PEPFAR platforms. http://www.fic.nih.gov/About/Staff/Policy-Planning-Evaluation/Pages/pepfar-ncd-project.aspx |
| Research to Inform the Prevention of Asthma in Healthcare | Research Initiative | CDC | NCI | This collboration between CDC and NCI aims to Characterize the exposure of health care workers to disinfectants and other chemicals |
| Research-Tested Intervention Program Database (RTIPs) | Resource Development | SAMHSA | NCI | The Research-Tested Intervention Program Database (RTIPs) is a searchable database of cancer control interventions and program materials and is designed to provide program planners and public health practitioners easy and immediate access to research-tested materials. http://rtips.cancer.gov/rtips/index.do |
| Revision of CDC Guidelines | Committee, Work group, Advisory group, or Task Force | CDC | CC | The collaboration serves to revise guidelines for managing occupational exposures to HIV and managing healthcare workers infected with hepatitis B. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6103a1.htm?s_cid=rr6103a1_e |
| RISING-SUN Initiative U.S. Government Working Group | Committee, Work group, Advisory group, or Task Force | CDC, SAMHSA | NIMH | Reducing the Incidence of Suicide in Indigenous Groups – Strengths United through Networks (RISING SUN) Initiative is a collaborative effort among key international stakeholders from Arctic Council States affected by suicide, and includes mental health researchers, service providers, government officials, and indigenous community members. The RISING-SUN U.S. Government working group convenes Department of Health and Human Services members of the RISING SUN Scientific Advisory Group (National Institute of Mental Health, Centers for Disease Control and Prevention, Substance Abuse and Mental Health Services Administration) and Department of State staff who support the activities of the Arctic Council''s Sustainable Development working group. The RISING-SUN U.S. Government working group exchanges information that facilitates the conduct of the RISING SUN initiative, which is coordinated by NIMH. https://www.nimh.nih.gov/about/organization/gmh/risingsun/index.shtml |
| Ruth L. Kirschstein National Research Service Award Program | Training Initiative | AHRQ, HRSA | OD/OER | The National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service Award program provides predoctoral and postdoctoral training to meet the nation’s need for investigators in biomedical, behavioral, and clinical research. In accordance with the Public Health Service Act (Public Law 1118, Section 219), NIH annually transfers a portion of these funds to the Agency for Healthcare Research and Quality and Health Resources and Services Administration to foster the training of health services and primary care researchers. http://grants.nih.gov/training/nrsa.htm |
| RxNorm | Resource Development | FDA | NLM | RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software. By providing links between these vocabularies, RxNorm can mediate messages between systems not using the same software and vocabulary. http://www.nlm.nih.gov/research/umls/rxnorm/ |
| Sabbatical in Clinical Research Management Program | Training Initiative | FDA, OS | CC, FIC, NCATS, NEI, NHLBI, NIAID, NIDCR, NIDDK | Experienced investigators come to the National Institutes of Health (NIH) to learn about management of a clinical research enterprise, including topics such as planning and budget development, protocol writing and tracking and scientific review. Sabbaticals are self-directed, meaning that the participant chooses from a list of electives and helps determine how much time to spend studying each topic. The electives are offered by leaders at the NIH and other U.S. Department of Health and Human Services agencies with the NIH Clinical Center being the most heavily involved. http://www.cc.nih.gov/training/sabbatical/index.html |
| Safe to Sleep Partners | Public Education Campaign | ACF, CDC, HRSA, IHS | NICHD | The Safe to Sleep campaign has worked with dozens of groups in private corporations, nonprofit organizations, professional organizations, and national, state, and local public health agencies, to help with planning, testing, implementing, and evaluating safe sleep messages and strategies for getting those messages to parents and caregivers. Safe to Sleep Partners conduct activities related to promoting safe sleep for infants and reducing infant mortality. https://www.nichd.nih.gov/sts/campaign/Pages/collaborators.aspx |
| Safety and Efficacy Evaluations of Topical Microbicide (TM) Biomedical Prevention (BP) Products in the Repeat Low-Dose Macaque SIV/SHIV Infection Model | Research Initiative | CDC | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) and Centers for Disease Control and Prevention (CDC) recognize the need to perform preclinical safety and efficacy evaluations of candidate products in the repeat low-dose (RLD) macaque SIV/SHIV infection model established by CDC. NIAID established an interagency agreement with CDC to: 1) conduct safety and efficacy evaluations of Topical Microbicide/Biomedical Prevention products in the RLD macaque model, including pharmacokinetic/pharmacodynamic analyses of candidate biomedical prevention products; 2) utilize relevant macaque species, virus strains, and routes of infection to accomplish the proposed evaluations; and 3) perform other macaque studies as needed. |
| SAMHSA Recovery Month | Public Education Campaign | SAMHSA | NIDA | The Substance Abuse and Mental Health Services Administration (SAMHSA) annual public health observance for people in recovery from substance abuse; The National Institute on Drug Abuse (NIDA) is part of SAMHSA''s inter-agency planning committee and a promotional partner. http://www.recoverymonth.gov/ |
| Sample Collection and Characterization Studies of HIV Variant Strains for Global HIV Virus Panels | Research Initiative | FDA | NIAID | This initiative will characterize emerging HIV strains from blood donors and patients to characterize and analyze multiple, diverse isolates from different parts of the world. This activity is part of NIAID’s ongoing efforts to develop a well-characterized repository of HIV virus panels for diagnostics, and drug and vaccine studies. |
| Scientific Advisory Working Group for Development of Products for Mulitpurpose Prevention Technology | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NIAID, OD/DPCPSI/ORWH | The initiative for development of products for multipurpose prevention technology is a collaborative effort involving governmental and non-governmental agencies involved in research and development of therapeutic products that are designed for more than one indication. The indications include contraception as well as prevention of infection with HIV or other pathogens that can cause sexually transmitted infections (HSV, HPV, gonorrhea, chlamydia, etc). The collaborating agencies serving on the committee include the Office of Research on Women’s Health, NIAID, NICHD, USAID and the Bill & Melinda Gates Foundation. The Advisory Group’s main activities have been to identify gaps in product development efforts, create the desired target product profiles depending on the indications for the products, to communicate activities within the MPT field and to provide complementary expertise across the different fields of research. |
| SCOPE (Spinal Cord Injury Outcomes Endeavor) | Other | ACL | NICHD | The Spinal Cord Outcomes Partnership Endeavor (SCOPE) aims to enhance the development of clinical trial and clinical practice protocols that will accurately validate therapeutic interventions for spinal cord injury (SCI) leading to the adoption of improved best practices. http://scope-sci.org/ |
| SEARCH for Diabetes in Youth | Research Initiative | CDC | NIDDK | SEARCH is a multi-center study that identifies cases of diabetes in children/youth, providing data on incidence and prevalence in the U.S. as well as data on diabetes management and complications. http://www.searchfordiabetes.org |
| Secretary''s Tribal Advisory Committee (STAC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/OSP | The STAC’s primary purpose is to seek consensus, exchange views, share information, provide advice and/or recommendations; or facilitate any other interaction related to intergovernmental responsibilities or administration of HHS programs, including those that arise explicitly or implicitly under statute, regulation or Executive Order. This purpose will be accomplished through forums, meetings and conversations between Federal officials and elected Tribal leaders in their official capacity (or their designated employees or national associations with authority to act on their behalf). https://www.hhs.gov/about/agencies/iea/tribal-affairs/about-stac/index.html?language=es |
| Sleep Disorders Research Advisory Board | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NCATS, NCCIH, NCI, NIA, NICHD, NIDA, NIDDK, NINDS, NINR, OD/DPCPSI/OBSSR | The Advisory Board shall advise, assist, consult with, and make recommendations to the Director of the National Institutes of Health, through the Director of the Institute, and the Director of the Center concerning matters relating to the scientific activities carried out by and through the Center and the policies respecting such activities, including recommendations. (42 USC § 285b–7) http://www.nhlbi.nih.gov/meetings/sdrab/index.htm |
| Smokefree.gov | Resource Development | CDC, OS | NCI, OD/DPCPSI/OBSSR | Smokefree.gov is intended to help individuals quit smoking. Different people need different resources as they try to quit. The information and professional assistance available on this Web site can help to support both immediate and long-term needs as individuals become, and remain, a nonsmoker. Smokefree.gov allows individuals to choose the help that best fits their needs. This collaboration also includes a number of smoking cessation text message programs throughout the world: China, Caribbean, Guam, American Samoa, and Samoa. http://smokefree.gov/ |
| Smoking Cessation Services During CDC TIPS II Campaign | Public Education Campaign | CDC | NCI | To assist in ensuring that 1-800-QUIT-NOW''s counseling services and the National Cancer Institute''s text messaging service and web site (Smokefree.gov) have adequate capacity to meet the expected increased demand for services during the Centers for Disease Control and Prevention TIPS Campaigns |
| Smoking Cessation Workgroup | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, OS, SAMHSA | NIDA, NCI | Discussion of current HHS initiatives on efforts to support smoking cessation. |
| Society for Prevention Research Annual Meetings | Meeting/ Workshop | ACF, CDC | NIDA, NCI, NIAAA, NICHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The Society for Prevention Research was formed in 1991 and has grown from a small group of researchers focused on drug and alcohol abuse prevention and mental health to become a leading scientific organization devoted to advancing prevention science, with 700+ members and a multidisciplinary prevention focus that emphasizes drug abuse, mental health and HIV/AIDS prevention in addition to diverse, public health domains (e.g., obesity, violence, translational science). The annual meetings promote cross-fertilization of theory, methods, and intervention and provide an opportunity to enhance understanding of the underlying mechanisms of health-related issues with the goal of building the science of effective strategies, and for prevention and health promotion. http://preventionscience.org |
| Society for Prevention Research Planning Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC | NICHD, NCCIH, NIDA, OD/DPCPSI/ODP | The Society for Prevention Research is an organization dedicated to advancing scientific investigation on the etiology and prevention of social, physical and mental health, and academic problems and on the translation of that information to promote health and well being. The multi-disciplinary membership of SPR is international and includes scientists, practitioners, advocates, administrators, and policy makers who value the conduct and dissemination of prevention science worldwide. http://www.preventionresearch.org/about-spr/mission-statement/ |
| Specialized Centers of Research (SCOR) on Sex and Gender Factors Affecting Women''s Health | Research Initiative | FDA | OD/DPCPSI/ORWH, NIAMS, NICHD, NIDA, NIDDK, NIMH | The Specialized Centers of Research (SCOR) programs are large Center Programs (P50) that consist of 11 Centers that conduct interdisciplinary research focused on health issues that affect women and examine sex/gender contributions to health and disease. The currently funded SCORs are interdepartmental, intercollegiate, interinstitutional and focus on sex differences in musculoskeletal health, tobacco, addiction, substance abuse, reproductive health, urinary tract, depression, metabolic disorders and pain. The SCOR mechanism promotes collaborative research among scientists with varied expertise in order to achieve research objectives that are less likely to occur through other grant mechanisms. http://orwh.od.nih.gov/sexinscience/researchtrainingresources/scor.asp |
| Specificity and Quality of Influenza-Specific Antibodies | Research Initiative | FDA | NIAID | This collaboration supports the evaluation of specificity and quality of influenza-specific antibodies in human subjects that have been vaccinated or naturally infected with influenza. Specific tasks include the construction of phage display libraries, production of recombinant proteins, development of surface plasmon resonance assays and the use of these technologies to measure antibody affinity maturation. |
| Standards for Genetic Testing Report | Research Initiative | AHRQ, CDC, OS | NLM, NHGRI | This activity aims to develop a standard reporting format for genetic variations using Logical Observation Identifiers Names and Codes (LOINC) and HL7, for electronic medical records health information exchange, and activities of the Office of the Secretary. |
| Standards for Microbiome Measurements Workshop | Meeting/ Workshop | FDA | OD/DPCPSI, NCI, NHGRI, NIAID, OD/DPCPSI/OSC | This workshop was designed to seek input on defining reference materials, reference data, and reference methods for human microbiome community measurements. https://www.nist.gov/news-events/events/2016/08/standards-microbiome-measurements-workshop |
| State Cancer Profiles | Resource Development | CDC | NCI | The objective of the State Cancer Profiles Web site is to provide a system to characterize the cancer burden in a standardized manner in order to motivate action, integrate surveillance into cancer control planning, characterize areas and demographic groups, and expose health disparities. The focus is on cancer sites for which there are evidence based control interventions. Interactive graphics and maps provide visual support for deciding where to focus cancer control efforts. http://statecancerprofiles.cancer.gov/ |
| Steering Committee of the Scientific Interest Group in Glycobiology | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK | The Steering Committee is comprised of NIH intramural scientists and program staff as well researchers from the Food and Drug Administration (FDA), and the National Institute of Standards and Technology. The committee organizes a seminar series; an annual NIH/FDA Glycosciences Research Day Meeting (averaging 250 people in attendance); a Mentoring & Networking Luncheon for graduate students and postdoctoral fellows to meet with staff from federal agencies and learn about NIH extramural programs; and it offers a Special Topics in the Glycosciences Course every other year. In addition the GlycoSIG maintains an email listserve to distribute information on meetings, jobs, funding opportunities and seminars. The SIG cross posts with other NIH SIG’s that share interests. |
| Stimulating Peripheral Activity to Relieve Conditions | Research Initiative | FDA | OD/DPCPSI, NCATS, NEI, NHLBI, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NINDS, OD/DPCPSI/OSC | The Stimulating Peripheral Activity to Relieve Conditions (SPARC) program''s central goal is to provide an integrated, predictive neural circuit map that illustrates the physiology and biological mechanisms underlying peripheral nervous system control of internal organ function. SPARC is collaborating with the FDA''s CDRH to facilitate discovery of new therapeutic uses for existing neuromodulation devices as well as improvements that make these devices more effective and/or minimally invasive. SPARC also coordinates with DARPA''s ElectRx program to minimize research overlap while ensuring complimentary efforts are undertaken to collectively advance the neuromodulation field as a whole. https://commonfund.nih.gov/sparc/index |
| Strategic Multisite Initiative for the Identification, Linkage and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) | Research Initiative | CDC | NICHD, NIDA, NIMH | The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) was awarded grant money to expand their project of increasing availability of HIV testing for adolescents 12-24 and the provision of adolescent-focused healthcare services for those adolescents who are diagnosed with HIV infection. The project’s expansion includes all the ATN sites across the U.S. The Eunice Kennedy Shriver National Institute of Child Health and Human Development is collecting data to evaluate the effectiveness of adolescent oriented linkage to care services for the HIV infected adolescents. This collaboration has the potential to improve the health of American youth, both by identifying those with undiagnosed HIV and bringing them into adolescent-friendly treatment programs and by reducing the chances of them further spreading the virus to others. There is a committee "SMILE in CARING for YOUTH" that monitors activities related to the National Institutes of Health-Centers for Disease Control and Prevention collaboration on enhancing treatment and retention in care of HIV youth. |
| Structured Data Capture (SDC) Initiative | Resource Development | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NLM, NCI | The Structured Data Capture (SDC) Initiative is sponsored by the Department of Health and Human Services, Office of the National Coordinator (ONC), as part of the Standards and Interoperability Framework, a program developed to foster collaboration between the public and private sectors to promote interoperable exchange of health data and information. The SDC mission is to develop and validate a data architecture and exchange standards so that a structured set of data can be accessed from electronic health record systems, merged with comparable data and made accessible for purposes other than clinical care, such as research, patient safety and public health. The SDC Working Group on Common Data Elements and Forms, chaired by NLM/NIH with NCI/NIH participation, evaluated and selected two ISO standards to serve as the basis for definitions of Common Data Elements and electronic Case Report Forms (eCRF) under the initiative: ISO/IEC 11179 (Metadata Registries and Data Elements metamodel) and ISO/IEC 19763-13 (Forms metamodel). |
| Structured Data Capture Forms and Common Data Element Working Groups | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | NCI, NLM | This working group designed a Structured Data Capture (SDC) form and Data Element structure, as well as developed XML artifacts and an implementation guide. Provided expertise on ISO 11179 and 19763-13. We participated in a connectathon with CDC and FDA in 2015, and are monitoring activity ongoing. The 2016 connectathon is testing version 2 for the form design, we intend to realign our forms to enable transformation between NCI forms and SDC forms once the standard is stabilized. http://wiki.siframework.org/Structured+Data+Capture+Initiative |
| Study of Cancer Among United States Firefighters | Research Initiative | CDC | NCI | A retrospective cohort study to evaluate the relationship between occupational exposures of firefighters and cancer risk. http://www.cdc.gov/niosh/firefighters/ffcancerstudy.html |
| Study to Assess the Incidence of Type 1 Diabetes in Young Adults | Research Initiative | CDC | NIDDK | The goal of this study is to develop, implement, and evaluate a population-based, timely, low-cost surveillance system for the assessment of the incidence of type 1 diabetes among young adults in the United States. The study will determine the incidence of type 1 diabetes among young adults and will include an Islet Autoantibody Standardization Program (ISAP)-certified central laboratory for the measurement of diabetes auto anti-bodies in all individuals identified with newly diagnosed diabetes. Incident cases of diabetes will be identified using electronic health records. |
| Sub-SPIRIT Ebola Environment Sampling Concept of Operations | Committee, Work group, Advisory group, or Task Force | FDA, OS, SAMHSA | NICHD | The goal of this effort is to develop concepts of operations (CONOPS) for strategic research, including both controlled-environment and systematic field studies, to improve our understanding of the real-world environmental fate and transport of the Ebola virus to provide additional data to support public health efforts to protect at-risk workers and the public. |
| Subcommittee of Disaster Reduction | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The Subcommittee on Disaster Reduction (SDR) is a Federal interagency body of the U.S. National Science and Technology Council under the Committee on Environment, Natural Resources and Sustainability. Chartered in 1988, the SDR provides a unique Federal forum for information sharing; development of collaborative opportunities; formulation of science- and technology-based guidance for policy makers; and dialogue with the U.S. policy community to advance informed strategies for managing disaster risks. Under its mandate, the SDR advises the White House Office of Science and Technology Policy (OSTP) and others about relevant risk reduction resources and the related work of SDR Member Agencies. Additional information about the subcommittee''s mandate is available in the SDR Charter. http://www.sdr.gov/ |
| Subcommittee on Ocean Science and Technology | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The purpose of the SOST is to advise and assist the Committee on Environment, Natural Resources, and Sustainability on national issues of ocean science and technology. In that capacity, the SOST is the lead interagency entity for Federal coordination on ocean science and technology. The SOST identifies ocean science and technology priorities, fosters and facilitates ocean science and technology activities, and contributes to Federal goals and agency missions in this area, including through collaborative interagency strategies. The SOST’s interagency efforts expand knowledge, provide advice, and offer recommendations regarding the advancement of ocean science and technology across the federal government and with the broader ocean community, including international activities. https://obamawhitehouse.archives.gov/administration/eop/ostp/nstc/oceans |
| Subpopulations and Intermediate Outcome Measures in Chronic Obstructive Pulmonary Disease (COPD) | Research Initiative | FDA | NHLBI | SPIROMICS (SubPopulations and Intermediate Outcome Measures In Chronic Obstructive Pulmonary Disease Study) is an observational study of COPD (Chronic Obstructive Pulmonary Disease) that seeks to identify practical intermediate outcome measures and mechanistically homogeneous subgroups of patients with the disease. The study was developed in cooperation with the U.S. Food and Drug Administration and will be implemented with industrial partners. http://www2.cscc.unc.edu/spiromics |
| Sudden Death in the Young (SDY) Registry | Resource Development | CDC, HRSA | NINDS, NHLBI | The Sudden Death in the Young (SDY) Registry is a surveillance system to track sudden deaths in youths less than or equal to 19 years of age in up to 10 states and gather clinical data and a DNA sample to be used for research to explore the causes and risk factors for sudden death in the young. The SDY Registry is a collaboration between the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and Centers for Disease Control and Prevention (CDC). http://www.nhlbi.nih.gov/news/press-releases/2013/nih-and-cdc-launch-registry-for-sudden-death-in-the-young.html |
| Sudden Unexpected/Unexplained Infant Death (SUID)/Sudden Infant Death Syndrome (SIDS) workgroup | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS | NICHD | NICHD co-chairs with HRSA, a Federal Sudden Unexpected/Unexplained Infant Death (SUID) /Sudden Infant Death Syndrome (SIDS) Workgroup. The partner agencies include the Administration for Children and Families (ACF); Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH); Food and Drug Administration (FDA); Maternal and Child Health Bureau (MCHB), Health Resources and Services Administration (HRSA); the Indian Health Service (IHS); Division of Information and Education, HHS Office of Minority Health (OMH); Consumer Product Safety Commission (CPSC); and Office of the Deputy Assistant Secretary of Defense, Military and Community Family Policy, Family Advocacy Program, Department of Defense (DoD). The common commitment of the ACF, CDC, NIH, FDA, HRSA, IHS, HHS/OMH, CPSC, and DoD is to address the public health challenges of SIDS and SUID and opportunities for prevention in the United States. The purpose of the partnership is to establish and enhance relationships among Federal agencies with responsibilities for SIDS and SUID. The partner agencies intend to work together to improve communication and coordination, and to collaborate on a range of activities designed to reduce, and, ultimately, eliminate SIDS and SUID, including the elimination of racial, ethnic and socio-economic disparities. |
| Suicide Mortality Surveillance | Other | CDC | NIMH | Through the Suicide Mortality Surveillance project, the Centers for Disease Control and Prevention (CDC) will develop and refine a rapid suicide mortality surveillance system. Monitoring the trends in cause-specific mortality is critical for identifying emerging public health problems and in generating evidence for health policy development, implementation, and evaluation. Timely information is important for monitoring severity of the disease or condition, allocating resources, and facilitating preventive and control programs. The results from this study will yield valuable information about the validity, feasibility, and timeliness of the enhanced vital statistics system for rapid suicide surveillance. |
| Support for Implementation of Agency Public Access Policies | Resource Development | AHRQ, CDC, FDA, OS | NLM | NIH Public Access Policy was created by NIH and established in statute by Congress in the Consolidated Appropriations Act 2008, P. L. 110-161, enacted on 12/26/2007. It ensures that the public can access without charge peer-reviewed journal articles arising from NIH-funded research. Since 2008, the PubMed Central (PMC) database has served as the repository for journal articles subject to the NIH Public Access Policy. The Office of Science and Technology Policy (OSTP) coordinated the development of public access policies across federal science agencies, and OSTP released a directive in February 2013 to increase public access to scientific publications and digital data. NIH is collaborating with five divisions and offices in HHS and four agencies outside HHS to use PMC and related services in support of their public access policies. Interagency agreements have been signed with AHRQ, ASPR, CDC, FDA and ACL within HHS, as well as with NASA, NIST, VA and EPA. Researchers funded by CDC, VA, NIST, AHRQ, FDA and NASA have begun depositing manuscripts in PMC. |
| Support for the Federal Interagency Forum on Child and Family Statistics | Research Initiative | ACF, AHRQ, CDC, HRSA, SAMHSA | NICHD, NIDA, NIMH | The purpose of this Interagency Agreement is to provide funds to support the work of the Federal Interagency Forum on Child and Family Statistics (Forum). The purpose of the Forum is to foster collaboration among Federal agencies that produce or use statistical data on children and families. Specifically, the Forum seeks to improve both the quality and use of data on children and families by investigating questions of data quality, data measurement, and data integration; identifying information gaps and data inconsistencies; widening access to information on children and families through the annual publication American’s Children: Key National Indicators of Well-Being and other means; coordinating the development and use of statistical data bases among Federal agencies ; promoting communication among data producers, researchers, and public policymakers; and addressing concerns regarding collection, access, and dissemination of data. http://childstats.gov |
| Surveillance, Epidemiology and End Results (SEER) - Medicare Database | Resource Development | CMS | NCI | The Surveillance, Epidemiology, and End Results (SEER)-Medicare data are a unique resource that can be used for research related to the health care provided to persons with cancer. The database results from the linkage of two large population-based data sources: the SEER cancer registries data and the Medicare enrollment and claims files. http://healthservices.cancer.gov/seermedicare/ |
| Surveillance, Epidemiology, and End Results (SEER) Program | Resource Development | CDC | NCI | The Surveillance, Epidemiology, and End Results (SEER) program is the premier source for cancer statistics in the U.S. It collects information on incidence, prevalence and survival from specific geographic areas representing 26 percent of the US population. Through SEER, we develop reports on all of these information areas plus cancer mortality for the entire country. The site is intended for anyone interested in U.S, cancer statistics or cancer surveillance methods. http://seer.cancer.gov/ |
| Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) | Resource Development | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NLM | This activity provides support for SNOMED CT, a systematically organized computer processable collection of medical terminology covering most areas of clinical information such as diseases, findings, procedures, microorganisms, pharmaceuticals etc. It allows a consistent way to index, store, retrieve, and aggregate clinical data across specialties and sites of care. It also helps organizing the content of medical records, reducing the variability in the way data is captured, encoded and used for clinical care of patients and research. http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html |
| Targeting of Interleukin-13 Receptor a2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-ß and PTEN Signaling | Research Initiative | FDA | NIDCR, NIDCD | The activity is testing new animal models of head and neck squamous cell cancer with targeted treatments using Interleukin-13 Receptor alpha 2 antagonists. |
| Task Force for Combating Antibiotic-Resistant Bacteria (CARB) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | NIAID | Established by Executive Order 13676, the Task Force identifies actions that will provide for the facilitation and monitoring of implementation of this order and the National Strategy for CARB. The Task Force is co-chaired by the Secretaries of Defense, Agriculture, and HHS. |
| Task Force on Environmental Health Risks and Safety Risks to Children: Coordinated Federal Action Plan to Reduce Racial and Ethnic Asthma Disparities | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG | NHLBI, NCMHD, NIAID, NICHD, NIEHS, NINR | The Action Plan to Reduce Asthma Disparities promotes collaboration and coordination among Federal agencies to leverage existing resources to address the multi-leveled causes of asthma disparities. The Action Plan outlines four key strategies to improve the quality of care for children who have asthma and promote community programs and resources to support clinicians, children, and their families in following best practices for asthma management. |
| Technical and Clinical Consultation to Indian Health Service in Kidney Disease | Public Education Campaign | IHS | NIDDK | A National Institute of Diabetes and Digestive and Kidney Diseases senior staff member serves as Chief Clinical Consultant for Nephrology for the Indian Health Service. |
| Technical Consultation on Viral Hepatitis (HCV) Infection in Young Injection Drug Users | Meeting/ Workshop | CDC, OS, SAMHSA | NIDA, NIAID, NIDDK | This collaboration brings Federal and non-Federal clinician/researchers from academia, state public health departments and community together to present and discuss current research and other information on an emerging epidemic of viral hepatitis (HCV) infection in the 15-30 year group of Injection Drug Users (IDUs). http://www.drugabuse.gov |
| Technical Resources Assistance Center and Information Exchange (TRACIE) | Resource Development | OS | NLM | This activity is to develop the Technical Resources Assistance Center and Information Exchange (TRACIE), a resource center, database, and methodology for healthcare facilities and coalitions to obtain information and assistance in emergency preparedness and response. https://asprtracie.hhs.gov |
| Technology Transfer Policy Board | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OIR/OTT, NCI, NIAID, NIMH, OD/OER, OD/OSP | The purpose of the Public Health Service (PHS) Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board to the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) in establishing PHS technology transfer policies and modifying existing policies, as applicable. |
| Teen Dating Violence Workgroup | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OS, SAMHSA | NICHD, NIAAA, NIDA, NIMH | Recognizing that adolescents experience high rates of sexual assault and intimate partner violence, the Teen Dating Violence Workshop was established in 2006, to keep federal agencies informed about teen dating violence efforts and initiatives across the federal government. http://www.nij.gov/topics/crime/intimate-partner-violence/teen-dating-violence/research-agenda.htm |
| Terminology Standards for Medicare Assessment Instruments | Resource Development | CMS | NLM | NLM is working with CMS to develop LOINC codes for all of the CMS Medicare assessment instruments. http://loinc.org |
| Text4baby | Public Education Campaign | ACF, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIDCR, NICHD, NIDA, NIDDK | Free health text messaging service for pregnant women and new mothers. Those who text "BABY" (or “BEBE” for Spanish) to 511411 receive weekly text messages, timed to their due date or their baby''s birth date through the baby’s first year. Messages, which have been vetted by both government and non-profit health experts, deal with topics such as nutrition, immunization, birth defect prevention, and oral health. http://www.text4baby.org |
| The Agricultural Health Study | Research Initiative | CDC, SAMHSA | NIEHS, NCI | The Agricultural Health Study (AHS) is a prospective study of cancer and other health outcomes (e.g. Parkinson’s disease, diabetes, thyroid disease, respiratory diseases, rheumatoid arthritis and other autoimmune disorders, and reproductive health) in a cohort of licensed pesticide applicators and their spouses from Iowa and North Carolina. The AHS began in 1993 with the goal of answering important questions about how agricultural, lifestyle and genetic factors affect the health of farming populations. The study is a collaborative effort involving investigators from National Cancer Institute, the National Institute of Environmental Health Sciences, the Environmental Protection Agency, and the National Institute for Occupational Safety and Health. More than 89,000 pesticide applicators and spouses in Iowa and North Carolina have participated in the study. Their participation has provided, and continues to provide, the data that researchers need to help the current and future generations of farmers and their families live healthier lives. Between 1993 and 1997, 52,394 licensed private pesticide applicators (mostly farmers) from Iowa and North Carolina enrolled, as did 32,345 of their spouses. The study also included 4,916 commercial pesticide applicators in Iowa in its first two phases. The average ages at enrollment were 47.1 years, 38.0 years, and 46.9 years for private applicators, commercial applicators and spouses. The study began by collecting baseline information from participants when they enrolled (1993-1997). Follow-up telephone interviews were conducted in the second (1999-2003), third phase (2005-2010), and fourth phases (2013-2015) of the study. At Phase 2, participants provided updated information on farming practices, lifestyle, and health and were asked to complete a dietary questionnaire and provide a sample of cheek cells as a source of DNA. The Phase 3 interview also updated information on farming practices, lifestyle, and health while Phase 4 focused on changes in health status. The cohort continues to be followed via linkages with cancer registries and vital statistics. Participants periodically participate in comprehensive sub-studies, including an investigation of genetic and environmental risk factors for asthma and other respiratory diseases and studies of Parkinson’s disease, neurobehavioral function and cognitive decline. Biological and environmental samples are being collected from a subset of the cohort to facilitate mechanistic studies that might explain links between pesticide and other exposures and increased risk for cancer and other conditions. http://www.aghealth.nih.gov/ |
| The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The NIH advises The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice research advances that can inform gynecologic clinical practice. |
| The American Congress of Obstetricians and Gynecologists (ACOG) reVITALize | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, HRSA | NICHD | The American College of Obstetricians and Gynecologists and the members of the Women’s Health Registry Alliance lead the reVITALize data definition standardization efforts to harmonize definitions for the data elements used in obstetrics and gynecology. The harmonization of these definitions is critical to assure that data sharing and aggregation can provide the kind of quality information we will need to provide the best care for women and newborns now and in the future. http://www.acog.org/About-ACOG/ACOG-Departments/Patient-Safety-and-Quality-Improvement/reVITALize |
| The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative | Research Initiative | FDA | NINDS, NCCIH, NIA, NIBIB, NIDA, NIDCD, NIMH, OD/DPCPSI/OBSSR | The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is part of a new Presidential focus aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. Long desired by researchers seeking new ways to treat, cure, and even prevent brain disorders, this picture will fill major gaps in our current knowledge and provide unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought. http://braininitiative.nih.gov/ |
| The Critical Path Institute (C-Path) International Neonatal Consortia (INC) | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NHLBI | The International Neonatal Consortium (INC) is a coalition of industry, academia, patient representatives, the FDA, the European Medicines Agency (EMA), other governmental agencies, professional organizations, foundations, and the Critical Path Institute (C-Path) that will focus on accelerating the development of safe and effective treatments for neonates. http://c-path.org/programs/inc/ |
| The Critical Path Institute (C-Path) Global Pediatrics Trials Consortium | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development by facilitating unique partnerships among a wide range of stakeholders, has formed a new consortium, the Global Pediatric Clinical Trials Network Pre-Launch Consortium (“Pre-Launch Consortium”). According to Dr. Janet Woodcock, Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), “Health care providers must have high-quality, reliable data to inform treatment decisions for their pediatric patients. C-Path has leveraged its expertise and stakeholders to support the development of a first-of-its-kind pediatric clinical trial network. The Pre-Launch Consortium signals an important step toward efficient and sustainable pediatric data collection and development of better treatments for children. I strongly support this effort and look forward to working with this global consortium.” The mission of the Pre-Launch Consortium will be the formation of an independent non-profit entity that will operate a novel global pediatric clinical trials network (“Network”). The Pre-Launch Consortium will establish the Network, create its organizational and operating framework, and identify its leadership team. This work will involve collaborators from academia, government, scientific, and regulatory agencies, industry, foundations, child health advocacy groups, and other important stakeholders. http://c-path.org/critical-path-institute-establishes-the-global-pediatric-clinical-trials-network-pre-launch-consortium/ |
| The Effect of Various Drugs on the Retina | Research Initiative | FDA | NEI | Using powerful in vivo imaging technology, it is possible to view the retina at the cellular level. This collaboration seeks to monitor changes to the retina for drugs that are known to cross the blood/retina barrier to better understand possible toxicity. |
| The Environmental Determinants of Diabetes in the Young (TEDDY) | Research Initiative | CDC | NIDDK, NIAID, NICHD, NIEHS | This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes. http://www.teddystudy.org |
| The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) | Research Initiative | CDC | NCI | EMBLEM provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: 1. The association of malaria-resistance genes with endemic BL. 2. Host genetic polymorphisms associated with BL using genome-wide association methods. 3. The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. 4. The role of malaria immunology and phenotype of inflammation in BL. 5. The complexity of coinfection with different P. falciparum malaria genotypes in BL. 6. The interaction between helminthic parasites, HIV, malaria, and EBV in BL. 7. The immunohistochemistry and molecular pathology of BL. 8. The impact of malaria, helminthic parasites, and HIV on childhood BL. http://emblem.cancer.gov/ |
| The Federal Tuberculosis Task Force | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS | NIAID, NICHD | The Federal Tuberculosis (TB) Task Force is a coalition composed of the Federal agencies and organizations involved in U.S. TB control efforts. Established in 1991, the Task Force facilitates coordination of activities between Federal agencies. It was created by the Director of the Centers for Disease Control and Prevention (CDC) to address the outbreaks of multidrug-resistant (MDR) TB occurring during the 1985-1992 surge in TB cases. The TB Task Force is co-chaired by CDC and NIAID. http://www.cdc.gov/tb/about/taskforce.htm |
| The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study | Research Initiative | CDC | NIDDK, NHLBI | The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) is a long-term study of different treatments for type 2 diabetes. A major challenge in diabetes treatment is to determine which of the many possible drugs is the best choice among people already treated with metformin, the most commonly used diabetes drug. GRADE is a randomized clinical trial of participants diagnosed with type 2 diabetes within the past 10 years who are already on metformin. Participants will be randomly assigned to 1 of 4 commonly-used glucose-lowering drugs (glimepiride, sitagliptin, liraglutide, and basal insulin glargine), plus metformin, and will be followed for up to 7 years. The goal of the GRADE Study is to determine which combination of two diabetes medications is best for achieving good glycemic control, has the fewest side effects, and is the most beneficial for overall health in long-term treatment for people with type 2 diabetes. https://portal.bsc.gwu.edu/web/grade |
| The Healthy Brain Initiative | Public Education Campaign | ACL, CDC | NIA | The Healthy Brain Initiative, or Roadmap, is a project of the Centers for Disease Control and Prevention (CDC) and the Alzheimer''s Association. NIA, along with other HHS participation and a representative from the Administration for Community Living/Administration on Aging, help refine recommendations for state and local governments, with use of Federal resources, to address brain health/dementia in communities. http://www.cdc.gov/aging/healthybrain/index.htm |
| The Impact of Tobacco Use on Oral Health and the Oral Microbiome | Research Initiative | CDC, FDA | NCI | U.S. Food and Drug Administration Intramural Center of Tobacco Regulatory Science Award Program funded a project examining how tobacco affects oral health and the oral microbiome in the National Health and Nutrition Examination Survey (NHANES) study. |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants | Research Initiative | CDC | NCI | A cohort study of approximately 10,000 Pan Am flight attendants to determine cancer incidence (primarily breast cancer) associated with cosmic radiation and circadian disruption from their work. |
| The Interagency Committee on Human Nutrition Research (ICHNR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK | The Interagency Committee on Human Nutrition Research (ICHNR) provides a mechanism for communicating among the various Federal agencies to enhance the coordination of human nutrition research activities. https://www.nal.usda.gov/fnic/interagency-committee-human-nutrition-research |
| The Interagency Committee on Human Nutrition Research (ICHNR) Dietary Guidelines Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD, NIDDK, OD/DPCPSI/ODS | The Interagency Committee on Human Nutrition Research (ICHNR) dietary guidelines subcommittee serves to improve planning, coordination, and communication among federal agencies engaged in research in nutrition and/or nutrition policies, surveillance, technologies, and related issues. The key focus of the Subcommittee on Dietary Guidelines is to gain perspectives from Federal stakeholders regarding the Dietary Guidelines Advisory Committee''s (DGAC) deliberations and identify any gaps or concerns that are important to Federal programs; and to engage USDA and HHS agencies in the DGA policy development process. |
| The Intersection of Violence and HIV Risk in Women Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR | This working group was established to address the research issues on violence and HIV in women including research gaps, current knowledge and current interventions. The working group conducted meetings separately and together with the White House working group in which they provided information and recommendations to the White House Violence against Women and HIV Initiative. The activities of this working group were integrated into the National HIV/AIDS Strategy. |
| The MDEpiNet TMJ RoundTable | Meeting/ Workshop | AHRQ, FDA | NIDCR | This workshop facilitated collaboration of stakeholders to address data on implant performance, surgical outcomes, and adverse events in an effort to: develop outcome and assessment and reporting tools based on patient input, intersection of patient biology, anatomy, genetics, physiology with TMJ medical devices, and clinical patient-centered outcomes to better target therapies. |
| The Mental Health Block Grant Ten Percent Set Aside (MHBG) Evaluation | Other | SAMHSA | NIMH | Substance Abuse and Mental Health Services Administration (SAMHSA) is sponsoring an evaluation of first episode psychosis treatment programs funded through the federal 10% Mental Health Block Grant Set Aside. Through an inter-agency agreement, the National Institute of Mental Health (NIMH) is co-funding the evaluation and is actively involved in all phases of the evaluation design and planning. |
| The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB, OD/OSP | This subcommittee of the National Science and Technology Council''s Committee on Technology is responsible for coordinating the National Nanotechnology Initiative (NNI). The NNI was established in 2001 to coordinate federal research and development in nanotechnology by providing a vision of the long-term benefits and opportunities offered by nanotechnology and acting as a locus for communication, cooperation, and collaboration between federal agencies involved in nanotechnology research and development. In 2011, the NSET developed a strategic plan that encompasses a comprehensive nanotechnology R&D initiative built on shared goals, priorities, and strategies that complement agency-specific missions and activities. http://www.nano.gov/nset |
| The Science of Sex and Gender in Human Health | Training Initiative | FDA | OD/DPCPSI/ORWH | This is a Web-based course that offers a scientific understanding of the major physiological differences between the sexes; their influence on illness and health outcomes; and their implications for policy, medical research, and health care. http://sexandgendercourse.od.nih.gov/ |
| The SMART Vaccines 2.0 Platform: Decision-Support for Prioritizing Vaccine R&D and Introduction (SMART Vaccines 2.0) | Resource Development | OS | FIC | The prototype decision-support tool, SMART Vaccines, was delivered to the National Vaccine Program Office (NVPO) by the Institute of Medicine (IOM) in early 2015. In support of the National Vaccine Action Plan, NVPO charged the IOM to develop a tool that reflected the dynamic and complex nature of decision-making among multiple stakeholders within the vaccine decision-making space—comprising the different interests, roles, and priorities of individuals engaged in vaccine research, research funding, purchasing, immunization programs, and policy. The current design of the tool seeks to capture the components of this decision-making process and to model how those elements interact to ultimately influence how an individual or an organization might prioritize its strategic and financial investments in new research and targets for vaccines or newly available vaccines for introduction into national immunization schedules. By attempting to more uniformly define the components of the process and allowing individuals to rank the importance of each, the tool generates a score that allows for a comparison among different inputs of vaccine targets and/or existing vaccines and the impact of each on the resulting score. NVPO and FIC are collaborating in support of both agencies’ missions related to developing and implementing strategies for increasing the prevention of human diseases through immunization. As part of a process to build a fully functional tool, SMART Vaccines 2.0, the NVPO and FIC are engaging relevant stakeholder organizations and individuals to assist in the prototype’s transformation to a more widely-accessible, relevant, and responsive tool for use in support of prioritizing the scientific, technical, and financial commitments of decision makers in the broad vaccine development and delivery community. Collaboration efforts support the following objectives: 1) Provision of capabilities to transform the existing SMART Vaccines tool to a web-based platform (html open-source model) that can be supported and sustained for public access; 2) Iterative adaptation and refinement of the tool -or suite of tools- that is responsive to: - dynamic and emerging information/inputs (e.g., disease burden, antigen-specific technology, and economic data); - ongoing assessment/validation of methodologies; and, - user/stakeholder feedback 3) Expansion and updating of the data warehouse (model supporting data) and standardized formats for data sharing; 4) Dissemination and use of the tool (and/or derivative tools) supported by direct engagement and training of the public sector, academic, and private sector stakeholders and decision-makers associated with vaccine development, purchasing, and deployment/implementation programs; and, 5) Identifying an external hosting organization for the tool that is sustainable and provides global access to the tool by embedding it an infrastructure that utilizes existing resources for maintenance of standards and capabilities To support these objectives, at least 2 piloting opportunities have been identified in which the relevant organizational stakeholders have agreed to utilize the SMART Vaccines 2.0 web-based tool in support of a targeted decision-making process. The focus of these decision-making efforts is related to the prioritization of resource-allocation for vaccine research and development and/or the introduction of new or existing vaccines into current immunization schedules. NVPO and FIC are supporting the following deliverables: 1) Provision of capabilities to utilize the web-based SMART Vaccines 2.0 platform in support of piloted applications; 2) Direct engagement of NVPO/FIC (and partner organizations) technical assets, staffing, and training in support of the pilot organization’s use of the SMART Vaccines 2.0 tool; 3) Modification and enhancement of the tool’s back-end model supporting algorithms and data-sourcing and acquisition capabilities for alignment with the pilot organizations specific decision-support needs; 4) Evaluation of the implementation and outcome of the piloted projects and the responsive of the SMART Vaccines 2.0 platform in this process; 5) Assessment of the long-term sustainability of the SMART Vaccines initiative based on the following: - an evaluation of the tool produced from the pilot project and the feasibility of its on-going adaptation for other related decision-making processes; - the opportunities and limitations associated with data availability in support of the SMART Vaccines approach; - an evaluation of the likelihood of use by key decision-makers in the vaccine research, development, and delivery communities; - the viability of commitments from external technical experts and organizations to continue to support the ongoing and dynamic modifications that will be required to adapt the SMART Vaccines tool for individual decision-making needs; and, - the likelihood of external stakeholder funding opportunities to support the sustained human, technical, and financial needs required for long-term viability of a publicly accessible SMART Vaccines tool. |
| The Sudden Death in the Young Case Registry | Resource Development | CDC | NHLBI, NINDS | The SDY Case Registry is a collaborative effort between the National Institutes of Health, the Centers for Disease Control and Prevention, and the Michigan Public Health Institute. Its goals are to: 1) describe the incidence of SDY in the United States using population-based surveillance, 2) compile data from SDY cases to create a resource of information and deoxyribonucleic acid (DNA) samples for research, 3) encourage standardized approaches to investigation, autopsy, and categorization of SDY cases, 4) develop partnerships between local, state, and federal stakeholders towards a common goal of understanding and preventing SDY, and 5) support families who have lost loved ones to SDY by providing resources on bereavement and medical evaluation of surviving family members. The SDY Case Registry will provide valuable incidence data and will enhance understanding of characteristics of SDY cases to inform development of targeted prevention efforts. |
| The United States Renal Data System (USRDS) | Resource Development | CMS, HRSA | NIDDK | The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the U.S. The missions of the USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients. http://www.usrds.org |
| Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | A group of Therapeutics for Rare and Neglected Diseases (TRND) Program staff and U.S. Food and Drug Administration (FDA) staff from the Center for Drug Evaluation and Research (CDER) meet on a semi-monthly basis to discuss projects for the TRND program. The purpose of this working group is to discuss the scientific progress toward the eventual goal of an Investigational New Drug Application for each project. Results of experiments are discussed, and TRND staff takes the feedback of FDA/CDER staff into consideration when developing future project plans. https://ncats.nih.gov/trnd |
| Tobacco and Nicotine Research Interest Group (TANRIG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | OD/DPCPSI/OBSSR, NCI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIDA, NIEHS, NIMH, NINR, OD/DPCPSI/ODP | The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant U.S. Department of Health and Human Services agencies. http://sigs.nih.gov/tobacco/Pages/default.aspx |
| Tobacco Product Disease Risks | Research Initiative | FDA | NCI | Associations of cigarette and non-cigarette tobacco products with total and cause-specific mortality in Current Population Survey linked mortality dataset |
| Tobacco Regulatory Science Program (TRSP) | Research Initiative | FDA | OD/DPCPSI/ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIDCR, NIEHS, OD/OER | Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources. https://prevention.nih.gov/tobacco-regulatory-science-program |
| Tox21 - Memorandum of Understanding on High Throughput Screening, Toxicity Pathway Profiling, and Biological Interpretation of Findings | Research Initiative | FDA | NIEHS, NCATS | This Memorandum of Understanding sets in place mechanisms to strengthen existing collaborations in the research, development, validation, and translation of new and innovative test methods that characterize key steps in toxicity pathways. Central is the exploration of high throughput screening assays and tests using phylogenetically lower animal species as well as high throughput whole genome analytical methods, to evaluate mechanisms of toxicity. Ultimately, the data generated by these new tools is to be provided to risk assessors to use in the protection of human health and the environment. Success is expected to result in test methods for toxicity testing that are more scientifically and economically efficient and models for risk assessment that are more biologically based. http://www.ncats.nih.gov/tox21 |
| Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of U.S. and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation. http://www.cdc.gov/drugresistance/tatfar/ |
| Trans-NIH American Indian and Alaska Native Health Communications and Information Workgroup | Committee, Work group, Advisory group, or Task Force | ACL, IHS | NIAMS, CC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORWH, OD/OCPL | Formed in 2005, the Trans-NIH AI/AN Health Communications and Information Work Group provides a forum for health education and communications staff from National Institutes of Health (NIH) Institutes, Centers, and Offices to share strategies and effective communication approaches to develop and disseminate health information to American Indian and Alaska Native communities. In partnership with the Indian Health Service (IHS) and the Administration on Aging/Administration for Community Living (AoA/ACL), the Work Group conducts outreach to 1,600 IHS Community Health Representatives (CHRs) and 600 AoA/ACL Title VI grantees nationwide through quarterly e-newsletters featuring NIH health information. The e-newsletter, which replaced quarterly hard-copy mailings, features a wide range of health topics and is distributed to IHS CHRs and AoA/ACL grantees that provide services to Native elders. The purpose of the project is to increase awareness among CHRs and Title VI grantees about the availability of free or low-cost, science-based health information for patients and the general public. http://www.niams.nih.gov/About_Us/Mission_and_Purpose/Community_Outreach/Multicultural_Outreach/AIAN_WG/default.asp |
| Trans-NIH Plan for HIV-Related Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS | OD/DPCPSI/OAR, CSR, FIC, NCATS, NCCIH, NCI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR, OD/DPCPSI/ORIP, OD/DPCPSI/ORWH | Each scientific area of the strategic plan is developed by Coordinating Committees comprised of representatives from the NIH Institutes and Centers and scientific experts from other agencies, including CDC, HRSA, VA, USAID, DoD, and PEPFAR. These committees assist in developing the annual Trans-NIH Plan for HIV-Related Research to ensure that the AIDS research budget funds the highest priority HIV/AIDS research. The plan 1) frames the development of the NIH AIDS research budget; 2) determines the use of NIH AIDS-designated dollars; 3) tracks and monitors HIV/AIDS research expenditures; and 4) informs the public, the scientific community, Congress, and the AIDS-affected communities about the NIH HIV/AIDS research agenda. The Plan also shapes the NIH investment in HIV/AIDS research. http://www.oar.nih.gov/strategicplan/ |
| Trans-NIH Structural Birth Defects Working Group (SBDWG) | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDCR, NIDDK, NIEHS, NINDS | The Trans-NIH SBDWG brings together extramural program officials from NIH components whose missions include research into structural birth defects, with the ultimate goal of facilitating advances in our understanding of the etiology, mechanisms, epidemiology, prevention, and treatment of structural birth defects. http://www.nichd.nih.gov/NIHstructuralbirthdefectsWG |
| Transformation of PROWL Survey into Electronic Form. | Health Survey | FDA | NEI, NLM | In 2016, the FDA posted the final version of the Patient-Reported Outcomes with Lasik (PROWL) survey instrument developed in collaboration with the National Eye Institute (NEI) and the Department of Defense (DoD). The survey is intended to collect data to help better understand the potential risk of severe problems that can result from LASIK. The NEI is collaborating with the National Library of Medicine (NLM) to recreate the form in an electronic format to allow for incorporation in electronic data capture systems. |
| Transplant Cancer Match Study | Research Initiative | HRSA | NCI | A study linking databases of U.S. transplant recipients, donors, and wait list candidates to multiple U.S. cancer registries to evaluate the spectrum of cancer risk in transplant recipients. http://transplantmatch.cancer.gov/ |
| Traumatic Brain Injury Common Data Elements Standards - Interagency Steering Committee | Resource Development | CDC | NINDS, CIT | The Traumatic Brain Injury (TBI) Common Data Elements (CDE) Standards – Interagency Steering Committee provides oversight to a Federal scientific initiative to develop and utilize common data elements for TBI. http://www.commondataelements.ninds.nih.gov/TBI.aspx#6 |
| Treating for Two Interagency Working Group (Medications in Pregnancy) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NICHD, OD/DPCPSI/ORWH | This workgroup supports of the objectives of the Treating for Two Initiative, which aims to improve the health of women and babies by working to identify the safest treatment options for the management of common conditions before and during pregnancy. |
| Treating for Two: Safe Medication Use in Pregnancy Initiative | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | OD/DPCPSI/ORWH, NICHD | The initiative provides expert input for the development of a conference on systematic, evidence-based review of specific medications used during pregnancy and adverse fetal outcomes. http://www.cdc.gov/pregnancy/meds/treatingfortwo/index.html |
| Trends in Hormone Concentrations in U.S. Men and Relationship to Endocrine Disrupting Chemicals in the National Health and Nutrition Examination Survey (NHANES) Population | Research Initiative | CDC | NCI | An examination of serum hormone levels of men in the National Health and Nutrition Examination Survey (NHANES) population to determine whether levels have declined over time and whether they correlate with serum levels of endocrine disrupting chemicals. |
| Trial to Assess Chelation Therapy 2 (TACT2) | Research Initiative | CDC | NIDDK, NCCIH, NHLBI, NIEHS | Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction. http://tact2.org/ |
| Tribal Epidemiology Centers Program | Research Initiative | IHS | NIMHD | To develop Epidemiology Centers and public health infrastructure for American Indian/Alaska Native communities. http://www.ihs.gov/epi/index.cfm?module=epi_tec_tecs |
| Tribal Health Research Advisory Council (HRAC) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | NIMHD | To support the activities of the Council, including obtaining input from tribal leaders on health research priorities and needs, and dissemination of information. http://minorityhealth.hhs.gov/hrac/ |
| Tularemia Animal Model Qualification Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This working group is collaborating on qualification of primate model of pneumonic tularemia under FDA''s Animal Model Qualification/Drug Development Tools Program. Animal model qualification is a regulatory decision and will be published on the FDA web site when final. Collaboration includes exchange of study data, study reports, and agreements on regulatory strategy for model qualification. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284078.htm |
| U. S. Government Interagency Working Group on Nanotechnology Environmental, and Health Implications (NEHI), of the Nanoscale Science, Engineering, and Technology Subcommittee (NSET) of the National Science and Technology Council (NSTC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIEHS | The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee and Nanotechnology Environmental, and Health Implications (NEHI) Working Group provide leadership in establishing the national nanotechnology environmental, health, and safety research agenda and in communicating data and information related to environmental and health aspects of nanotechnology between National Nanotechnology Initiative (NNI) agencies and with the public. NNI activities support the development of new tools and methods required for the research that will enable risk analysis and assist in regulatory decision-making. NNI agencies engage and interact with regional, state, and local groups, educational institutions, industry-supported groups, and non-governmental organizations to enhance the impact and value of NNI efforts and to provide a collaborative approach. http://www.nano.gov/nehi |
| Understanding and Identifying the Needs for Medical Devices | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | The Institute of Medicine Rare Diseases and Orphan Products 2010 Report recommended that the FDA and NIH perform an assessment of unmet devices needs, and determine the impediments, and options for overcoming these impediments. The assessment will document examples of compelling unmet needs across sections of medical specialties culminating in a report and publication. Collaborating are the Office of rare Diseases Research at NCATS, and the Office of Orphan Product Development and other parts of the FDA. |
| Unified Medical Language System Metathesaurus (UMLS) | Resource Development | AHRQ, CDC, CMS, FDA | NLM | NLM's Unified Medical Language System (UMLS®) facilitates the development of computer systems that behave as if they understand the meaning of the language of biomedicine and health. To that end, NLM produces and distributes the UMLS Knowledge Sources (databases) and associated software tools (programs) for use by system developers in building or enhancing electronic information systems that create, process, retrieve, integrate, and/or aggregate biomedical and health data and information, as well as in informatics research. By design, the UMLS Knowledge Sources are multi-purpose. |
| Urban Waters Federal Partnership | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | This partnership will reconnect urban communities, particularly those that are overburdened or economically distressed, with their waterways by improving coordination among federal agencies and collaborating with community-led revitalization efforts to improve our Nation''s water systems and promote their economic, environmental and social benefits. https://www.epa.gov/urbanwaterspartners |
| Urinary Luteinizing Hormone and Fibroid Development | Research Initiative | CDC | NIEHS | This collaboration is an examination of the association between basal luteinizing hormone levels and fibroid development. |
| US Government Zika Vaccine Development Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | NIAID established the Zika Vaccine Development Working Group, which includes representatives from various US Government agencies (BARDA, CDC, FDA) to coordinate research efforts, mobilization of domestic and international research infrastructure, and partnerships with industry to accelerate the development of a safe and effective Zika vaccine. |
| US Preventive Services Task Force (USPSTF) | Resource Development | AHRQ | OD/DPCPSI/ODP, NCI | The U.S. Preventive Services Task Force (USPSTF) is an independent panel of non-Federal experts in prevention and evidence-based medicine and is composed of primary care providers. The USPSTF conducts scientific evidence reviews of a broad range of clinical preventive health care services (such as screening, counseling, and preventive medications) and develops recommendations for primary care clinicians and health systems that are published in the form of "Recommendation Statements." The Agency for Healthcare Research and Quality (AHRQ) has been authorized by the U.S. Congress to convene the Task Force and to provide ongoing scientific, administrative, and dissemination support to the Task Force. The NIH Office of Disease Prevention (ODP) works closely with AHRQ and the USPSTF to provide scientific input from NIH Institutes and Centers on draft research plans, draft evidence reviews, and clinical practice guidelines to be included in the Guide to Clinical Preventive Services. The ODP also disseminates information to NIH Institutes and Centers about high-priority evidence gaps for clinical preventive services that have been identified by the USPSTF. http://www.uspreventiveservicestaskforce.org/ |
| US Public Health Service (USPHS) Physicians Professional Advisory Committee (PPAC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NIAID | The purpose of this committee is to provide advice and consultation to the Surgeon General on issues relating to the professional practice and personnel activities, civil service, and Commissioned Corps of the Medical Category. Provides advisory assistance to the Chief Professional Officer and to the Agency and/or Program Heads of the USPHS and to non-PHS programs that routinely use USPHS personnel. https://dcp.psc.gov/osg/physician/default.aspx |
| Value Set Authority Center (VSAC) | Resource Development | AHRQ, CDC, CMS, OS | NLM | The National Library of Medicine (NLM) provides an online repository of value sets (code sets from standardized medical vocabularies) that are used for clinical quality measurement in the CMS EHR Incentive Program (meaningful use). The Value Set Authority Center (VSAC) provides downloadable access to all official versions of vocabulary value sets contained in the 2014 Clinical Quality Measures (CQMs). Each value set consists of the numerical values (codes) and human-readable names (terms), drawn from standard vocabularies such as SNOMED CT® , RxNorm, LOINC and ICD-10-CM, which are used to define clinical concepts used in clinical quality measures (e.g., patients with diabetes, clinical visit). http://vsac.nlm.nih.gov |
| Violence Against Women Steering Committee (DHHS VAW) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/ORWH, NIA, NIAAA, NICHD, NIDA, NIMH, NLM, OD/DPCPSI, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR | The DHHS Violence Against Women Act (VAWA) steering committee is chaired by the Office on Women’s Health (OWH). The VAWA committee has the responsibility for coordinating the Department of Health and Human Services (DHHS) response to issues related to violence against women and their children, and also coordinates DHHS violence related activities with those of other Federal agencies. The members of the committee establish links with professional societies in the health and social service fields to increase attention to women’s health and violence issues. The members of the committee also serve as resource experts for the National Advisory Committee on VAW, which is chaired by the HHS Secretary and the DOJ Attorney General. http://womenshealth.gov/about-us/who-we-are/groups-committees/steering-committee.html |
| Viral Hepatitis Implementation Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIDDK, NIDA | Building on the success of the nation’s first comprehensive cross-agency action plan, released in 2011, the U.S. Departments of Health and Human Services (HHS), Housing and Urban Development (HUD), Justice (DOJ), and Veterans Affairs (VA) released a 3-year update of the plan in April 2014. The updated Viral Hepatitis Action Plan builds on the foundation of and momentum generated by the original action plan and seeks to harness: new recommendations for health care providers regarding screening for hepatitis C; promising new developments in treatments for hepatitis C; mounting public awareness of and concern about hepatitis B and hepatitis C; and the expansion of access to viral hepatitis prevention, diagnosis, care, and treatment offered by the Affordable Care Act. http://www.hhs.gov/ash/initiatives/hepatitis/ |
| Vitamin D Standardization Program (VDSP) | Research Initiative | CDC | OD/OSP, OD/DPCPSI/ODS | The NIH Office of Dietary Supplements (ODS) collaborates with CDC and others on the VDSP, which is an international collaborative effort to standardize the laboratory measurement of vitamin D status. The goal of the program is to improve the detection, evaluation, and treatment of vitamin D deficiency and insufficiency by promoting the standardized laboratory measurement of serum total 25-hydroxyvitamin D [25(OH)D]. VDSP promotes the standardized laboratory measurement of total 25(OH)D (a measure of vitamin D status) to improve clinical and public health practice worldwide. https://ods.od.nih.gov/Research/vdsp.aspx |
| Waterpipe- A Public Workshop | Meeting/ Workshop | FDA | NCI | The purpose of this workshop, held in March 2016, was to gather scientific information and stimulate discussion among scientists about waterpipes and waterpipe tobacco (hookah). It was intended to better inform FDA about these products through the exchange of scientific information, but is not intended to seek advice or consensus. http://www.fda.gov/TobaccoProducts/NewsEvents/ucm480233.htm |
| White House Interagency Committee on the Implementation of the US Strategy to Prevent and Respond to Gender-Based Violence Globally | Committee, Work group, Advisory group, or Task Force | ACF | NIDA, OD/DPCPSI/ORWH | Led by the Secretary of State and the Administration of the United States Agency for International Development, this working group was established by President Obama’s Executive Order 13623 - Preventing and Responding to Violence Against Women and Girls Globally. The working group’s charges were to address gender-based violence, which shall coordinate implementation of the Strategy by the executive departments and agencies that are members of the Working Group. http://www.presidency.ucsb.edu/ws/index.php?pid=101708 |
| White House Office of National Drug Control Policy (ONDCP) Electronic Health Records (EHRs) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA | NIDA, NIAAA, NIMH | This interagency working group coordinates initiatives across the U.S. Department of Health and Human Services to improve efforts to leverage meaningful use of electronic health records, health information technology, and related research and implementation activities as a means to improve quality, safety, and efficiency for substance use disorder research and treatment. |
| Work Group on Harmonizing Hemoglobinopathy Data Sets | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NLM, NCATS, NHLBI, NICHD, NIGMS, OD/OER | The mission of the Workgroup for Harmonizing Hemoglobinopathy Data Sets is to create a resource for federal programs and extramural communities to use in data systems which incorporate data elements in hemoglobinopathies. Specifically this entails establishing a Hemoglobinopathies Uniform Medical Language including: identifying specific goals and objectives for the kind of data that are required by these programs; case definitions for electronic data systems at all levels; consensus about conditions and data elements to be included; and differentiation between data needs for surveillance and for registries/biorepository. |
| Workgroup on Research Related to Evidence Based Policy | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OS, SAMHSA | NIDA | This workgroup focuses on research issues surrounding evidence-based policy. Discussions generally include cross cutting questions-- e.g., What is evidence-based? What are key lessons that have been learned as evidence-based policy has been rolled out? In addition, this group provides updates on meetings and projects related to evidence-based policy. |
| Working Groups to Develop Federal HIV/AIDS Prevention and Treatment Guidelines | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | OD/DPCPSI/OAR, NICHD, NIMH | Working Groups of HIV experts from across the country, including physicians, pharmacists, researchers, and HIV treatment advocates responsible for writing, reviewing, and updating HIV/AIDS prevention and treatment guidelines. http://www.aidsinfo.nih.gov/Guidelines/?MenuItem=Guidelines&Search=On |
| Yale Specialized Center of Research (SCOR) on Gender-Sensitive Treatment for Tobacco Dependence | Research Initiative | FDA | NIDA, OD/DPCPSI/ORWH | The Yale-Specialized Center of Research (SCOR) is bringing together leading basic and clinical science experts to establish an interdisciplinary, translational, cross-species program of research aimed at identifying novel therapeutics to address the critical health disparity that female smokers face. http://medicine.yale.edu/psychiatry/scor/index.aspx |
| Zika Supplement for Virus Tissue Tropism During Pregnancy | Resource Development | FDA, HRSA | NIAID | This activity addressed a time-critical public health crisis to understand Zika virus (ZIKV) and HIV in the Americas. This supplement leverages unique existing collaborations and resources from the parent award to develop models for ZIKV pathogenesis that currently do not exist. The investigators have the ideal expertise in virology, immunology, primate models of pregnancy, and pediatrics to quickly establish a relevant animal model for ZIKV infection of pregnant women. This supplement will perform initial studies of virus replication and pathogenesis in pregnant female macaques and their offspring. This will directly address a rapidly expanding public health emergency in the Americas that may threaten vulnerable HIV+ populations. https://zika.labkey.com/project/OConnor/begin.view? |
| Zoster Working Group of the CDC Advisory Committee for Immunization Practices | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The Working Group discusses new zoster vaccines and makes recommendations to the Advisory Committee for Immunization Practices (ACIP) on how to use zoster vaccines. |
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government
organization in the United States.
A .gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.